<!DOCTYPE html>

<html lang="en">


<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
      
      
        <link rel="prev" href="..">
      
      
        <link rel="next" href="../Oncology/">
      
      
      <link rel="icon" href="../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.5.3, mkdocs-material-9.5.12">
    
    
<title>Literature Survey (VPE)</title>

    
      <link rel="stylesheet" href="../assets/stylesheets/main.7e359304.min.css">
      
        
        <link rel="stylesheet" href="../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
  <!-- Add scripts that need to run before here -->
  <!-- Add jquery script -->
  <script src="https://code.jquery.com/jquery-3.7.1.js"></script>
  <!-- Add data table libraries -->
  <script src="https://cdn.datatables.net/2.0.1/js/dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/2.0.1/css/dataTables.dataTables.css">
  <!-- Load plotly.js into the DOM -->
	<script src='https://cdn.plot.ly/plotly-2.29.1.min.js'></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/buttons/3.0.1/css/buttons.dataTables.css">
  <!-- fixedColumns -->
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/dataTables.fixedColumns.js"></script>
  <script src="https://cdn.datatables.net/fixedcolumns/5.0.0/js/fixedColumns.dataTables.js"></script>
  <link rel="stylesheet" href="https://cdn.datatables.net/fixedcolumns/5.0.0/css/fixedColumns.dataTables.css">
  <!-- Already specified in mkdocs.yml -->
  <!-- <link rel="stylesheet" href="../docs/custom.css"> -->
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/dataTables.buttons.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.dataTables.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/jszip/3.10.1/jszip.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/pdfmake.min.js"></script>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/pdfmake/0.2.7/vfs_fonts.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.html5.min.js"></script>
  <script src="https://cdn.datatables.net/buttons/3.0.1/js/buttons.print.min.js"></script>
  <!-- Google fonts -->
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Intro.js -->
  <script src="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/intro.min.js"></script>
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/intro.js@7.2.0/minified/introjs.min.css">


  <!-- 
      
     -->
  <!-- Add scripts that need to run afterwards here -->

    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../assets/_mkdocstrings.css">
    
      <link rel="stylesheet" href="../custom.css">
    
    <script>__md_scope=new URL("..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

<header class="md-header" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href=".." title="Literature Survey for Swathi" class="md-header__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Literature Survey for Swathi
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Immunology
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="white" data-md-color-accent="black"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
      <div class="md-header__source">
        <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
            
<nav class="md-tabs" aria-label="Tabs" data-md-component="tabs">
  <div class="md-grid">
    <ul class="md-tabs__list">
      
        
  
  
  
    <li class="md-tabs__item">
      <a href=".." class="md-tabs__link">
        
  
    
  
  Home

      </a>
    </li>
  

      
        
  
  
    
  
  
    <li class="md-tabs__item md-tabs__item--active">
      <a href="./" class="md-tabs__link">
        
  
    
  
  Immunology

      </a>
    </li>
  

      
        
  
  
  
    <li class="md-tabs__item">
      <a href="../Oncology/" class="md-tabs__link">
        
  
    
  
  Oncology

      </a>
    </li>
  

      
    </ul>
  </div>
</nav>
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
                
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" hidden>
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    


  


<nav class="md-nav md-nav--primary md-nav--lifted" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href=".." title="Literature Survey for Swathi" class="md-nav__button md-logo" aria-label="Literature Survey for Swathi" data-md-component="logo">
      
  <img src="../assets/VPE.png" alt="logo">

    </a>
    Literature Survey for Swathi
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/VirtualPatientEngine/literatureSurvey" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 496 512"><!--! Font Awesome Free 6.5.1 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2023 Fonticons, Inc.--><path d="M165.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6zm-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3zm44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9zM244.8 8C106.1 8 0 113.3 0 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C428.2 457.8 496 362.9 496 252 496 113.3 383.5 8 244.8 8zM97.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1zm-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7zm32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1zm-11.4-14.7c-1.6 1-1.6 3.6 0 5.9 1.6 2.3 4.3 3.3 5.6 2.3 1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2z"/></svg>
  </div>
  <div class="md-source__repository">
    VPE/LiteratureSurvey
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href=".." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    <li class="md-nav__item md-nav__item--active">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
      
      <a href="./" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    Immunology
  </span>
  

      </a>
      
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../Oncology/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Oncology
  </span>
  

      </a>
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
                
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              <article class="md-content__inner md-typeset">
                
                  

  
  


  <h1>Immunology</h1>

<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
</head>

<body>
  <p>
  <i class="footer">This page was last updated on 2026-01-12 09:25:15 UTC</i>
  </p>

  <div class="note info" onclick="startIntro()">
    <p>
      <button type="button" class="buttons">
        <div style="display: flex; align-items: center;">
        Click here for a quick intro of the page! <i class="material-icons">help</i>
        </div>
      </button>
    </p>
  </div>

  <!--
  <div data-intro='Table of contents'>
    <p>
    <h3>Table of Contents</h3>
      <a href="#plot1">1. Citations over time on Immunology</a><br>
      <a href="#manually_curated_articles">2. Manually curated articles on Immunology</a><br>
      <a href="#recommended_articles">3. Recommended articles on Immunology</a><br>
    <p>
  </div>

  <div data-intro='Plot displaying number of citations over time 
                  on the given topic based on recommended articles'>
    <p>
    <h3 id="plot1">1. Citations over time on Immunology</h3>
      <div id='myDiv1'>
      </div>
    </p>
  </div>
  -->

  <div data-intro='Manually curated articles on the given topic'>
    <p>
    <h3 id="manually_curated_articles">Manually curated articles on <i>Immunology</i></h3>
    <table id="table1" class="display" style="width:100%">
    <thead>
      <tr>
          <th data-intro='Click to view the abstract (if available)'>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th data-intro='Highest h-index among the authors'>Highest h-index</th>
          <th data-intro='Recommended articles extracted by considering
                          only the given article'>
              View recommendations
              </th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f2918cad295af222dcbefbcbfa7b2c18903efa6" target='_blank'>
                Bispecific T cell engager therapy for refractory rheumatoid arthritis
                </a>
              </td>
          <td>
            Laura Bucci, M. Hagen, T. Rothe, M. Raimondo, F. Fagni, Carlo Tur, Andreas Wirsching, J. Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena L. Pachowsky, Markus Eckstein, S. Alivernini, A. Zoli, G. Krönke, S. Uderhardt, A. Bozec, Maria-Antonietta D’Agostino, G. Schett, Ricardo Grieshaber-Bouyer
          </td>
          <td>2024-04-26</td>
          <td>Nature Medicine</td>
          <td>95</td>
          <td>47</td>

            <td><a href='../recommendations/8f2918cad295af222dcbefbcbfa7b2c18903efa6' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Background Mesenchymal stromal cell derived extracellular vesicles (MSC-EVs) are a promising therapeutic for neuroinflammation. MSC-EVs can interact with microglia, the resident immune cells of the brain, to exert their immunomodulatory effects. In response to inflammatory cues, such as cytokines, microglia undergo phenotypic changes indicative of their function e.g. morphology and secretion. However, these changes in response to MSC-EVs are not well understood. Additionally, no disease-relevant screening tools to assess MSC-EV bioactivity exist, which has further impeded clinical translation. Here, we developed a quantitative, high throughput morphological profiling approach to assess the response of microglia to neuroinflammation-relevant signals and whether this morphological response can be used to indicate the bioactivity of MSC-EVs. Results Using an immortalized human microglia cell-line, we observed increased size (perimeter, major axis length) and complexity (form factor) upon stimulation with interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Upon treatment with MSC-EVs, the overall morphological score (determined using principal component analysis) shifted towards the unstimulated morphology, indicating that MSC-EVs are bioactive and modulate microglia. The morphological effects of MSC-EVs in TNF-γ/IFN-α stimulated cells were concomitant with reduced secretion of 14 chemokines/cytokines (e.g. CXCL6, CXCL9) and increased secretion of 12 chemokines/cytokines (e.g. CXCL8, CXCL10). Proteomic analysis of cell lysates revealed significant increases in 192 proteins (e.g. HIBADH, MEAK7, LAMC1) and decreases in 257 proteins (e.g. PTEN, TOM1, MFF) with MSC-EV treatment. Of note, many of these proteins are involved in regulation of cell morphology and migration. Gene Set Variation Analysis revealed upregulation of pathways associated with immune response, such as regulation of cytokine production, immune cell infiltration (e.g. T cells, NK cells) and morphological changes (e.g. Semaphorin, RHO/Rac signaling). Additionally, changes in microglia mitochondrial morphology were measured suggesting that MSC-EV modulate mitochondrial metabolism. Conclusion This study comprehensively demonstrates the effects of MSC-EVs on human microglial morphology, cytokine secretion, cellular proteome, and mitochondrial content. Our high-throughput, rapid, low-cost morphological approach enables screening of MSC-EV batches and manufacturing conditions to enhance EV function and mitigate EV functional heterogeneity in a disease relevant manner. This approach is highly generalizable and can be further adapted and refined based on selection of the disease-relevant signal, target cell, and therapeutic product.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e655e5284ada5880ec741fd1452f6a9e088a59" target='_blank'>
                Microglia Morphological Response to Mesenchymal Stromal Cell Extracellular Vesicles Demonstrates EV Therapeutic Potential for Modulating Neuroinflammation
                </a>
              </td>
          <td>
            K. R. Daga, A. M. Larey, Maria G. Morfin, Kailin Chen, Sara Bitarafan, Jana Carpenter, Hannah M. Hynds, Kelly M. Hines, Levi B. Wood, Ross A. Marklein
          </td>
          <td>2024-07-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>

            <td><a href='../recommendations/a1e655e5284ada5880ec741fd1452f6a9e088a59' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e665b02560db74abd44a14d0e0ad225c2a41b63b" target='_blank'>
                Myeloid progenitor dysregulation fuels immunosuppressive macrophages in tumors
                </a>
              </td>
          <td>
            Samarth Hegde, Bruno Giotti, Brian Y. Soong, Laszlo Halasz, J. Berichel, Assaf Magen, Benoit Kloeckner, Raphaël Mattiuz, Matthew D. Park, Adam Marks, Meriem Belabed, Pauline Hamon, Theodore Chin, Leanna Troncoso, Juliana J Lee, Dughan Ahimovic, Michael J. Bale, Grace Chung, D. D’souza, K. Angeliadis, T. Dawson, S. Kim-Schulze, R.M. Flores, Andrew J. Kaufman, Florent Ginhoux, S. Josefowicz, Sai Ma, A. Tsankov, T. Marron, Brian D. Brown, M. Merad
          </td>
          <td>2024-06-28</td>
          <td>bioRxiv</td>
          <td>4</td>
          <td>135</td>

            <td><a href='../recommendations/e665b02560db74abd44a14d0e0ad225c2a41b63b' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d3c93b16e6c2ea8684026f637118f57acb1b437f" target='_blank'>
                Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection
                </a>
              </td>
          <td>
            H. Ichise, Emily Speranza, Federica La Russa, T. Veres, Colin J. Chu, Anita Gola, Ronald N. Germain
          </td>
          <td>2024-07-07</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>11</td>

            <td><a href='../recommendations/d3c93b16e6c2ea8684026f637118f57acb1b437f' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

        <tr id="Gastrointestinal (GI) B cells and plasma cells (PCs) are critical to mucosal homeostasis and the host response to HIV-1 infection. Here, high resolution mapping of human B cells and PCs sampled from the colon and ileum during both viremic and suppressed HIV-1 infection identified a reduction in germinal center (GC) B cells and follicular dendritic cells (FDCs) during HIV-1 viremia. IgA+ PCs are the major cellular output of intestinal GCs and were significantly reduced during viremic HIV-1 infection. PC-associated transcriptional perturbations, including type I interferon signaling, persisted in antiretroviral therapy (ART)-treated individuals, suggesting ongoing disruption of the intestinal immune milieu during ART. GI humoral immune perturbations were associated with changes in the intestinal microbiome composition and systemic inflammation. These findings highlight a key immune defect in the GI mucosa due to HIV-1 viremia. One Sentence Summary Intestinal germinal center B cell reduction in HIV-1 infection linked to reduced IgA+ plasma cells and systemic inflammation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2ab6d82fe97aac3e9bb88e1a47a346848d1ab7ff" target='_blank'>
                Gastrointestinal germinal center B cell depletion and reduction in IgA+ plasma cells in HIV-1 infection
                </a>
              </td>
          <td>
            F. Cossarini, J. Shang, A. Krek, Z. Al-taie, Ruixue Hou, Pablo Canales-Herrerias, M. Tokuyama, M. Tankelevich, Adam Tillowiz, D. Jha, A. Livanos, L. Leyre, M. Uzzan, G. Martínez-Delgado, Matthew Tylor, Keshav Sharma, A. Bourgonje, Michael Cruz, G. Ioannou, T. Dawson, D. D’souza, S. Kim-Schulze, Ahmed Akm, Judith A. Aberg, Benjamin K. Chen, Sacha Gnjatic, A. Polydorides, Andrea Cerutti, C. Argmann, I. Vujkovic-Cvijin, M. Suarez-Farinas, F. Petralia, J. Faith, S. Mehandru
          </td>
          <td>2024-05-20</td>
          <td>bioRxiv</td>
          <td>3</td>
          <td>52</td>

            <td><a href='../recommendations/fc131532914bbcb165dc44342891066be53f33b0' target='_blank'>
              <i class="material-icons">open_in_new</i></a>
            </td>

        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/ Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
          <th>View recommendations</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

  <div data-intro='Recommended articles extracted by contrasting
                  articles that are relevant against not relevant for Immunology'>
    <p>
    <h3 id="recommended_articles">Recommended articles on <i>Immunology</i></h3>
    <table id="table2" class="display" style="width:100%">
    <thead>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </thead>
    <tbody>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/046a4759f61fd2ed00479ddd2426526fb3c7aa64" target='_blank'>
              Myeloid reprogramming by poly(I:C) recruits progenitor-exhausted CD8+ T cells and sensitizes rhabdoid tumors to PD-1 blockade
              </a>
            </td>
          <td>
            Valeria Manriquez, Sofia Cavada-Silva, Kévin Beccaria, L. L. Niborski, Amaury Leruste, W. Richer, Mathias Vandenbogaert, Zhi-Yan Han, C. Sedlik, Jordan Denizeau, Jeremy Mesple, Zoé Fusilier, L. Laëtitia Lesage, Jérémie Goldstein, Yohan Gerber-Ferder, Stéphanie Fitte-Duval, Federico Marziali, R. Mena-Osuna, Jimena Tosello-Boari, Rachida Bouarich-Bourimi, Maria Florencia Pacini, Y. Missolo-Koussou, Mylène Bohec, Sylvain Baulande, Philippe Benaroch, J. Helft, Hélène D Moreau, J. Waterfall, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="ABSTRACT Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. HPV-negative HNSCC, arising in diverse upper airway mucosal niches, is particularly aggressive, with poor 5-y survival and a limited response to immune checkpoint inhibitors. A deeper understanding of the tumor-localized immune landscape is essential to uncover actionable immunotherapeutic targets. Here, we integrated two single-cell RNA sequencing (scRNA-seq) datasets from 29 samples totaling nearly 300,000 immune cells to dissect immune rewiring during tumor progression and lymph node metastasis in HPV-negative HNSCC. We identified distinct shifts in adaptive immune cell populations across 14 peripheral blood mononuclear cell (PBMC) and 21 tumor-infiltrating immune cell (TIC) states. Notably, TICs exhibited enriched interferon response and immunomodulatory gene signatures, in contrast to PBMCs, indicating tumor-specific immune imprinting. Ligand–receptor analysis revealed that immunosuppressive crosstalk between macrophages and cytotoxic cells was associated with advanced disease. To spatially validate these transcriptional states, we conducted multiplexed immunofluorescence profiling on nine locally invasive HPV-negative HNSCCs, all from the ventrolateral tongue mucosa. Spatial proteomics confirmed peritumoral enrichment of activated (CD107a+, ICOS+) NK and CD8+ T cells and intratumoral accumulation of exhausted (PD-1+, PD-L1+) phenotypes, mirroring pseudotime trajectories inferred from scRNA-seq. These findings highlight spatially localized cytotoxic cell exhaustion as a key immune evasion mechanism in HPV-negative HNSCC and underscore the value of integrating spatial and single-cell data to reveal therapeutic vulnerabilities.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e184d6ff5ae8303f9ef6f76673a4a076479b44fb" target='_blank'>
              Single-cell landscape of peripheral and tumor-infiltrating immune cells in HPV-negative HNSCC
              </a>
            </td>
          <td>
            Rômulo Gonçalves Agostinho Galvani, Adolfo Alexis Rojas Hidalgo, Carlos Alberto Biagi-Junior, B. Matuck, Jelte Martinus Maria Krol, Brittany T. Rupp, Nikhil V. Kumar, Khoa L. A. Huynh, Jinze Liu, Siddharth Sheth, Vinicius Maracaja-Coutinho, K. Byrd, Patricia Severino
          </td>
          <td>2025-12-30</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e10756da93e249564dafc2b41fce10c7b1ebac2e" target='_blank'>
              Dual PD-L1/TIGIT blockade induces PNAd⁺ HEV-like vessels and CD62L⁺ lymphocyte recruitment, driving rhabdoid tumor rejection
              </a>
            </td>
          <td>
            Stéphanie Fitte-Duval, Sofia Cavada Silva, R. Mena-Osuna, Owen Hoare, L. L. Niborski, Jordan Denizeau, Laëtitia Lesage, W. Richer, C. Sedlik, Kévin Beccaria, Maëva Veyssière, Rachida Bouarich-Bourimi, Jérémie Goldstein, Federico Marziali, Jimena Tosello Boari, J. Masliah-Planchon, Zhi-Yan Han, Dario Rocha, Mylène Bohec, Sylvain Baulande, J. Waterfall, Valeria Manriquez, Franck Bourdeaut, Eliane Piaggio
          </td>
          <td>2025-12-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4⁺ T-cells, and CD8⁺ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads. Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS–ICOSL pathway, and are enriched for ICOS⁺ Th1-like CD4⁺ T cells and ICOSLhigh cDC1s. CD8⁺ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon-γ–responsive program that sustains CD8⁺ T-cell function and prevents dysfunction. Functionally, ICOSL⁺ cDC1s are required for tumor eradication in vivo. In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6a060eabfcbbb0a36b483e2912054f711b0272" target='_blank'>
              Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint Blockade
              </a>
            </td>
          <td>
            Mehdi Chaib, M. Aminu, Shelley M Herbrich, Mahshid Arabi, Yue Xuan, Akshay V. Basi, Anna Casasent, Marc D. Macaluso, Kenneth H. Hu, Matthew M. Gubin, Xi Chen, James J. Mancuso, Sreyashi Basu, Sonali Jindal, Jared K. Burks, S. Watowich, Jia Wu, James P. Allison, Padmanee Sharma
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>58</td>
        </tr>

        <tr id="Tumor-specific CD8+ T lymphocytes play a critical role in anticancer immunity but frequently become dysfunctional and exhausted within the immunosuppressive tumor microenvironment. Although immune checkpoint inhibitors can restore T-cell activity, resistance to these treatments remains a significant challenge. Therefore, understanding the transcriptional and regulatory mechanisms underlying CD8+ T-cell exhaustion is crucial for the development of effective therapies. We developed two murine models of acquired immune checkpoint inhibitor resistance through prolonged anti-PD1 treatment. To gain insight into CD8+ T-cell exhaustion, we performed single-cell multiomics analysis, including both scRNA-seq and scATAC-seq, to capture gene expression profiles and chromatin accessibility. Moreover, we collected three external datasets to validate the results in silico. We further assessed the therapeutic potential of Runx2 through marker expression and cytotoxicity assays. Our single-cell analysis revealed distinct T-cell subsets, including early and terminally exhausted populations, along with their exhaustion trajectories. Runx2 was identified as a key transcription factor associated with CD8+ T-cell exhaustion in both models and correlated with immunotherapy response in clinical data. Additionally, functional marker expression and cytotoxicity assays demonstrated that inhibiting Runx2 improved CD8+ T-cell cytotoxicity. These findings highlight the role of Runx2 as a crucial regulator of CD8+ T-cell exhaustion in the context of prolonged immune checkpoint inhibitor treatment. Targeting Runx2 may provide a novel strategy to overcome immune checkpoint inhibitor resistance and enhance therapeutic efficacy, offering promising avenues for combination therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4efed637bde0b584b5806d223ee2a3f6b51d5e91" target='_blank'>
              Transcriptional dynamics of CD8+ T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution
              </a>
            </td>
          <td>
            Tzu-Yang Tseng, Ching-Hung Hsieh, Hsuan-Cheng Huang, Yu-Ching Wu, Chiun Hsu, Chia-Lang Hsu, D. Ou, Hsueh‐Fen Juan
          </td>
          <td>2025-12-01</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>44</td>
        </tr>

        <tr id="ABSTRACT Long-term non-progressors (LTNPs) represent a valuable model to investigate immunological features associated with non-progression in chronic HIV infection. In this study, single-cell RNA sequencing was performed on peripheral blood mononuclear cells obtained from 12 individuals, including 4 LTNPs, 4 typical progressors (TPs), and 4 healthy donors (HDs). Compared with TPs, LTNPs exhibited a higher percentage of naive T cells, whereas TPs showed a higher percentage of CD8+ Effector-GNLY cells. LTNPs also exhibited lower gene-expression scores related to T-cell activation, cytotoxicity, inflammation, and interferon-alpha response across multiple effector-state T-cell subsets. GO enrichment analysis showed that compared with HDs and TPs, LTNPs exhibited downregulation of migration, translation, and antiviral response pathways in both CD4+ and CD8+ T cells, with upregulation of stress/inflammatory response and differentiation programs in CD4+ T cells and of immune differentiation/activation pathways in CD8+ T cells. High-dimensional weighted gene co-expression network analysis (hdWGCNA) further revealed higher module eigengene expression of innate and myeloid-related modules and lower expression of B-cell and cytotoxicity-related modules in LTNPs compared with TPs. Additionally, HIV-1 RNA+ cells were detected more frequently in TPs than in LTNPs and predominantly identified within CD4+ T cells. Together, these findings reveal a transcriptionally balanced and favorable immunological profile associated with non-progressive HIV infection and inform the design of immune-based strategies toward a functional HIV cure. IMPORTANCE Understanding molecular traits associated with natural control in LTNPs is critical for advancing HIV remission and cure strategies. Using single-cell RNA sequencing, we found that LTNPs had more naive T cells and fewer CD8+ effector-GNLY cells than typical progressors, along with lower activation, cytotoxicity, inflammation, and IFN-α scores across effector-state T-cell subsets. Differential expression and GO analyses showed predominant downregulation of migration, translation, and antiviral pathways, while preserving early activation markers. Co-expression network analysis revealed higher innate/immune-regulatory module activity and lower B-cell and cytotoxicity modules in LTNPs. HIV-1 RNA+ cells were detected less frequently in LTNPs and mainly detected in CD4+ T cells. These findings highlight balanced immune programs in LTNPs, which may inform strategies toward a functional HIV cure. Understanding molecular traits associated with natural control in LTNPs is critical for advancing HIV remission and cure strategies. Using single-cell RNA sequencing, we found that LTNPs had more naive T cells and fewer CD8+ effector-GNLY cells than typical progressors, along with lower activation, cytotoxicity, inflammation, and IFN-α scores across effector-state T-cell subsets. Differential expression and GO analyses showed predominant downregulation of migration, translation, and antiviral pathways, while preserving early activation markers. Co-expression network analysis revealed higher innate/immune-regulatory module activity and lower B-cell and cytotoxicity modules in LTNPs. HIV-1 RNA+ cells were detected less frequently in LTNPs and mainly detected in CD4+ T cells. These findings highlight balanced immune programs in LTNPs, which may inform strategies toward a functional HIV cure.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a6171a97ed7fcf5c1b6659f49943539558df22b4" target='_blank'>
              Single-cell transcriptome profiling reveals immunological fitness of HIV long-term non-progressors
              </a>
            </td>
          <td>
            Minjuan Shi, Rongfeng Chen, Tongjin Wu, Yu Liao, Tongxue Qin, Ziyu Wen, Junqi Liu, Xiu Chen, Beibei Lu, Chunxing Yi, Li Ye, Hao Liang, Caijun Sun, Junjun Jiang
          </td>
          <td>2025-11-24</td>
          <td>Journal of Virology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1342f808c2fd345588c30c0266370e6a04636995" target='_blank'>
              RIG-I RNA agonist activates immunostimulatory macrophages to enhance checkpoint immunotherapy for glioblastoma
              </a>
            </td>
          <td>
            Han Xu, Sungwoon Lee, Felipe Leser, Olga Fedorova, Peiwen Lu, Eric Song, Mehdi Touat, Anne Eichmann, Akiko Iwasaki, A. Pyle, Jean-Leon Thomas
          </td>
          <td>2026-01-08</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8+ T cell responses. Constitutive Tmem33-/- mice exhibited delayed melanoma tumor growth and increased CD8+ T cell infiltration. Antigen-specific CD8+ compartments in tumors of Tmem33-/- mice showed TCF-1+PD-1+ progenitor-exhausted cell (Tpex) enrichment, elevated effector function and reduced exhaustion, alongside improved effector memory expansion and T-bet expression in draining lymph nodes. We highlight that TMEM33 functions intrinsically within the T cell compartment, as TMEM33 deletion (1) enhanced polyclonal activation of naive CD8+ T cells ex vivo, (2) promoted preferential Tpex accumulation among adoptively transferred naive OT-I cells in B16F10-OVA tumors and draining lymph nodes, and (3) improved the potency of ex vivo-expanded OT-I cells in controlling tumor growth during adoptive cell therapy. Finally, in a large, prospectively recruited metastatic melanoma cohort, lower TMEM33 expression in patient CD8+ T cells significantly correlated with improved survival and elevated TCF-7 (encoding TCF-1). Collectively, our findings define TMEM33 as a formerly unrecognized intrinsic determinant of tumor-directed CD8+ T cell fate that limits Tpex maintenance, and restrains cell therapy responses, suggesting that its modulation may strengthen immunotherapeutic efficacy. One sentence summary TMEM33 intrinsically limits progenitor exhausted CD8+ T cells, scales anti-tumor responses and predicts melanoma patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b5c85fa3ccdffaf374a3f09dd7d217b43c30d4c" target='_blank'>
              TMEM33 deletion potentiates anti-tumor CD8 + T cell immunity
              </a>
            </td>
          <td>
            Matthew T Jackson, Tianming Zhao, G. Milotay, I. Pedroza-Pacheco, Yanshu Cai, Claire Willis, S. Phyu, Bruno Beernaert, Jamie TW Kwon, Hala Estephan, Vinnycius Pereira Almeida, Maria Aggelakopoulou, Silvia Panetti, Christian Zierhut, Tim Elliott, Eleni Adamopoulou, J. Rehwinkel, Malcolm JW Sim, Amit Grover, Dmitry I. Gabrilovich, Benjamin P. Fairfax, E. Honoré, D. Withers, John C. Christianson, Eileen E. Parkes
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c11565e00df96d730b6130fa5ba4b31516b47635" target='_blank'>
              PI3Kδ promotes T cell effector differentiation and plasticity during chronic infection
              </a>
            </td>
          <td>
            Andrea C. Pichler, J. Cannons, Dominic P. Golec, Julie M. Reilley, Dan Corral, Eduard Ansaldo, Qin Xu, Subrata Paul, Paul Schaughency, Francisco A. Otaizo-Carrasquero, Stacie M. Anderson, Anshu Deewan, Dorian B. McGavern, Pamela L. Schwartzberg
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="ABSTRACT The cancer-immunity cycle is regulated by a series of stimulatory and inhibitory factors. The stimulator of interferon genes (STING) pathway, a key stimulator of type I interferon production, connects innate and adaptive immunity to promote antitumor responses. Using a syngeneic pancreatic tumor model, we characterized the single-cell landscape changes induced by STING stimulation. Our findings revealed that STING agonist treatment reprograms transcription across multiple cell lineages, enhances innate immune responses and activates lymphocytes, thereby promoting antitumor effects. Single-cell transcriptome sequencing identified significant increases in monocytes, neutrophils, macrophages, and CD8 T cells, indicating augmented tumor inflammation. Differential gene expression analysis highlighted upregulated genes related to immune cell effector mechanisms and antigen presentation. Functional assays confirmed the enhanced tumor killing effects induced by STING activation. These results underscore the potential of STING agonists in reprogramming the tumor microenvironment to potentiate antitumor immunity, although clinical translation remains challenging owing to pharmacokinetic limitations and potential systemic toxicity. Further research is needed to optimize STING agonist delivery and dosage for effective cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/dbc5d5398d9317cc8645ea9323e07cb973e30cab" target='_blank'>
              cGAS-STING signaling in the tumor microenvironment induces myeloid cell activation and favors T cell-mediated antitumor immunity
              </a>
            </td>
          <td>
            Meiqi Ren, Zhichao Eric Ai, Yan Zhang, Linghong Shi, Yafei Liu, Haixia Liu, Hong C. Shen, Xiangyu Yao, Zhipeng Yan
          </td>
          <td>2025-11-30</td>
          <td>Cancer Biology & Therapy</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5d6aac86da3cbb3bd85a8ebe57c0ff220d334a71" target='_blank'>
              Circulating immune profiling reveals impaired monocyte states and trajectories driving immunosuppression in glioblastoma
              </a>
            </td>
          <td>
            A. Scafidi, T. Kaoma, Claudia Cerella, Eleonora Campus, K. Grzyb, Bakhtiyor Nosirov, Frida Lind-Holm Mogensen, E. Klein, Raul Da Costa, A. Skupin, Frank Hertel, G. Berchem, Michel Mittelbronn, A. Cosma, Beatrice Melin, Simone P. Niclou, Petr V Nazarov, A. Gołȩbiewska, Aurélie Poli, A. Michelucci
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e088dcd4f395d6c7df482c6c35fcef0137dc41" target='_blank'>
              An epigenetic switch in vascular phenotype augments anti-tumor immunity
              </a>
            </td>
          <td>
            Dae Joong Kim, Mitchell T McGinty, S. Anandh, C. Riedstra, Yuvraj Sethi, Melanie R. Rutkowski, A. C. Dudley
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/275812dc3294ac678dbefad1e9f5e6d112d20c5e" target='_blank'>
              SP140 limits type I interferon–driven pathology, preserving T cell motility and promoting resistance in tuberculosis
              </a>
            </td>
          <td>
            Maxime Caouaille, Léa Fromont, Tomoyo Shinkawa, Marion Faucher, Aizat Iman Abdul Hamid, Serge Mazères, Yaël Duvergé, Yohan Lorreyte, Emmanuelle Näser, S. Behar, Emma Lefrançais, O. Neyrolles, Denis Hudrisier
          </td>
          <td>2025-12-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>64</td>
        </tr>

        <tr id="Dogs play a major role in sustaining transmission of Leishmania infantum to people, thus prevention and treatment of canine leishmaniosis (CanL) to reduce transmission represents an unmet public health need. Although advances have been made in understanding how immunopathology correlates to infectiousness as CanL progresses, the immune mechanisms underlying transition between disease stages and terminal decline remain ill-defined. To address this knowledge gap, we generated a comprehensive atlas of peripheral immune cells from control dogs and naturally-infected dogs using single-cell RNA sequencing. The LeishDog Atlas captures the cellular and transcriptional complexity underlying CanL, tracing shifts in immune composition and gene expression across progressive, well-defined disease stages. Notably, we identified distinct myeloid, CD4+ and CD8+ T cell phenotypes and transcriptional states associated with disease progression. This resource provides a valuable framework for understanding systemic immune dysregulation in CanL, including determinants of T cell exhaustion and myeloid cell activation, and establishes a foundation for comparative, translational, and mechanistic studies of CanL immunopathology and transmissibility.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8412687f28e64e4d6b2558529c494e2ee4440eca" target='_blank'>
              A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis
              </a>
            </td>
          <td>
            Danielle P. Uhl, Daniel J. Holbrook, Max C Waugh, S. Dey, Najmeeyah Brown, Karen I. Cyndari, Jacob J. Oleson, Paul M. Kaye, Christine A. Petersen
          </td>
          <td>2025-12-21</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0a82efc5b2c9cc4922bf6d2b205d9310648f4f84" target='_blank'>
              Single-cell multiomics reveals epigenetic rewiring of splenic memory B cells in murine malaria reinfection
              </a>
            </td>
          <td>
            Montserrat Coronado, Á. Vincelle-Nieto, Isabel G. Azcárate, S. Pérez-Benavente, A. Puyet, Amalia Díez, José M. Bautista, A. Reyes-Palomares
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>25</td>
        </tr>

        <tr id="Severe fever with thrombocytopenia syndrome virus (SFTSV) infection is associated with poor clinical outcomes and defective humoral immunity yet the immunometabolic mechanisms underlying B cell dysfunction remain incompletely defined. Through integrated single‐cell RNA sequencing and B cell receptor (BCR) repertoire profiling of peripheral B cells from SFTS patients, we dissected the molecular signatures between survivors and fatal cases. Functional validation and metabolic flux analysis were further performed. Seven transcriptionally distinct B cell subsets were identified. Fatal cases exhibited a marked expansion of CXCR3+Ki‐67+CXCR5‐ extrafollicular plasmablasts, coupled with depletion of naïve and memory B cells. These plasmablasts exhibited hyperactivation of interferon‐response genes (IFI27, ISG15), upregulation of inflammatory mediators (S100A8/A9), and contraction of BCR diversity, with skewed usage of λ‐light chains. Pseudotime trajectory analysis and metabolic scoring revealed progressive upregulation of oxidative phosphorylation, glycolysis and endoplasmic reticulum stress during terminal differentiation. In fatal cases, B cells exhibited suppressed antigen presentation capacity and impaired immunoglobulin gene expression, alongside heightened oxidative stress and elevated CD39 levels. Furthermore, analysis of SFTSV‐infected versus uninfected B cells revealed that infected plasmablasts displayed enhanced inflammatory and migratory features, including upregulated CXCR3 and CCR10 expression, suggesting direct viral modulation of B cell function and trafficking. Our study reveals that dysfunctional, metabolically reprogrammed plasmablasts underlie humoral immune failure in fatal SFTS. These findings provide mechanistic insight into B cell‐mediated immunopathogenesis and highlight potential targets for prognostic evaluation and immunomodulatory intervention.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3800a9aa69e7fadce2b5246f5ad88f00ce2eb14b" target='_blank'>
              Dysregulated B Cell Responses in Severe Fever With Thrombocytopenia Syndrome Revealed by Single‐Cell RNA Sequencing
              </a>
            </td>
          <td>
            Hongyan Hou, Siyu Zou, Teding Chang, Yun Wang, Ting Wang, Wei Wei, Rujia Chen, Renren Ouyang, Hui Hu, Shiji Wu, Feng Wang
          </td>
          <td>2025-12-01</td>
          <td>Journal of Medical Virology</td>
          <td>1</td>
          <td>27</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/457d4de587553b09db9c04406c900e3b240f5c8f" target='_blank'>
              CD74 regulates antitumor immunity in melanoma by reprogramming dendritic cell immunogenicity and migration
              </a>
            </td>
          <td>
            Eleftheria Maranou, Gayoung Park, Pauline Weinzettl, Jonna Alanko, Otto I. Pulkkinen, Sarah E. Coupland, Marko Salmi, Carlos R. Figueiredo
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fab0829fa668d3f68087f51374ae0be2ba943151" target='_blank'>
              Perturbational single-cell profiling of patient tumors defines lineage- and context-specific programs of innate immune resistance
              </a>
            </td>
          <td>
            C. Perry, A. Frey, Y. Fei, J. Wang, P. Costa, H. N. Amin, S. Ghadermarzi, D. Levine, W. Tong, A. Koda, M. Mackie, M. He, Y. Nie, K. Clulo, F. Ouerghi, J. Wei, T. Cordero Dumit, M. Yaskolko, M. Ding, A. Caldera, O. Kyrysyuk, L. Lum, J. W. Allen, W. Guo, A. Naqash, A. Elliot, A. Vanderwalde, M. Capelletti, T. Adeyelu, S. Barry, M. Hugaboom, A. Bacchiocchi, H. Kluger, M. Bosenberg, A. Iwasaki, D. Braun, J. Clune, D. van Dijk, K. Olino, J. Ishizuka
          </td>
          <td>2025-12-12</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/674509938f9c563edb49d12a46467f6b4538fa2f" target='_blank'>
              Single-Cell Dissection of Immunometabolic Rewiring in the Porcine Ileum during Salmonella Typhimurium Infection
              </a>
            </td>
          <td>
            José M. Suárez-Cárdenas, Tomàs Montserrat-Ayuso, Mónica Alfonso-Núñez, A. Esteve-Codina, Raúl Fernández-Rodríguez, Antonio Romero-Guillén, Tránsito García-García, Cristina Arce, Amparo Martínez Martínez, Juan J. Garrido, S. Zaldívar-López
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0f2da4d4f0c7553db626f5b050820f95d44bcc37" target='_blank'>
              Single-cell multi-omic landscape reveals anatomical-specific immune features in adult and pediatric sepsis
              </a>
            </td>
          <td>
            Qian Ye, Xiaofei Lai, Yuliang Liu, Zhengtao Zhang, Yueqiang Fu, Jie Luo, Chengjun Liu, Jun Duan, Hao Ding, Yuhan Liu, Zhi Ao, Yang Tao, Shanmu Ai, Wei Huang, Lei Jiang, Yi Liu, Fang Xu, Ju Cao
          </td>
          <td>2025-12-03</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Type 2 diabetes mellitus (T2DM) worsens stroke outcomes, but the underlying mechanisms linking T2DM to systemic immune dysfunction remain unclear. We investigated whether T2DM alters bone marrow (BM) hematopoiesis and dysregulate immune signaling following ischemic stroke in mice. Single-cell RNA sequencing, GeoMx digital spatial profiling (DSP), nCounter, and flow cytometry were used to analyze BM cells from control (db/+, Ctrl) and diabetic (db/db, T2DM) mice underwent experimental stroke or sham surgery. Diabetes caused marked structural remodeling of BM, with reduced cellularity and imbalance of hematopoietic lineages. Pseudotime trajectory analysis revealed impaired differentiation and maturation signatures of hematopoietic progenitor cells (HPC1) and granulocytes, and overactivation toward monocytes in diabetes after stroke. CellChat analysis demonstrated reorganization of intercellular communication, with hematopoietic progenitor cells (HPC1) and monocytes emerging as dominant signaling hubs through upregulated MIF, SIRP, and THBS pathways. AUCell enrichment indicated increased glycolysis and oxidative phosphorylation but reduced interferon-γ (IFN-γ) signaling, reflecting metabolic activation coupled with immune dysregulation. DSP and nCounter further confirmed upregulation of genes in the MIF, SIRP and THBS pathways in CD115⁺ monocytes and Ly6G⁺ neutrophils, indicating proinflammatory and migratory activation in diabetic bone marrow. Our data suggest that T2DM reprograms hematopoiesis and signaling networks, leading to maladaptive myeloid responses and impaired immune regulation after stroke. This maladaptive BM environment amplifies inflammation and limits repair, linking diabetic metabolic stress to worsened ischemic outcomes. Targeting bone marrow immune dysfunction may offer a therapeutic strategy to improve stroke recovery in diabetic patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ab79f630ee108b9ad79cdd23cb73d99a2673e4d" target='_blank'>
              Type 2 diabetes Reprograms Bone Marrow Hematopoiesis and Dysregulates Immune Signaling in Response to Stroke
              </a>
            </td>
          <td>
            Hongxia Zhang, Wanjun Gu, Kailin Yu, Chia-Ling Tu, Wenhan Chang, Jialing Liu
          </td>
          <td>2025-12-30</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9e77e33cbcc04a9a109c08426224fcfb14cc985" target='_blank'>
              Hallmarks of adaptive immunity in a metastatic clear cell renal cell carcinoma (ccRCC) long-term elite survivor
              </a>
            </td>
          <td>
            Felicia Tucci, Edward Drydale, James Bancroft, Sakina Amin, Jane Pernes, Giulia Gardumi, Tinashe Kanyowa, Maria Lima, Nadia Nasreddin, Olivia Lombardi, Simon J. Leedham, A. Rendek, Lisa Browning, Emmanuel Bugarin Estrada, Ruddy Montandon, Santiago Revale, H. Slawinski, David Mole, Andy Protheroe, Shivan Sivakumar, R. Bashford-Rogers
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Hematopoietic bone marrow progenitors are increasingly implicated as an origin of immunosuppression in cancer. We have previously shown that trained immunity induction using nanomedicine potentiates checkpoint blockade therapy. Here, we studied how this approach’s induction of trained immunity systemically overcomes the immunosuppressive tumor microenvironment. We found changes in the tumor microenvironment to mirror functional changes in the hematopoietic system in a melanoma mouse model. Single cell sequencing methods disclosed a shift in the tumor-associated macrophage population from immunosuppressive to antitumorigenic. Uniquely, a trained immunity and checkpoint blockade combination therapy mobilized natural killer cells which, in conjunction with the functional changes in the myeloid cell compartment, effectively activated T cells. Last, we established the effectiveness of our approach in mouse models of breast, lung, and pancreatic cancer. Collectively, our data show that the systemic induction of trained immunity rebalances the immune system for effective checkpoint blockade therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/779280ac3e11ac6a4d5d5956af8561bae6f79622" target='_blank'>
              Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment
              </a>
            </td>
          <td>
            Bram Priem, Lisa Willemsen, Tom Anbergen, Yuri van Elsas, Jeroen Deckers, David P. Schrijver, Stijn R. J. Hofstraat, Iris V. Messing, J. Munitz, Dionne Honing, Geoffrey Prévot, Yohana C. Toner, Judit Morla, William Wang, A. Ranzenigo, Isabella Sirchia, T. Post, Raphaël Duivenvoorden, E. Kluza, G. Cremers, J. Kreijtz, C. Pérez-Medina, M. V. van Leent, Abraham J. P. Teunissen, Roy van der Meel, Yi Zhou, C. Glass, J. Ochando, L. A. Joosten, Z. Fayad, R. Netea-Maier, M. Netea, M. D. de Winther, Thijs J. Beldman, A. Griffioen, Willem J. M. Mulder
          </td>
          <td>2026-01-01</td>
          <td>Science Advances</td>
          <td>0</td>
          <td>125</td>
        </tr>

        <tr id="Myelodysplastic syndrome (MDS) is characterized by bone marrow failure, clonal evolution and leukemic progression, but the pathophysiologic processes driving these events remain incompletely understood. Here, by establishing a comprehensive single-cell transcriptional taxonomy of human MDS, we reveal that inflammatory remodeling of bone marrow stromal niches is a common early feature, irrespective of the genetic driver landscape. We identify an activated CD8-T-cell subset as a source of stromal inflammation via TNF-receptor signaling, which prompts the inflammatory rewiring and loss of repopulating ability of residual normal hematopoietic stem/progenitor cells (HSPC). Mutant HSPCs display relative resistance to this inflammatory stress and reside predominantly in a transcriptional ‘high output’ state, providing a biological framework to their competitive advantage in an inflammatory microenvironment. Consistent with this, stromal inflammation associates with leukemic progression and reduced survival. Our data thus support a model of immune-stromal inflammatory signaling driving tissue failure and clonal evolution in the hematopoietic system. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, we provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human MDS. Mechanisms of clonal evolution in myeloid neoplasms remain incompletely understood. Darwinian theory predicts that the (micro)environment of clone-propagating stem cells may contribute to clonal selection. Here, authors provide data fitting this model, establishing a relationship between stromal niche inflammation, inflammatory stress in HSPCs, clonal resistance and leukemic evolution in human myelodysplastic syndrome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7d21dc014f548d4524dba3eed50e502490dcae8e" target='_blank'>
              An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome
              </a>
            </td>
          <td>
            Lanpeng Chen, Yujie Bian, Eline Pronk, Claire van Dijk, Tim V.D. van Tienhoven, R. Hoogenboezem, E. Bindels, Dennis Bosch, Sadaf Fazeli, A. D. de Graaf, Theresia M. Westers, M. Kholmatov, Judith B. Zaugg, Pedro L. Moura, Eva Hellström-Lindberg, A. A. van de Loosdrecht, J. Jansen, M. Sanders, M. H. Raaijmakers
          </td>
          <td>2025-11-18</td>
          <td>Nature Communications</td>
          <td>1</td>
          <td>48</td>
        </tr>

        <tr id="Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I⁻/MHC-II+), we can cure mice with a regimen that includes radiation therapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3⁺ T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4⁺ T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/77253e2042c64402b4c27c711448fdd4c49c02c6" target='_blank'>
              Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing
              </a>
            </td>
          <td>
            AK Erbe, Arika S. Feils, Anqi Gao, Sabrina N. VandenHeuvel, Simon Boyenga, Alina A. Hampton, M. Heck, Jen Zaborek, Dan V. Spiegelman, N. Tsarovsky, A. Hoefges, A. Pieper, Peter M. Carlson, Mildred A. Felder, Ravi B Patel, S. Gillies, Alexa R. Heaton, Zachary S. Morris, Huy Q. Dinh, A. Rakhmilevich, Paul M. Sondel
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>1</td>
          <td>54</td>
        </tr>

        <tr id="Cancer immunotherapies, from checkpoint blockade to adoptive cell therapies like tumor-infiltrating lymphocytes (TILs), have revolutionized cancer treatment but are limited by variable efficacy and significant toxicities. A central challenge is identifying ideal T-cell populations that effectively eliminate tumors without causing off-target damage, a distinction not captured by existing biomarkers. We show that co-expression patterns of chemokine receptors (CRs) CXCR3, CCR5, and CXCR6 on CD8+ T cells provide a functional “code” defining subsets with divergent roles in on-target immunity versus off-target inflammation. In mouse and human melanoma, a triple-positive (CXCR3+CCR5+CXCR6+) T-cell subset is essential for tumor control, and its genetic signature correlates with positive clinical response, while a distinct CCR5+CXCR6+ subset drives liver immune-related adverse events (IRAEs). Crucially, this CR code reveals that immunotherapy actively reshapes T-cell trafficking patterns, uncovering profound heterogeneity within conventional populations and distinguishing potent anti-tumor progenitors from cells predisposed to exhaustion or off-target migration. This work establishes CR co-expression as a practical tool, providing a surface marker-based strategy to identify and enrich optimized T cells for adoptive therapies, thereby offering a framework to uncouple efficacy from toxicity. One Sentence Summary Co-expression of CCR5, CXCR6, and CXCR3 provides a functional ’code’ that separates T-cell-mediated anti-tumor efficacy from off-target toxicity, enabling the selection of superior cells for safer and more effective cancer immunotherapies. Graphical Abstract Highlights · CXCR6, CXCR3 and CCR5 co-expression signature stratifies patient survival in human melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 are critical effectors with high proliferative, cytotoxic, and activation profile in human and mice melanoma · CD8+ T cells co-expressing CXCR6, CXCR3 and CCR5 drive anti-tumoral responses during checkpoint blockade in both human and mice">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ffb2ffb5ffbc1f04ce6b70ec760612828941d302" target='_blank'>
              A Conserved Landscape of Chemokine Receptor Co-expression Defines the Functional States of CD8+ T Cells in Melanoma
              </a>
            </td>
          <td>
            Rodney Macedo, David W. Harle, Kevin Hoffer-Hawlik, X. Wang, Thomas McMahon-Skates, Alexandra Matschiner, Kirubel Belay, Yvonne M. Saenger, Benjamin Izar, Elham Azizi, Ran Reshef
          </td>
          <td>2025-12-16</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Current therapies for inflammatory bowel disease (IBD) often fail to achieve complete remission and are associated with systemic toxicity owing to their broad immunosuppressive effects. To overcome these limitations, we developed a bioengineered extracellular vesicle (EV) platform that modulates key immune signaling pathways to efficiently restore the T-cell balance in inflamed intestinal tissues. EVs derived from Wharton’s jelly mesenchymal stem cells were engineered to display PD-L1 on their surface and encapsulate miR-27a-3p. Surface PD-L1 engages the PD-1 checkpoint in activated T cells, attenuating T-cell receptor signaling via SHP2-mediated dephosphorylation of ZAP70 and AKT. In parallel, miR-27a-3p suppresses prohibitin 1 (PHB1), a mitochondrial regulator of Th17 cell bioenergetics and inflammatory function, thereby reducing Th17 polarization and increasing the number of FOXP3⁺ regulatory T cells. These dual-targeting EVs preferentially localized to inflamed intestinal tissues via chemokine (CCR2/CXCR4) and PD-1-dependent mechanisms. In humanized mouse models of colitis, these EVs attenuated mucosal inflammation, suppressed effector T-cell responses, and preserved epithelial integrity. In IBD patient-derived colonoid cultures, PD-L1/miR-27a-3p EVs maintained epithelial viability and barrier integrity without inducing cytotoxicity or structural disruption. Transcriptomic and single-cell analyses revealed the downregulation of inflammatory and exhaustion signatures, along with the enrichment of regulatory subsets. Collectively, this study presents a cell-free immunotherapeutic approach that reprograms T cells in inflamed tissues through the PD-1 and mitochondrial signaling pathways while maintaining intestinal epithelial integrity, offering a promising therapeutic strategy for IBD and other T cell-driven inflammatory disorders.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/21a759c51278c1cf53050a54d395a9872336d71e" target='_blank'>
              Engineered extracellular vesicles reprogram T cells by targeting PD-1 and PHB1 signaling in inflammatory bowel disease
              </a>
            </td>
          <td>
            Mi-Kyung Oh, Hyun Sung Park, Dong-Hoon Chae, Aaron Yu, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Byeonghwi Lim, Jun-Mo Kim, Jordan E. Axelrad, Kyung Ku Jang, Jong Pil Im, S. Koh, Byung-Soo Kim, Kyung-Rok Yu
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Most patients with hepatocellular carcinoma (HCC) develop resistance to immune checkpoint blockade (ICB) or STING agonists despite their immune-stimulating activities. Here, we identify increased intratumoral B-cell infiltration as a mediator of acquired resistance. In HCC models with liver fibrosis in male mice, anti-PD-1 ICB or the STING agonist BMS-986301 increase intratumoral B-cell infiltration, circulating IL-10, and TIM-1+ B-cells, promoting tertiary lymphoid structure formation. B-cell depletion combined with ICB or STING agonism improves survival, and STING agonism inhibits distant metastasis. In addition, co-targeting STING and TIM-1 enhances B-cell differentiation and antigen presentation, reduces intratumoral TIM-1+ B-cells, and increases CD86 and MHC class II expression, thereby augmenting CD8+ T-cell-mediated anti-tumor immunity. These findings reveal that B-cells contribute to ICB and STING therapy resistance in HCC, and that B-cell depletion or TIM-1 blockade can overcome acquired resistance to these immunotherapies. B cell subsets expanding during tumor progression have been associated with impaired anti-tumor responses and resistance to immunotherapy. Here the authors report that STING agonism or anti-PD-1 induce intratumoral B cell infiltration, and that depleting B-cells improves response to immunotherapies in preclinical models of hepatocellular carcinoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3aef0adfea1b3ee9cc082a0682a2dafd6789c8d9" target='_blank'>
              Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Xin Liu, Zelong Liu, Chengzhan Zhu, Tatsuya Kobayashi, Pin-Ji Lei, Yue Shi, Dandan Yuan, Jianguo Wang, Min Li, Aya Matsui, Kassiana Mafra, Tomofumi Ando, Ken Kojo, Rieke Schleinhege, Kento Miyazaki, Peigen Huang, Ming Kuang, Lloyd Bod, Dan G. Duda
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7f17946ac3dbb8efa92226c7ce4112035350abc3" target='_blank'>
              STAT1-Mediated Regulation of IL-17A/CEBPB/NF-κB Axis in HIV-1 Infected Human Cerebral Organoids Reveals Therapeutic Targets for Neuroprotection
              </a>
            </td>
          <td>
            Karthick Chennakesavan, Malaroviyam Samikkannu, Shreyan Gupta, Olasunkanmi Israel Tayo, Arpan Acharya, James J. Cai, S. Byrareddy, T. Samikkannu
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Glioblastoma (GBM) remains one of the most lethal brain tumors, characterized by extensive immune evasion and a macrophage-dominated tumor microenvironment (TME). However, the molecular determinants governing tumor-associated macrophage (TAM) states and their immunoregulatory functions remain poorly understood. We integrated bulk- and single-cell transcriptomic datasets (TCGA, CGGA, Ivy GAP, and Brain Immune Atlas) to systematically characterize the expression, prognostic relevance, and immune contexture of the myeloid biomarker membrane-spanning 4-domain A6A, MS4A6A, in GBM. Differential expression, survival, and pathway enrichment analyses were performed. Single-cell mapping and CellChat modeling delineated MS4A6A-associated TAM subpopulations, intercellular communication networks, and ligand–receptor signaling dynamics. Spatial transcriptomic validation and pharmacogenomic modeling were conducted to assess anatomic enrichment and therapeutic vulnerabilities. High MS4A6A expression predicted unfavorable survival and correlated with increased stromal and immune infiltration. Single-cell analyses localized MS4A6A predominantly to TAMs, especially Regulatory- and Ribo-TAM states enriched for antigen presentation, T-cell regulation, and ribosomal biogenesis pathways. CellChat analysis revealed that MS4A6A-high TAMs exhibited markedly enhanced communication with CD4+ T cells and Tregs through upregulated PGE2–PTGER2/PTGER4, PECAM1–CD38, and THBS1–CD36 signaling axes, implicating MS4A6A in prostaglandin-driven immune suppression. Spatial profiling confirmed preferential localization of MS4A6A within perivascular and angiogenic niches. Pharmacogenomic prediction indicated that MS4A6A-high tumors were more sensitive to ERK, mTOR, and CDK4/6 inhibition. MS4A6A defines a macrophage-centered, immunosuppressive ecosystem in GBM, mediated by the activation of the PGE2 signaling axis. These findings position MS4A6A both as a prognostic biomarker and as a potential therapeutic node linking myeloid reprogramming to actionable pathway vulnerabilities in glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2aace77685200c650b039b4e217d58ff78ecf5af" target='_blank'>
              The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis
              </a>
            </td>
          <td>
            Jianan Chen, Qiong Wu, Anders E. Berglund, Robert J. Macaulay, James J. Mulé, Arnold B. Etame
          </td>
          <td>2025-12-20</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f4859db7f189b6a6bbd72e6ca91f2b3fc441772" target='_blank'>
              Non-selective beta-blockers reduce bystander CD8+ T cell activation in decompensated liver cirrhosis
              </a>
            </td>
          <td>
            Ayesha Lietzau, Ines Tapken, So-Young Kim, Roni Souleiman, Erich Freyer, A. R. Kraft, Sarah S Schütte, T. Tergast, Benjamin Maasoumy, Heiner Wedemeyer, Isabell Drath, G. Zurek, Eui-Cheol Shin, Markus Cornberg, Christian Niehaus
          </td>
          <td>2025-11-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Reducing calorie intake through dietary restriction (DR) slows tumour growth in mammals, yet the underlying mechanisms are poorly defined. Here, we show that DR enhances anti-tumour immunity by optimizing CD8+ T cell function within the tumour microenvironment (TME). Using syngeneic xenograft tumour models, we found that DR induces a profound reprogramming of CD8+ T cell fate in the TME, favouring the expansion of effector T cell subsets with enhanced metabolic capacity and cytotoxic potential, while limiting the accumulation of terminally exhausted T cells. This metabolic reprogramming is driven by enhanced ketone body oxidation, particularly β-hydroxybutyrate (βOHB), which is elevated in both the circulation and tumour tissues of DR-fed mice. βOHB fuels T cell oxidative metabolism under DR, increasing mitochondrial membrane potential and tricarboxylic acid cycle-dependent pathways critical for T cell effector function, including acetyl-CoA production. By contrast, T cells deficient for ketone body oxidation exhibit reduced mitochondrial function, increased exhaustion and fail to control tumour growth under DR conditions. Importantly, DR synergizes with anti-PD1 immunotherapy, further augmenting anti-tumour T cell responses and limiting tumour progression. Our findings reveal that T cell metabolic reprogramming is central to the anti-tumour effects of DR, highlighting nutritional control of CD8+ T cell fate as a key driver of anti-tumour immunity. Dietary restriction promotes the expansion of effector T cells via ketone bodies, which enhances anti-tumour immunity and synergizes with immunotherapy in mice.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/319855c1ff8d38af76a937b591f2130f59f83394" target='_blank'>
              Dietary restriction reprograms CD8+ T cell fate to enhance anti-tumour immunity and immunotherapy responses
              </a>
            </td>
          <td>
            Brandon M Oswald, Lisa M. DeCamp, Joseph Longo, Michael S. Dahabieh, Nicholas Bunda, Benjamin K. Johnson, M. Watson, Shixin Ma, Samuel E. J. Preston, Ryan D. Sheldon, Michael P. Vincent, Abigail E. Ellis, Molly T. Soper-Hopper, Christine N. Isaguirre, Dahlya Kamarudin, Hui Shen, Kelsey S. Williams, Peter A. Crawford, S. Kaech, H. Jang, Evan C. Lien, Connie M. Krawczyk, Russell G. Jones
          </td>
          <td>2025-12-01</td>
          <td>Nature Metabolism</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Macrophages serve both as a first line of defense against invading pathogens and mediate tissue homeostasis. These cells are inherently responsive and heterogeneous and lie on a spectrum of activation states book-ended by M1-like (inflammatory) and M2-like (anti-inflammatory) extremes. The study of human macrophages is necessary to unravel the complex signals and environmental cues that these cells integrate to create their varied phenotypes. In vitro protocols to differentiate human monocytes into macrophages use many distinct activation stimuli at variable concentrations and for differing durations of treatment that can impact macrophage fate. These variations can make it challenging to reproduce findings and compare datasets across research environments. Additionally, few protocols to date have performed rigorous characterization with input material from frozen peripheral blood mononuclear cells (PBMCs). This is important since the availability of fresh blood can often be limiting and can lead to a loss of standardized procedures, particularly for cell therapy applications. Here, we have developed a comprehensive protocol to generate human macrophages from monocytes where we rigorously characterize the impact of differentiation conditions and polarization conditions on human macrophages. We compared 4 conditions for M1-like (50 ng/mL LPS, 50 ng/mL IFNγ, 20 ng/mL IFNγ + 10 ng/mL LPS and 20 ng/mL IFNγ + 100 ng/mL LPS) and for M2-like (10 ng/mL IL-4, 20 ng/mL IL-4, 20 ng/mL IL-13 and 20ng/mL IL-4 + 20 ng/mL IL-13). We provide a detailed protocol for their characterization using several ‘omics readouts, including their cytokine production and transcriptomes. We also perform depolarization experiments to determine durability of macrophage immunophenotype post-removal of polarizing stimuli for 0 to 72 hours. Finally, we demonstrate that nuclei can be isolated and profiled by snRNA-seq directly from macrophages in culture, alleviating the need to detach these adherent cells for downstream multi-ome analyses. Taken together, we provide a comprehensive, detailed and streamlined procedure for the differentiation and characterization of human macrophages from monocytes isolated from frozen PBMCs. This is important for enabling the study of macrophages in a more systematic way from biobanked material.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/26c17554acac58c3bbed110d75791474cfdb01fd" target='_blank'>
              A streamlined and comprehensive protocol for the generation and multi-omic analysis of human monocyte-derived macrophages
              </a>
            </td>
          <td>
            Olivia Palmer, Laurent Perreard, Fred W Kolling Iv, Patricia A. Pioli, Brittany A. Goods
          </td>
          <td>2025-12-01</td>
          <td>BMC Biotechnology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/71b827598caa3b92c66b1747f1e4d291bdfd16d5" target='_blank'>
              Multi-omics Analysis of Human Blood Cells Reveals Unique Features of Age-associated Type2 CD8 Memory T cells
              </a>
            </td>
          <td>
            Hiroyuki Matsui, Marlene Cervantes, Mir M. Khalid, Alan Tomusiak, Varun B. Dwaraka, Jorge Landgrave-Gomez, Prasanna Vadhana Ashok Kumaar, Qingwen Chen, Jesica Lasky-Su, Jake Stone, Ritesh Tiwari, Ryan Kwok, Shuntaro Ichikawa, Benjamin D. Ambrose, Rebeccah Riley, G. Hormazabal, Ariel Floro, Andreea Cristina Alexandru, Ryan Smith, B. Schilling, Herbert Kasler, Eric Verdin
          </td>
          <td>2026-01-07</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/34649c6562aa2175c877d0871438b8882a670ac3" target='_blank'>
              Integrated single-cell analysis reveals interferon-driven immune signatures in a DENV1 human infection model
              </a>
            </td>
          <td>
            A. Vermeersch, T. Verdonckt, C. Struyfs, E. De Meester, A. Waickman, , K. Ariën, O. Lagatie, F. van Nieuwerburgh
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Abstract Immune checkpoint blockade (ICB) has revolutionized the treatment of advanced malignancies such as melanoma. However, a significant proportion of patients fail to respond, owing to mechanisms that remain poorly understood. Here, we developed murine melanoma cell lines (R1 and R2) derived from MO4 tumors and that are resistant to anti-PD−1 therapy. These resistant cells exhibited increased tumor initiation capacity in vivo correlating with enhanced spheroid formation in vitro, and greater invasiveness and metastatic potential in a lung macrometastasis model. Mechanistically, both R1- and R2- derived tumors showed enrichment of a cancer stem cell (CSC)-like population overexpressing Wnt3a, which correlated with reduced infiltration and impaired function of CD8+ tissue-resident memory (TRMs) T cells. This suggested a functional link between Wnt-driven cancer stemness and TRMs dysfunction. Pharmacological inhibition of Wnt/β-catenin signaling in vitro enhanced CD8+ T cell proliferation and expression of functional markers. Notably, Wnt/β-catenin inhibition in vivo reversed anti-PD−1 resistance in resistant tumors, coinciding with reduced OCT4+Wnt3a+ CSC-like cells and restoration of TNFα+CD8+ TRMs. Finally, transcriptomic analysis of publicly available melanoma cohorts showed that enrichment of the Wnt pathway correlates with poor prognosis and ICB resistance, highlighting this pathway as a potential druggable negative regulator of ICB efficacy in melanoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9f77e7d52138792d22d71c5dbfbe6f13abb61e07" target='_blank'>
              Wnt3a-expressing cancer stem cells impair CD8+ TRM function, contributing to immunotherapy resistance in Melanoma
              </a>
            </td>
          <td>
            Julian A. Gajón, Ángel Juárez-Flores, Fatima Mendoza-Roldan, J. Hernández-Aceves, Samira Muñoz-Cruz, Armando Pérez-Torres, E. Fuentes-Pananá, L. C. Bonifaz
          </td>
          <td>2025-12-03</td>
          <td>Oncoimmunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Purpose
Colorectal cancer (CRC) lung metastases exhibit high recurrence rates after resection, underscoring the need for improved therapeutic strategies. This study aimed to characterize the tumor microenvironment (TME) of CRC lung metastases and identify the factors associated with recurrence.


Materials and Methods
Fifteen CRC patients who underwent lung metastasectomy were enrolled. Multiplex immunohistochemistry (IHC), whole exome sequencing, transcriptome profiling, and single-cell RNA sequencing (scRNA-seq) were conducted on matched tumor, adjacent and distant normal lung tissues. Immune cell populations and gene expression profiles were analyzed and correlated with clinical recurrence outcomes.


Results
Exome and transcriptome analyses revealed frequent TP53, KRAS, and APC mutations. Most tumors corresponded to consensus molecular subtypes 2 and 4, characterized by immune-depleted and fibrotic features. Tumors showed downregulation of effector T and NK cell signatures. IHC revealed reduced density and increased distance of CD8+ T cells and macrophages from the epithelial cells. scRNA-seq demonstrated increased regulatory T cells and decreased NK and effector T cells in tumor. Tumor-associated macrophages (TAMs), particularly SPP1 (osteopontin)-expressing subsets, were markedly enriched in tumor and correlated with suppressed effector T cella activity. High SPP1 expression was associated with early recurrence and poor overall survival. Patients with recurrence had higher proportion of PD-1+ CD8+ T cells in adjacent normal tissues.


Conclusion
Immunosuppressive features including enrichment of SPP1+ TAMs and depletion of effector T and NK cells contribute to recurrence after CRC lung metastasectomy. Therapeutic strategies targeting both TAMs and T cells may enhance clinical outcomes in this patient population.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ae972bf762bae15538dd4da3de79b673b4d58b2d" target='_blank'>
              Immunosuppressive Tumor Microenvironment in Colorectal Cancer Lung Metastases: Implications for Recurrence After Metastasectomy.
              </a>
            </td>
          <td>
            Minsuk Kwon, Minkyue Shin, M. An, Y.J. Jeon, T. Hong, Jung Kyong Shin, Sung Hee Lim, Yoonah Park, Y. Cho, Seung-Tae Kim, Y. Choi, Jeeyun Lee
          </td>
          <td>2025-12-17</td>
          <td>Cancer research and treatment</td>
          <td>0</td>
          <td>43</td>
        </tr>

        <tr id="Background Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung cancer stem cells secrete SAA, which contributes to tumor progression by inhibition of TH1 immunity. Here, we extended our studies to examine the mechanism of SAA mediated immunosuppression in both antigen-presenting cells (APCs) and the subsequent activation of T cells. Methods & results Using ex vivo co-culture systems and in vivo mice models, we found that SAA impaired dendritic cell and macrophage activation and drove macrophages toward an M2 phenotype with reduced antigen presentation. Lung cancer cells overexpressing SAA also consistently showed impaired CD8+ T cell infiltration and cytotoxicity, while SAA neutralization were efficient at enhancing CD8+ T cell activation and response to anti-tumor immunity. Mechanistically, we found that the immunosuppressive phenotype induced by SAA on APCs is mediated in part by CD36. Critically, inhibiting SAA by neutralization antibody recovered APC activity and enhanced T cell-dependent tumor control. Conclusion our results identify SAA as an important immunosuppressive mediator in the tumor microenvironment, implying that the SAA neutralizing antibody may be a potential target for the improvement of lung cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1f10076dc13711bdee9c69a81615daf0299024df" target='_blank'>
              SAA restricts T cell mediated anti-tumor immunity by limiting antigen presentation in lung cancer
              </a>
            </td>
          <td>
            Mei Huang, Run Shi, Cong Xu, Yihan Zhang, Xiaoyue Du, S. Wen, Chunbin Wang, F. Jiang, Guoren Zhou, Xin Wang, Bo Shen
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/938f1648314d21b17f5602b7a84c055f9ef0d7b2" target='_blank'>
              Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: Insights from in vitro assays§
              </a>
            </td>
          <td>
            Miriam Kelm, Nourhan Nasr, S. Bendig, Dieter Kabelitz, M. Lustig, H. Trautmann, A. Laqua, Christian Peters, D. Wesch, Heiner Oberg, Ottmar Janssen, T. Valerius, C. Baldus, A. Scheffold, M. Brüggemann, G. Chitadze
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>49</td>
        </tr>

        <tr id="This study systematically evaluated the immunomodulatory function of PD-L1-positive mesenchymal stem cells (PD-L1(+) MSCs) using single-cell RNA sequencing (scRNA-seq) and investigated their roles in suppressing inflammation and regulating pathological bone formation in curdlan-induced SKG ankylosing spondylitis (AS) mouse models. scRNA-seq identified MSC subpopulations with high immunomodulatory capacity and key biomarker PD-L1 for subpopulation classification. In vitro co-culture experiments were conducted to evaluate the effects of MSC subpopulations on T-cell proliferation and TNF-α levels. In vivo experiments were performed in forty-eight SKG mouse models to analyze the effects of MSC subpopulations on joint inflammation scores, T-cell subset proportions, inflammatory cytokines, histopathology, and pathological bone formation. scRNA-seq revealed significant heterogeneity in MSCs under inflammatory stimulation, with the immunomodulatory subpopulation exhibiting high expression of PD-L1 and IDO. In vitro experiments demonstrated that PD-L1(+) MSCs significantly suppressed T-cell proliferation and reduced TNF-α levels. Joint redness and swelling scores showed that the PD-L1(+) MSC group exhibited the most significant improvement in arthritis, while the IL-17Ai, PD-L1(-) MSC, and MSC groups also effectively reduced inflammation, with significantly lower scores than the model control(MC) group. Histological analysis revealed severe inflammatory cell infiltration in the MC group, while the IL-17Ai, PD-L1(+) MSC, and MSC groups exhibited reduced infiltration. Immunohistochemical analysis further confirmed these findings, with PD-L1(+) MSCs exhibiting a significant reduction in TNF-α and IL-17A-positive cells (P < 0.0001 and P < 0.01, respectively).PD-L1(+) MSCs regulated immune responses by reducing Th17 cell proportions, increasing Th2 and Treg cell proportions, and significantly lowering pro-inflammatory cytokines IFN-γ, IL-17A, and TNF-α. MicroCT analysis indicated that the PD-L1(+) MSC, MSC, and IL-17Ai group effectively suppressed pathological bone formation through immunomodulation, whereas the PD-L1(-) MSC group showed weaker effects, underscoring the importance of PD-L1 in regulating bone formation. hUC-MSCs demonstrated significant therapeutic effects in the AS mouse model, particularly the PD-L1(+) MSCs, which inhibited joint inflammation and pathological new bone formation through immunomodulatory mechanisms. These findings provide valuable insights into the therapeutic mechanisms of AS treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/454abfd41ac3fcba3b2ed2de727cc6ae38577ec2" target='_blank'>
              Single—cell RNA sequencing identifies PD—L1 + mesenchymal stem cells with enhanced immunomodulatory capacity and alleviated the degree of ectopic new bone formation in ankylosing spondylitis
              </a>
            </td>
          <td>
            Xiqing Luo, Liuzhong Zhou, Xianghui Wen, Jinwei Li, Dong Liu, Budian Liu, Shenghui Wen, Jie-Ruo Gu
          </td>
          <td>2025-12-01</td>
          <td>Stem Cell Research & Therapy</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4-CD8-TCRαβ T cells that interact with CXCL16 expressing non-classical monocytes. Leukemia cell intrinsic transcriptional rewiring in these patients is associated with activation of Rap1 signaling. Inhibiting Rap1 signaling results in increased sensitivity to the BCL2/BCL-XL inhibitor navitoclax. Our study provides insights into the immune microenvironment of pediatric hematologic malignancies, forming the basis for identifying potential (immuno) therapeutic targets and risk stratification for treatment. Understanding of the immune microenvironment in pediatric acute T cell lymphoblastic leukemia is limited. By analyzing single-cell transcriptome, surface protein expression and immune repertoire data, the authors here identify non-malignant CD4-CD8- TCRαβ T cells that are present in a subset of patients with Rap1 signaling in leukemia cells and are associated with adverse clinical outcome in patients with low minimal residual disease.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb527a6740e54a5aab04ff54dc24e5f1755e30d3" target='_blank'>
              Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia
              </a>
            </td>
          <td>
            Caroline R. M. Wiggers, Eugene Y Cho, Merve Ozdemir, Gbolahan Bamgbose, Justin Hegel, Julia Frede, Frederike Warlitz, Tayla B. Heavican-Foral, Ioana Pop, R. Shraim, P. Pölönen, Victoria B. Koch, T. Tran, C. Mullighan, D. Teachey, Jacob R. Bledsoe, Yana Pikman, Marian H. Harris, Andrew E. Place, Lewis B. Silverman, Jens G. Lohr, Birgit Knoechel
          </td>
          <td>2025-11-21</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>108</td>
        </tr>

        <tr id="Tumor-infiltrating regulatory T (Treg) cells contribute to immune evasion and are associated with poor prognosis in solid tumors. While CD47 blockade has demonstrated efficacy in hematologic malignancies, its application in solid tumors is hindered by the antigen sink effect and lack of tumor selectivity. Here, we report a rationally designed aptamer-siRNA chimera that selectively targets intratumoral Treg cells by exploiting their co-expression of PD-L1 and CD47 within the tumor microenvironment. The PD-L1 aptamer enables selective binding to PD-L1⁺ Treg cells and simultaneously inhibits PD-L1-mediated immune suppression. Conjugated CD47 siRNA silences CD47 expression, abrogating the “don’t eat me” signal and facilitating phagocytic clearance. Mechanistically, this chimera efficiently depletes tumor-infiltrating Treg cells with negligible impact on peripheral cells, and leads to a pronounced increase in intratumoral CD8⁺ T cell infiltration. Further investigation revealed that the chimera impairs Treg migration by disrupting glycolysis-related signaling pathways, including pERK1/2 and pRac1, and induces metabolic reprogramming characterized by reduced glycolysis, increased oxidative metabolism, and elevated fatty acid oxidation (FAO). In murine hepatocellular carcinoma models, treatment with the chimera significantly inhibited tumor growth, reduced angiogenesis, and prolonged survival. Our findings highlight a dual immune checkpoint-targeting strategy that integrates selective delivery with gene silencing, offering a tumor-specific, non-antibody approach for Treg depletion and a promising avenue for solid tumor immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a1e08750a58059534a9ab521c1290cb1dabc0d16" target='_blank'>
              Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera
              </a>
            </td>
          <td>
            Yu Zeng, Xiaoli Chen, Wenqiong Huang, Chi Ho Chan, Ziqi Chen, Minchuan Lyu, Yumeng Liu, Meijun Liu, Aiping Lyu, Claudio Mauro, Yuanyuan Yu, Kenneth C P Cheung
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Fibrotic colorectal cancers (CRC) are largely microsatellite-stable and display desmoplastic stroma with poor immune infiltration. Here we identify thrombospondin-2 (THBS2) as a key regulator of the immune-exclusionary phenotype in fibrotic CRC. THBS2 is highly expressed by matrix cancer-associated fibroblasts at the tumor front. In an orthotopic model using desmoplastic tumor organoids, global or fibroblast-specific Thbs2 deletion disrupts the exclusionary barrier and increases intratumoral CD8 T cells. Mechanistically, THBS2 limits recruitment of CXCR3+ CD8 T cells by restraining dendritic- and macrophage-derived CXCL9/10. Depletion of these myeloid cells or blockade of CXCL9/10-CXCR3 signaling abolishes the enhanced CD8 T-cell influx and antitumor efficacy. Spatial profiling demonstrates that THBS2 loss induces proximity between CD8 T cells and myeloid cells and upregulates chemokines. Despite increased infiltration, CD8 T cells manifest exhaustion, rendering tumors highly susceptible to immune checkpoint blockade. THBS2 thus represents a tractable CAF-restricted target to overcome immune exclusion in fibrotic CRCs. Desmoplastic stroma is a hallmark of aggressive colorectal cancer. Matrix cancer-associated fibroblasts derived THBS2 establishes a fibrotic, immune-exclusionary barrier that limits CD8+ T cell infiltration, while its inhibition restores CXCR3-mediated T cell recruitment and enhances response to immune checkpoint blockade.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/388320818ae6ea3dc30b0402479bdd593842387a" target='_blank'>
              Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer
              </a>
            </td>
          <td>
            Kosuke Iwane, Y. Nakanishi, Yu Muta, Jiayu Chen, Kento Yasumura, Mayuki Omatsu, Naoki Aoyama, Munehiro Ikeda, Yoko Masui, Liyang Cai, Go Yamakawa, K. Hamada, Kenta Mizukoshi, Munenori Kawai, Kei Iimori, Shinnosuke Nakayama, Nobukazu Agatsuma, Takahiro Utsumi, M. Nagao, T. Maruno, Y. Hiramatsu, N. Kakiuchi, M. Nakagawa, Y. Fukui, Yukina Kusunoki, H. Kasashima, Masakazu Fujimoto, Yoshiro Itatani, T. Kogame, A. Fukuda, Masakazu Yashiro, K. Maeda, K. Kabashima, K. Obama, Seishi Ogawa, Maria T. Diaz-Meco, J. Moscat, Hiroshi Seno
          </td>
          <td>2025-11-23</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>88</td>
        </tr>

        <tr id="Liver cancer incidences increase dramatically beyond 55 years of age, suggesting that age-associated changes contribute critically to tumor initiation. However, the mechanisms linking liver aging and cancer initiation are not well defined. This study investigates the role of CD44, a marker of liver tumor-initiating cells (TIC), in age-associated liver pathophysiology. Aged livers showed accumulation of CD44-expressing hepatocytes exhibiting enrichment of immune modulatory genes and activation of the immunosuppressive IL6/JAK/STAT3 pathway. Indeed, in adoptive transfer assays, antigen-exposed CD8+ T cells mounted a lower IFN-γ response in aged livers than in young livers, indicating an immunosuppressive aged milieu. Concordantly, spatial analyses showed that the proximal neighbourhoods of Cd44-expressing hepatocytes are enriched in T cells exhibiting reduced cytokine and chemokine gene expression. Finally, hepatocyte-specific knock out of Cd44 mitigated the IL6/JAK/STAT3 gene signature in aged livers. Overall, these findings suggest that CD44 expression in aged hepatocytes promotes activation of the immunosuppressive IL6/JAK/STAT3 pathway and this is associated with impaired T cell effector function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b8cfbe41c4f5eea58d4484e39d30b0c559a09da" target='_blank'>
              Aging-induced hepatocyte CD44 drives IL6/STAT3 signaling and associates with impaired neighboring T cell function
              </a>
            </td>
          <td>
            Armin Gandhi, Kathryn Lande, Yichen Li, Filipe A. Hoffman, Michael LaPorte, Shirong Tan, Garrett Evensen, Benji Portillo, M. Teneche, Rouven Arnold, Adarsh Rajesh, Jessica Proulx, Shanshan Yin, Aaron P. Havas, Charlene Miciano, Qian Yang, Elizabeth Smoot, S. Mamde, Andrew Davis, Kevin Y. Yip, Allen Wang, Bing Ren, April Williams, S. Kaech, Peter D. Adams
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eda924ce01379c46e7af9cc01dc3f59feafe7bb9" target='_blank'>
              Myeloid cells contribute to bystander CD8 T cell accumulation in metabolic-associated steatohepatitis and are sufficient for fibrosis
              </a>
            </td>
          <td>
            Cynthia Lebeaupin, Katelyn L. Donahue, Stephen M. Christensen, Shoh Asano, Marc H. Wadsworth, Kathryn Bound, Saurav De, James McMahon, Franklin Schlerman, Chang Wang, Xiao Chen, A. M. Barron, Thomas A. Wynn, Kevin M. Hart, Thomas Fabre
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Age is a dominant risk factor for all major breast cancer subtypes. However, the mechanisms by which aging influences tumor development remain unclear. Using a novel mouse model whereby breast cancer is induced in situ in young and old wild-type mice via intraductal delivery of a lentivirus encoding the HER2/neu oncogene, we found that old mice exhibited a higher oncogene-induced tumor burden than young mice. Old tumor cells showed reduced expression of interferon-related genes, particularly the T cell-recruiting chemokines Cxcl9 and Cxcl10, linked to their altered chromatin accessibility. CXCL9/10 expression also declined with age in human HER2+ tumors. Correspondingly, old tumors exhibited fewer T cells within tumor lesions. Targeted interventions showed that decreased expression of Cxcl9/10 is responsible for reduced T cell infiltration and weakened anti-tumor immunity. These results show how aged tumor cells are impaired in their recruitment of immune cells, leading to a defective anti-tumor immune response.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b38011df7fcbd774b6090832583a2578934863ea" target='_blank'>
              Aging alters tumor cell - T cell crosstalk to promote breast cancer progression
              </a>
            </td>
          <td>
            Shanshan Yin, Kay T Yeung, S. Mamde, Kate Lin, Armin Gandhi, Xue Lei, Andrew Davis, Rouven Arnold, Jing Yang, P. Adams
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) immunotherapy is limited by antigenic heterogeneity and an immunosuppressive microenvironment. This study engineered chimeric antigen receptor macrophages (CAR-Ms) targeting stress-inducible NKG2D ligands (NKG2DLs), broadly overexpressed in HCC, to enhance phagocytic clearance and remodel immunity. NKG2DL expression in HCC and association with survival were analyzed. CAR-Ms were constructed by fusing the NKG2D extracellular domain to FcγRI signaling. In vitro assays assessed phagocytosis, cytokine secretion, signaling, and T cell interactions. Therapeutic efficacy was evaluated in immunocompetent mice bearing subcutaneous, orthotopic, or metastatic HCC models, with or without anti-PD-L1. Tumor progression, immunity, and survival were analyzed via bioluminescence imaging, flow cytometry, histopathology, and serum biochemistry. Statistics analyses were performed using t-tests, ANOVA, and log-rank tests. NKG2DLs were significantly upregulated in human HCC and correlated with poor prognosis. CAR-Ms selectively engulfed NKG2DL⁺ tumor cells, polarized to an M1 phenotype, and activated PI3K-AKT and cGAS-STING pathways, driving phagocytosis and pro-inflammatory cytokines secretion. They enhanced T cell chemokines (Cxcl10, Ccl5) and antigen presentation, boosting T cell recruitment and activation in vitro. In subcutaneous models, CAR-Ms suppressed tumor growth, reprogrammed tumor-associated myeloid cells toward M1, and induced durable immune memory (100% tumor rejection upon rechallenge), with T cell activation. In orthotopic models, CAR-M monotherapy induced complete regression by week 5 and 100% survival, with elevated CD8⁺ T cells and CAR-M specifically homing to liver tumors. CAR-Ms suppressed metastasis in peritoneal/pulmonary models. Combining CAR-Ms with PD-L1 blockade accelerated tumor clearance and survival versus monotherapies, enhancing T cell cytotoxicity. Safety assessments showed no significant organ toxicity based on histopathology and serum biochemistry. NKG2D-directed CAR-Ms eliminate HCC through integrated innate phagocytosis, adaptive immune activation, and myeloid reprogramming, overcoming key therapeutic barriers. Combination with anti-PD-L1 enhances therapeutic efficacy by leveraging innate-adaptive crosstalk, providing a promising approach for HCC immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/928340f1c482d3cc3031b9813af988a397a41c2c" target='_blank'>
              Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Zihao Zhao, Wenjing Zheng, Yang He, Han Zhang, Lingling Zhang, Yi Huo, Junwei Jiang, Chen Zhang, Haohan Lyu, Weiwei Qin, Chen Liu, Feng Chang, Lequn Shan, Tao Wang, Wenjie Song
          </td>
          <td>2025-12-13</td>
          <td>Molecular Cancer</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c9fa5c1ee49d7d4c736812a4f10f208818145e4f" target='_blank'>
              Characterizing cellular subpopulations critical to treatment response in autoimmune diseases
              </a>
            </td>
          <td>
            Siqi Sun, Mulini Pingili, S. Yadav, Zhuoya Wan, Michael Macoritto, Kathleen Smith, Jing Wang, Dan Chang, N. Mahi
          </td>
          <td>2026-01-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Stem-like T cells (TSL) represent a distinct subset of CD4+ and CD8+ T cells characterized by self-renewal, multipotent differentiation, and long-term persistence, and have emerged as pivotal regulators of immune responses in chronic disease contexts. Despite growing interest, the developmental programs, molecular signatures, and clinical relevance of TSL remain incompletely understood, limiting their translational potential. Recent evidence highlights the central role of key transcription factors such as TCF-1 and BCL6, metabolic circuits including the Wnt-β-catenin and STAT3 pathways, and microenvironmental signals in sustaining the identity and function of TSL subsets. In various pathologies—including chronic infections, cancer, autoimmunity, and transplant rejection—TSL cells contribute to both immune persistence and pathogenic activation through their capacity to replenish exhausted effectors or differentiate into inflammatory subtypes. These cells not only shape immune trajectory but also hold promise as dynamic biomarkers and therapeutic targets. Targeted modulation of TSL via cytokine supplementation, immune checkpoint blockade, adoptive transfer, or niche interference is under investigation, with encouraging results in preclinical and early translational studies. This review outlines the molecular regulation and functional diversity of stem-like CD4+ and CD8+ T cells, evaluates their disease-specific roles, and discusses strategies to harness or inhibit these populations for precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/957ce990207260aaa43e17d3f30590a154a82c00" target='_blank'>
              Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases
              </a>
            </td>
          <td>
            Wang Zhan, Longyong Lai, Shuan Ran, Yuan Li, Jiulu Zhao, Jie Wu, Chao Guo, Jikai Cui, Jiahong Xia
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Objectives This study aimed to investigate the role of natural killer (NK) cell and interferon (IFN) signaling in the peripheral circulation of anti-MDA5+ dermatomyositis (DM) patients, particularly in the context of interstitial lung disease (ILD) development. Methods Peripheral blood mononuclear cells (PBMCs) from six newly diagnosed, active anti-MDA5+ DM patients (3 with ILD, 3 without ILD) were analyzed using single-cell RNA sequencing (scRNA-seq), focusing on NK cell features. The correlation between serum cytokine levels and ILD severity assessed by HRCT scores was further analyzed. Flow cytometry in an independent cohort validated NK cell apoptosis, and in vitro experiments evaluated IFN-induced apoptosis in NK-92 cells. Results ScRNA-seq revealed widespread activation of IFN responses in PBMCs from anti-MDA5+ DM-ILD patients, with pronounced upregulation in innate immune cells (e.g., NK cells and monocytes). A reduction in circulating NK cell proportions was observed in ILD patients. Serum levels of cytokines (IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12P70, TNF-α, and IFN-α) positively correlated with the radiologic severity of ILD as quantified by HRCT scores. Flow cytometry confirmed significantly decreased NK cell counts and increased apoptosis in the ILD group. PBMCs from healthy donors exposed to an ILD-like cytokine milieu exhibited upregulated IFN pathway genes (ISG15, MX2, IFIT3), EIF2AK2 (encoding protein kinase R), and apoptosis-related genes (BCL2, BAX2). In vitro, IFN stimulation directly induced apoptosis in NK-92 cells. Conclusion Excessive IFN activation drives NK cell apoptosis in anti-MDA5+ DM-ILD, contributing to NK cell depletion and ILD development. IFN-related biomarkers may serve as valuable indicators for assessing ILD severity in these patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f561d51a5fa1e3b04b78d86a4673eadd69564ec1" target='_blank'>
              Exhaustion of NK cells and interferon activation in anti-MDA5+ dermatomyositis are associated and determine the development of ILD
              </a>
            </td>
          <td>
            Chenyi Shao, Yan Zhen, Nana Xia, Xueliang Zhang, Ninghui Yan, Mengmeng Zhou, Yiyuan Guo, Limin Tan, Qiang Guo
          </td>
          <td>2025-12-08</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background Colorectal cancer (CRC) progression is shaped by the tumor microenvironment, particularly tumor-associated macrophages (TAMs), which often adopt immunosuppressive functions. CD300e, a myeloid receptor involved in immune regulation, has an uncharacterized role in CRC. Methods Functional studies were conducted in azoxymethane/dextran sodium sulfate and MC38 murine CRC models using CD300e systemic and myeloid-specific CD300e knockout mice, and adoptive transfer experiments assessed macrophage-intrinsic effects. Human studies included analysis of CD300e expression in matched tumor and normal tissue from patients with CRC and in vitro co-culture of patient-derived colon tumor organoids with monocytes to study CD300e induction and TAM polarization. Results In vivo, CD300e deficiency led to reduced tumor burden, enhanced major histocompatibility complex expression on TAMs, and improved T-cell responses. CD300e-deficient macrophages exhibited increased phagocytic activity, antigen presentation, and support for T-cell proliferation and cytotoxicity. Adoptive transfer confirmed that macrophage-intrinsic CD300e expression is sufficient to suppress T-cell function and promote tumor growth. In patients with CRC, CD300e is selectively upregulated in tumor-infiltrating monocytes and macrophages, driving a suppressive phenotype marked by impaired antigen presentation. Tumor-derived signals in vitro induce CD300e expression and promote a protumorigenic macrophage profile. Conclusions Our findings identify CD300e as a critical regulator of macrophage-mediated immune suppression in CRC and a potential target for reprogramming TAMs to enhance immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/16c56c500ab6751223d28c46c0f7327dc521a283" target='_blank'>
              CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming
              </a>
            </td>
          <td>
            Annica Barizza, Stefania Vassallo, L. Masatti, Mattia Laffranchi, Sofia Giacometti, S. Lonardi, Mattia Bugatti, Sara Coletta, C. Della Bella, M. D’Elios, Simone Pizzini, A. Rosato, W. Vermi, Matteo Fassan, G. Spolverato, Silvano Sozzani, E. Calura, R. Sommaggio, Gaia Codolo
          </td>
          <td>2025-07-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>63</td>
        </tr>

        <tr id="Background Colorectal carcinoma exhibits high heterogeneity, comprising subtypes that show poor efficacy of T cell-based immunotherapies, such as programmed cell death protein 1 (PD-1) checkpoint inhibitors. Although natural killer (NK) cells are considered a promising approach for cancer immunotherapy, it remains unclear what molecular mechanisms drive NK cell activation or suppression within the tumor microenvironment. Moreover, limitations in human tumor models that reflect the diversity of individual patient tumors hinder the ability to effectively select patients who would benefit most from NK cell-based therapies. Methods Here, we established a co-culture platform of genetically diverse colorectal cancer (CRC) patient-derived organoids (PDOs) with primary allogeneic NK cells. We performed bulk RNA sequencing analysis of sorted NK cells after exposure to PDOs and aligned gene expression signatures derived from our findings with publicly available single-cell RNA sequencing data of NK cells from peripheral blood and CRC tissues of patients. Moreover, we evaluated identified pathways using flow cytometry and IncuCyte live-cell imaging analysis to quantify phenotypic alterations and NK cell-mediated killing of PDOs over time, respectively. Ultimately, we tested CRISPR-Cas9-edited NK cells and PDOs, small molecule compounds, and clinically relevant monoclonal antibodies (mAbs) to increase NK cell potency. Results On co-culture, NK cells acquired common transcriptional signatures related to hypoxia and transforming growth factor-beta (TGF-β), similar to NK cells infiltrating CRC tissues of patients. In addition, we observed patient-specific differential PDO susceptibilities to NK cell-mediated lysis. Major histocompatibility complex class I deficiency and natural killer group 2, member D (NKG2D)-ligand expression on PDOs facilitated NK cell-mediated cytotoxicity, and induced phenotypic NK cell diversification related to activation and the acquisition of inflammation and tissue-residency-related transcriptional signatures. Genetic or pharmaceutical targeting of hypoxia-inducible factors HIF1A/EPAS1 or TGF-βR1, or the addition of anti-CEACAM1 mAbs, enhanced NK cell-mediated PDO killing or activation, respectively. Conclusions The NK cell/PDO co-culture platform allows the identification of both common and patient-specific impacts of the tumor microenvironment on NK cell function and can aid the development of patient-tailored immunotherapies. The majority of CRC (CMS2/CMS3) PDOs from our cohort were susceptible to NK cell-mediated killing and induced NK cell activation, highlighting the potential of NK cells for CRC immunotherapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9bfdbb13391ad7497b66effc8a4643668f2be84a" target='_blank'>
              Colorectal cancer organoids drive hypoxia, TGF-β, and patient-specific diversification of NK cell activation programs
              </a>
            </td>
          <td>
            Andreas von Kries, Irene Garcés-Lázaro, Bianca M Balzasch, Carsten Sticht, Indra A Shaltiel, Kim E. Boonekamp, Annika Sams, Alessia Triassi, Tomáš Hofman, Elke Burgermeister, J. Betge, Matthias P. Ebert, M. Boutros, Laura Helming, A. Stojanovic, A. Cerwenka
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>62</td>
        </tr>

        <tr id="Melanoma remains a major challenge in oncology because of its aggressive behavior and intricate immune interactions. Advances in immunophenotyping and single-cell atlas technologies have revealed heterogeneous regulatory T cell (Treg) subsets, among which peripheral blood CD39+PD-1+ Tregs have emerged as key mediators of systemic immunosuppression. This review summarizes current evidence on their immunoregulatory functions, emphasizing their role in suppressing anti-tumor immunity and contributing to poor clinical outcomes. By integrating immune atlas data with clinical observations, we outline the mechanisms by which this subset shapes both the tumor microenvironment and systemic immune responses. We further discuss their potential as prognostic biomarkers and therapeutic targets to optimize immunotherapy strategies. In addition, we highlight how this subset interacts with other immunosuppressive pathways, reinforcing resistance to immune checkpoint inhibitors. Despite these advances, challenges remain in fully characterizing this population and translating findings into clinical application. This review provides a comprehensive overview of the significance of CD39+PD-1+ Tregs in melanoma immunopathology and highlights future directions to advance precision immunotherapy and improve patient prognosis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc33012596eab785fba7e6d8eba704e87044622b" target='_blank'>
              CD39+PD-1+ regulatory T cells in melanoma: key drivers of systemic immunosuppression and prognostic biomarkers
              </a>
            </td>
          <td>
            Guanlin Qiao, Hongxia He, Xiaobing Wang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3bbdd9bcc92736e4b8070a3a41a9e7c618c1a80" target='_blank'>
              ILC2s govern imprinting of alveolar macrophage-mediated immunity upon secondary helminth infection in the lung
              </a>
            </td>
          <td>
            Jonathan Pollock, , Lisa-Marie Graf, Andreas Ruhl, Daniel Radtke, David Voehringer
          </td>
          <td>2025-12-23</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Resistance to immune checkpoint blockade (ICB) remains a major challenge in lung adenocarcinoma (LUAD), with stromal mechanisms underlying CD8⁺ T cell exhaustion still poorly understood. By integrating single-cell, bulk, and spatial transcriptomic datasets using EcoTyper, we identified a distinct immunosuppressive ecotype, EC10, enriched for TGF-β signaling and epithelial–mesenchymal transition. EC10 exhibited spatial co-localization of fibroblasts, malignant epithelial cells, and exhausted CD8+ T cells, and was consistently associated with immune exclusion, poor progression-free survival, and elevated TIDE scores across four ICB-treated LUAD cohorts. Cell–cell communication analyses revealed a dominant TGFB1–SERPINE1 signaling axis originating from fibroblasts, linking stromal remodeling to T cell dysfunction. In contrast, EC12 represented an inflamed, ICB-responsive state enriched in interferon signaling. These findings define EC10 as a spatially organized, fibroblast-driven immunosuppressive ecosystem predictive of ICB resistance, and highlight the therapeutic potential of targeting the TGF-β axis in LUAD. This research identifies a fibroblast-driven immunosuppressive ecosystem in lung adenocarcinoma, linking TGF-β signaling to immune resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/130525b051ffbdab87e5edbec0e75b95564de9c8" target='_blank'>
              Fibroblast TGF-β signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance
              </a>
            </td>
          <td>
            Seo-Young Lee, Youngjoo Lee
          </td>
          <td>2025-12-01</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterised by synovitis and progressive joint destruction. The complex network of immune cell interactions plays a crucial role in RA pathogenesis. Pro-inflammatory M1 macrophages initiate and amplify synovial inflammation by releasing cytokines that recruit and activate T cells and neutrophils, stimulate B-cell proliferation and autoantibody production. In contrast, M2 macrophages exert anti-inflammatory effects but are functionally impaired in RA. Macrophage-derived CXCL16 enhances CD4+ T-cell recruitment, activated CD4+ T cells differentiate into distinct helper T (Th) cell subsets and regulatory T (Treg) cells, both of which contribute to the pathogenesis of RA by producing specific cytokines. B-cells, known for their highly selective antigen uptake capability, process antigens derived from antigen-immunoglobulin immune complexes and subsequently present them to activate T cells and macrophages. They also contribute to chemokine-mediated recruitment, facilitating ectopic lymphoid structure formation and sustained autoantibody responses. Neutrophils, which are essential components of the innate immune system, are the first immune cells to migrate to inflamed sites and initiate defence responses. Significant infiltration of neutrophils has been observed in the synovial fluid of patients with RA, where they interact with macrophages to form neutrophil extracellular traps (NETs). NETs perpetuate citrullinated autoantigen generation and thereby promoting persistent inflammation and joint damage. In recent years, emerging evidence highlights mesenchymal stem cells (MSCs) as potential immunomodulators of regulating the RA microenvironment, by promoting anti-inflammatory phenotype polarisation, inducing T cell differentiation to Tregs, inhibiting the differentiation and proliferation of B cells, neutrophil recruitment and the forming of NETs. This review summarizes the macrophage-centred immunological crosstalk underlying RA, to inform clinical decision-making and contribute to the development of novel treatment strategies for RA by providing insights into the immunopathogenesis of RA and the therapeutic potential of MSCs.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/463c552e211634c4f90ecc9483a1c1df95d977af" target='_blank'>
              Macrophage-centred crosstalk with infiltrating immune cells in rheumatoid arthritis and its regulation by mesenchymal stem cells
              </a>
            </td>
          <td>
            Songyun Zheng, Hui Wang, Jianhui Mu, Xiaoyu Liu, Xianhua Jin, Zheng Li, Jinlan Jiang, Modi Yang
          </td>
          <td>2025-11-26</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Background/Objectives: Bone marrow mesenchymal stromal cells (MSCs) are therapeutic cells that adopt an immunomodulatory phenotype when exposed to pro-inflammatory cytokines. Recent research efforts uncovered that many therapeutic benefits of MSCs can be attributed to the secretion of extracellular vesicles (EVs) such as exosomes, small membrane vesicles of endocytic origin present in the cellular secretome. EVs’ formation and release are impacted by the autophagy pathway, which recycles proteins and organelles via lysosomal degradation. Methods: To evaluate how modulation of autophagy affects properties of MSC EVs enriched in exosomes under pro-inflammatory conditions, we treated the cells with either tamoxifen (TX) or chloroquine (CQ), two drugs known to stimulate or inhibit autophagy, respectively, together with IFNγ. MSC EVs enriched in exosomes were then purified from serum-free media, and their immunoregulatory properties were evaluated ex vivo using activated CD4 T cells; small RNA sequencing was also conducted to determine EVs’ microRNA content. Results: Our data indicate that MSCs treated with CQ + IFNγ yield EVs that possess somewhat higher capacity to decrease T cell proliferation compared to other EVs. Small RNA sequencing revealed that, although similar microRNAs were found in EVs isolated from all treated cells, the treatments exerted more effect on the levels of multiple microRNAs that are known to regulate either cancer or inflammation-related biological pathways in target cells. Conclusions: Overall, we conclude that the co-treatment of MSCs with TX or CQ in the presence of pro-inflammatory cytokine IFNγ has the potential to modulate microRNA content of EVs, potentially affecting biological properties of such EVs and their effect on target cells.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce2bb11a7de2fec2c7f0ea8f816d32970804b872" target='_blank'>
              Functional and Molecular Characterization of Extracellular Vesicles Enriched in Exosomes Released by Bone Marrow Mesenchymal Stromal Cells Exposed to IFNγ in Combination with Autophagy Modulators Tamoxifen or Chloroquine
              </a>
            </td>
          <td>
            Vladimir Beljanski, Maria J. Moreno Hollweg, Renee Potens, Tanner Blaylock, Andres B. Irausquin, Nikhila Paleati, L. Nathanson
          </td>
          <td>2025-12-24</td>
          <td>Non-Coding RNA</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Emerging evidence suggests a correlation between CD8+ T cell–tumour cell proximity and anti-tumour immune response1,2. However, it remains unclear whether these cells exist as functional clusters that can be isolated from clinical samples. Here, using conventional and imaging flow cytometry, we show that from 21 out of 21 human melanoma metastases, we could isolate heterotypic clusters, comprising CD8+ T cells interacting with one or more tumour cells and/or antigen-presenting cells (APCs). Single-cell RNA-sequencing analysis revealed that T cells from clusters were enriched for gene signatures associated with tumour reactivity and exhaustion. Clustered T cells exhibited increased TCR clonality indicative of expansion, whereas TCR-matched T cells showed more exhaustion and co-modulation when conjugated to APCs than when conjugated to tumour cells. T cells that were expanded from clusters ex vivo exerted on average ninefold increased killing activity towards autologous melanomas, which was accompanied by enhanced cytokine production. After adoptive cell transfer into mice, T cells from clusters showed improved patient-derived melanoma control, which was associated with increased T cell infiltration and activation. Together, these results demonstrate that tumour-reactive CD8+ T cells are enriched in functional clusters with tumour cells and/or APCs and that they can be isolated and expanded from clinical samples. Typically excluded by single-cell gating in flow cytometry, these distinct heterotypic T cell clusters are a valuable source to decipher functional tumour–immune cell interactions and may also be therapeutically explored. Tumour-reactive CD8+ T cells are enriched in functional clusters with tumour cells and/or antigen-presenting cells and can be isolated and expanded from clinical samples.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1100b9077e6e7f158509d2bfcdf86085e31d43e6" target='_blank'>
              Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
              </a>
            </td>
          <td>
            Sofía Ibáñez-Molero, J. Veldman, Juan Simon Nieto, Joleen J H Traets, Austin George, K. Hoefakker, Anita Karomi, R. Harkes, Bram van den Broek, Su Min Pack, L. Tas, Nils L Visser, Susan E. van Hal-van Veen, P. Alóndiga-Mérida, M. Alkemade, I. M. Seignette, R. Tissier, M. Nieuwland, M. van Baalen, Joanna Poźniak, Erik Mul, S. Tol, S. Stenqvist, L.M. Nilsson, Jonas A Nilsson, J. Haanen, W. V. van Houdt, D. Peeper
          </td>
          <td>2025-11-19</td>
          <td>Nature</td>
          <td>2</td>
          <td>59</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e56882b29e98563be8230a7fd202a7abeb1f4acf" target='_blank'>
              Intestinal Stem and Progenitor Cells Exhibit Distinct Adaptive Responses to Inflammatory Stress in IBD
              </a>
            </td>
          <td>
            B. Balasubramanian, Shivam Patel, Louis Gall, N. Hannan, William Dalleywater, Joerg Huelsken, C. Pin, G. Moran, Paloma Ordóñez-Morán
          </td>
          <td>2025-12-14</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Abstract Soft-tissue sarcomas (STS) are characterized by abundant extracellular matrix (ECM) deposition, yet the functional contribution of specific ECM components remains poorly understood. In this study, we identify periostin (POSTN), a matricellular protein, as a regulator of sarcoma progression and the tumor immune microenvironment. Analysis of human sarcoma datasets revealed that high POSTN expression correlates with poor prognosis and elevated expression of ECM-related and myeloid cell–associated genes. In murine genetic models of sarcoma, tumors expressing high levels of Postn displayed enhanced expression of ECM genes and monocyte-recruiting cytokines. Functional silencing of Postnin vivo reduced tumor growth without altering tumor cell proliferation or intrinsic signaling pathways, suggesting a noncell-autonomous mechanism. Instead, Postn-deficient tumors showed increased infiltration of CD4+ and CD8+ T cells and reduced proportions of immunosuppressive myeloid cells, including tumor-associated macrophages (TAM). Single-cell RNA sequencing revealed that Postn silencing reprograms the myeloid compartment, increasing IFN-responsive and proinflammatory subsets. Mechanistically, recombinant POSTN promoted monocyte migration and maturation into macrophages in vitro, supporting its role as a chemoattractant and differentiation cue. Therapeutic neutralization of POSTN partially recapitulated the immunologic remodeling but was insufficient to reduce tumor burden as monotherapy. Significance: Our findings position POSTN as a key stromal regulator in STS, linking tumor-derived ECM components to immune evasion via myeloid cell recruitment and education. These results open avenues for targeting POSTN as an adjuvant strategy to enhance the efficacy of immunotherapies and overcome the immune-excluded phenotype of sarcoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4fcb661ad1542d712f7aa5599bc104c08fe2694e" target='_blank'>
              Periostin Promotes Sarcoma Growth by Promoting Tumor-Associated Macrophage Migration and Differentiation
              </a>
            </td>
          <td>
            Jinfen Xiao, Kristin Ishaya, E. Ko, Annaliese Fowler, Marina T Broz, Jlenia Guarnerio
          </td>
          <td>2025-11-20</td>
          <td>Cancer Research Communications</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Lifelong immunosuppressive therapy is required to prevent allograft rejection in organ transplantation. Current immunosuppressants effectively suppress adaptive and innate immune responses, but their broad, antigen-non-specific effects often result in severe off-target complications. It remains a significant unmet medical need in transplant medicine. In this study we investigated immunosuppressant effects of four major immunosuppressant classes, including tacrolimus, prednisone, mycophenolate mofetil (MMF), and fingolimod (FTY), on the gut microbiome, metabolic pathways, lymphoid architecture and lymphocyte trafficking after up to 30-day chronic exposure. Despite their distinct mechanisms of action and not designed to target the gut, all immunosuppressive drugs induced profound and time-dependent alterations in both intestine gene expression and gut microbiome composition. Progressive alterations from moderate early, drug-specific changes to a strikingly convergent microbial dysbiosis, marked by significant expansion of pathobionts of Muribaculaceae, occurred across all drug classes. Concurrently, all drugs uniformly induced significant suppression of mucosal immunity including B cell, immunoglobulin, and antigen recognition. Time-dependent changes in lymph node (LN) reorganization and cellular composition were also observed, marked by a progressive shift toward pro-inflammatory phenotypes in gut-draining mesenteric LNs and a gradual loss of tolerogenic architecture in peripheral LNs. Drug-specific metabolic alterations and distinct phases of intestinal transcriptional responses were also characterized. Notably, MMF and FTY demonstrated the most robust immunomodulatory properties, and were able to acutely suppress alloantigen-induced inflammation through mediating regulatory T cell distribution and LN remodeling. Together, our findings show that immunosuppressants elicit complex, time-dependent effects that remodel the gut and exert compartment-specific impacts on lymphoid tissues, differentially affecting gut-draining mesenteric versus peripheral LN. Understanding these relationships offers new opportunities for refining immunosuppressive strategies to reduce treatment-related off-target complications and improve long-term organ transplant outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3e9ffe364b9010df902675300b16b741613e61f6" target='_blank'>
              Immunosuppressants rewire the gut microbiome-alloimmune axis through time-dependent and tissue-specific mechanisms
              </a>
            </td>
          <td>
            Long Wu, Allison Kensiski, Samuel J. Gavzy, Yang Song, H. W. Lwin, Michael France, Dejun Kong, Lushen Li, Ram Lakhan, V. Saxena, Wenji Piao, Marina W. Shirkey, Valeria R. Mas, Brendan Lohmar, Yan Shu, Jonathan S. Bromberg, B. Ma
          </td>
          <td>2025-11-26</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="CD8⁺ T lymphocytes are pivotal effectors of adaptive immunity, executing cytotoxic mechanisms essential for pathogen clearance, tumor surveillance and tissue protection. Their activity is shaped by antigenic stimulation, cytokine networks and the metabolic and structural architecture of the tissue microenvironment. Physical exercise has emerged as a potent, non-pharmacological modulator of CD8⁺ T cell biology, capable of influencing recruitment, activation, differentiation and functional persistence. Acute exercise mobilizes effector and memory subsets, enhances trafficking to peripheral tissues and transiently alters activation thresholds, while sustained training remodels subset composition, preserves mitochondrial competence and attenuates immunosenescence. These adaptations are orchestrated through integrated neuroendocrine, vascular and metabolic pathways that recalibrate chemokine gradients, nutrient availability and energetic support. However, the magnitude and direction of these effects are highly context-dependent, varying with host physiology, disease state and microenvironmental constraints. This Review integrates mechanistic and translational evidence across physiological and pathological settings—including cancer, infectious, neurological and metabolic diseases—to clarify when and how exercise can be leveraged to reinforce cytotoxic immunity. We highlight key methodological and biological challenges, and propose biomarker-guided, microenvironment-informed and adaptively titrated exercise interventions as a framework for advancing exercise from an adjunctive measure to a modulatory, precision immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/697b8e18eede93afa0da0c621d293296cae7424c" target='_blank'>
              Modulating CD8⁺ T cell immunity through exercise: mechanistic insights and implications for precision immunotherapy
              </a>
            </td>
          <td>
            Xinyuan Zhao, Xu Chen, Pei Lin, Yunfan Lin, Weiyao Feng, Meiyan Zou, Nina Li, Li Cui
          </td>
          <td>2026-01-01</td>
          <td>Theranostics</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47a86c6d791fa4b2001ba0e3619947d81149d6fc" target='_blank'>
              Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
              </a>
            </td>
          <td>
            Francesco Maura, Ciara L. Freeman, K. Maclachlan, Marta Larrayoz Ilundain, B. Ziccheddu, Erin W. Meermeier, Juan-Jose Garcés, Michael A Durante, Holly Lee, Ross S. Firestone, M. Menges, Kayla Reid, B. Diamond, M. Papadimitriou, A. Silva, P. Sudalagunta, Noémie Leblay, S. Ahn, Ethan Fuller, Edward Briercheck, Meaghen E. Sharik, Megan T. Du, Phaedra Agius, Doris K. Hansen, Xiaofei Song, Xiaohong Zhao, M. Meads, Jamie K. Teer, T. Jelínek, P. Hagner, Rachid C Baz, Melissa Alsina, A. Ramasubramanian, Eric L. Smith, S. Giralt, S. Mailankody, Leif Bergsagel, Paola Neri, M. Chesi, Jose-Al Martinez-Climent, Frederick L Locke, N. Bahlis, O. Landgren, Issam S. Hamadeh, S. Usmani, K. Shain
          </td>
          <td>2025-12-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="The cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) pathway acts as a pivotal innate immune sensor that detects cytosolic DNA and links genomic instability to antitumor immune activation. Therapeutic activation of this pathway has garnered substantial interest as a strategy to enhance cancer immunotherapy by promoting dendritic cell maturation, augmenting antigen presentation, and facilitating cytotoxic lymphocyte infiltration. However, the functional outcomes of cGAS–STING signaling are highly context dependent and influenced by both cell type and tumor microenvironmental (TME) conditions. Recent advances in single-cell and spatial transcriptomic profiling have revealed profound heterogeneity in cGAS–STING activation across distinct cellular and regional compartments within tumors. Acute and spatially restricted activation of the pathway can elicit potent antitumor immune responses, whereas chronic or dysregulated signaling may promote immune tolerance and tumor progression. Moreover, metabolic stress, epigenetic silencing, and microenvironmental immunosuppressive factors such as TGF-β and IL-10 can further modulate STING activity, leading to resistance to immunotherapy. Current translational efforts focus on next-generation STING agonists, nanoparticle-based delivery systems, and rational combination strategies with immune checkpoint blockade and metabolic modulators to overcome tumor-intrinsic resistance and minimize systemic toxicity. Understanding the cell-type-specific and spatial dynamics of cGAS–STING signaling is crucial for the rational design of precision immunotherapies. Future research should emphasize context-dependent modulation of STING activity to maximize therapeutic benefit while limiting adverse effects. Integrating multi-omics technologies and spatially guided drug delivery may ultimately enable personalized modulation of the cGAS–STING axis, transforming it into a clinically effective and safe strategy for cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7109afa0c002a7c13c763c36487000288fa7135" target='_blank'>
              Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Lusheng Wang, Sudi Zhu, Zhixian Ding, Jie Hong, Lijie Zheng, Jiting Sun, Yu Tang, Xiaohui Chen, Xiang Yong, Mengxue Hu, Zhimin Jiang, Yan Liu, Dan Wang, Heng Tang
          </td>
          <td>2026-01-07</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="T cells are central components of the adaptive immune system and play key roles in antitumor and antiviral responses. The diverse cell fates of T cells enable them to respond to different durations and strengths of antigen stimulation and various cytokine milieus in a context-dependent manner. During acute infection or vaccination, T cells differentiate into effector cells and later develop into memory cells after antigen clearance, which mediate immune protection against the same antigen. In contrast, during cancer and chronic infection, T cells fail to enter the canonical effector or memory cell differentiation path. Instead, antigen-specific T cells enter a dysfunctional, partially responsive state called exhaustion. Exhausted T cells are heterogeneous. A subset of exhausted T cells exhibits stem cell-like properties. These stem-like T cells sustain immunity through self-renewal and repopulation of terminally differentiated progenies. Stem-like properties are critical for T cell immunity induced by immunotherapy. This review summarizes recent advances in understanding the molecular mechanisms controlling the exhaustion and stemness of T cells and explores the potential of rewiring these circuits to increase the efficiency of T-cell-based immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/01145f359013ec590de5209ce820dcb252b3001d" target='_blank'>
              Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy
              </a>
            </td>
          <td>
            Zeyu Chen, Ziang Zhu, Taidou Hu, Chen Yao, Tuoqi Wu
          </td>
          <td>2025-12-19</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background Stem-like progenitor exhausted CD8+ T cells (TPEX), located within the tumor-draining lymph nodes (TDLNs), are responsible for maintaining tumor-specific responses in cancer. Although cytokines such as interleukin (IL)-15 are known to expand CD8+ T-cell subsets, transforming growth factor (TGF)-β in the TDLN is known to arrest the egress of these TPEX to the tumor microenvironment. We hypothesized that combining IL-15 stimulatory and TGF-β blocking activity would boost antitumor responses mediated by TPEX in the TDLN. Methods We developed a bifunctional TGF-βRII/IL-15 protein complex (HCW9218) and evaluated its antitumor activity in two murine models of melanoma and breast cancer. Peripheral blood, TDLN and tumor-infiltrating CD8+ T cells were characterized by flow cytometry following a single subcutaneous dose (s.c.) of HCW9218. Transcription profiling of CD8+ T cells in both murine models was performed. Synergistic activity of HCW9218 with immune-checkpoint inhibitors (ICIs) was evaluated. Finally, safety and immune profiling in patients with chemo-refractory/relapsed solid tumors was performed in a Phase 1 dose-escalating trial. Results HCW9218 was capable of localizing to the TDLNs and tumors after s.c. administration, neutralized TGF-β, expanded TPEX in TDLNs, increased chemokine-expressing effectors in peripheral circulation and promoted their infiltration into murine tumors. These data were corroborated in RNA sequencing analysis of TDLNs. ICIs significantly enhanced the effects of HCW9218 on TPEX and synergistically improved HCW9218 antitumor efficacy in melanoma and reduced spontaneous lung metastasis in breast cancer models. In a Phase 1 clinical trial, HCW9218 monotherapy was well-tolerated, reduced serum TGF-β levels, promoted and sustained CD8+ T-cell expansion in peripheral blood and CD8+ T-cell infiltration in tumor biopsies. Stable disease was reported for four of six subjects (67%) with advanced ovarian cancer treated with HCW9218. Conclusions Our findings demonstrate that combination therapy targeting immune cells critical for antitumor responses and blocking immune-suppressive environment significantly improves antitumor therapeutic efficacy. These findings provide a strong basis for using HCW9218 to enhance the efficacy of ICIs against solid tumors in the clinical setting.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f82b5cbb01e571f68c6670c836a87ce958c90377" target='_blank'>
              TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8+ T-cell subsets in lymph nodes and tumors
              </a>
            </td>
          <td>
            Varghese George, Hing C. Wong, M. Felices, M. Rubinstein, Niraj Shrestha, Natalia Valderrama, Hamidreza Farzaneh, Lin Kong, Crystal Gilkes, Alyssa Thompson, Megan Larson, Bai Liu, Xiaoyun Zhu, Gilles M Leclerc, Dongjun Chung, Juan Xie, Jordan E. Krull, Lucas Gomez, Leah Kanakaraj, Ann Bialik, J. Egan, Lijing You, Xianglan Liu, Rachael N. Teodorescu, Ana K Karen Gutierrez, Christian A Echeverri, Reynier Rodriguez, Zheng Wang, J. Xing, Neicy Gonzalez, P. Chaturvedi, Manish R Patel, R. Wangen, Qing Cao, P. Rhode, Jeffrey S Miller, Melissa A Geller
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>38</td>
        </tr>

        <tr id="Intracerebral hemorrhage (ICH) causes hematoma formation, leading to PHE, which is associated with leukocyte mobilization and increased inflammation at the site of brain injury. However, the fate of accumulated leukocytes within the hematoma and their impact on PHE expansion remain unknown. We performed single-cell immune profiling of hematoma cells from patients with acute ICH and reported a distinct phenotypic transformation of CD8+ T cells within the hematoma during the first 24 h after onset. In addition to enhanced IFN-γ production and migration capacity, these CD8+ T cells displayed remarkable glycolytic signatures. The metabolic fitness and functional reprogramming of hematomal CD8+ T cells are associated with the transcription factor FOXO1. Single-cell profiling of brain-infiltrating CD8+ T cells within the perihematomal tissues of ICH patients and cell culture assays revealed their capacity to activate microglia via the production of IFN-γ. Furthermore, the removal of hematomal CD8+ T cells reduced neuroinflammation, PHE expansion and neurological deficits in ICH mice. Thus, CD8+ T cells undergo metabolic and functional reprogramming within the hematoma during the acute phase of ICH, which contributes to PHE formation and neurological deterioration. FOXO1-driven metabolic reprogramming of hematomal CD8+ T cells drives the expansion of perihematomal edema following intracerebral hemorrhage—mechanisms and clinical implications CD8+ T cells within the hematoma are transformed during the first 24 h after ICH onset. These hematomal CD8+ T cells can possess remarkable glycolytic signatures and enhanced IFN-γ production and migration capacity, which are associated with the transcription factor FOXO1. The infiltration of CD8+ T cells in the brain augments perihematomal edema and neurological deterioration. (Figure created with BioRender). FOXO1-driven metabolic reprogramming of hematomal CD8+ T cells drives the expansion of perihematomal edema following intracerebral hemorrhage—mechanisms and clinical implications CD8+ T cells within the hematoma are transformed during the first 24 h after ICH onset. These hematomal CD8+ T cells can possess remarkable glycolytic signatures and enhanced IFN-γ production and migration capacity, which are associated with the transcription factor FOXO1. The infiltration of CD8+ T cells in the brain augments perihematomal edema and neurological deterioration. (Figure created with BioRender).">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/276070da491f835ea64518208e42721a08ff69fe" target='_blank'>
              FOXO1-driven metabolic reprogramming of hematomal CD8+ T cells drives the expansion of perihematomal edema following intracerebral hemorrhage
              </a>
            </td>
          <td>
            Jie Lin, Honglei Ren, Youliang Wang, Hanzhi Yu, Zhili Chen, Xintong Yu, Zhuyu Gao, Yan Zheng, Quanhong Wu, Yizhe Zhang, Qijian Lin, Rui Li, Decai Tian, Zhigang Cai, Qiang Liu, Ying Fu
          </td>
          <td>2025-11-14</td>
          <td>Cellular and Molecular Immunology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b9c592da5f3c0f4f7f748992e9cf8d10cdb0615b" target='_blank'>
              An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapy
              </a>
            </td>
          <td>
            Xiang Li, Jing Hu, Tian Zhang, Hongceng Li, Tao Wang, Yuxin Liu, Lan Zhang, Yonglong Wei, Shi Wei, Panpan Zhang
          </td>
          <td>2025-12-11</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Simple Summary Cancer can alter the behavior of immune cells to help tumors grow and spread. In this study, we explored how triple-negative breast cancer cells influence immune cells through direct contact and signals released by the tumor. We found that immune cells exposed to cancer cells become reprogrammed, showing increased growth and activation of pathways that support tumor progression. These changes were linked to a key signaling protein called STAT3. When STAT3 was blocked, the abnormal growth of monocytes was reduced, suggesting that targeting this pathway could help restore normal immune function. Our findings highlight how tumors manipulate immune cells towards a more pro-oncogenic phenotype and point to new strategies for improving cancer treatment by preventing immune cells from supporting tumor growth.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/49c41652e9aa2af643e0781e40ec3d484d82be01" target='_blank'>
              Tumor–Immune Cell Crosstalk Drives Immune Cell Reprogramming Towards a Pro-Tumor Proliferative State Involving STAT3 Activation
              </a>
            </td>
          <td>
            Karen Norek, Jacob Kennard, K. Fuh, Robert D. Shepherd, Kristina D. Rinker, O. Kharenko
          </td>
          <td>2025-12-30</td>
          <td>Cancers</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Smoldering multiple myeloma (SMM), which is in principle curable, may develop into life-threatening MM. Intestinal microbiota and gut-born T helper-17 (Th17) lymphocytes may contribute to this development, but the mechanisms are unclear. Here we demonstrate that administering the human commensal Prevotella melaninogenica to transgenic Vk*MYC mice that exhibit SMM-like phenotypes delays the evolution to full-blown MM. Mechanistically, P. melaninogenica increases the production of short-chain fatty acids (SCFA), thereby preventing the skewing of dendritic cells towards a pro-Th17 phenotype and subsequently accumulation of Th17 cells in the bone marrow of treated mice. P. melaninogenica or butyrate synergizes with anti-PD-L1 or anti-TIGIT to suppress myeloma progression by restraining Th17 cell expansion while inducing effector CD8+ T cells. P. melaninogenica also attenuates IL-17-mediated skin lesions that mimic anti-PD-L1-induced adverse events. Our results thus suggest that gut microbiota modulation or SCFAs administration may represent treatment options for patients affected by plasma cell dyscrasias. Smoldering multiple myeloma (SMM) may develop into life- threatening MM, with gut microbiota and Th17 possibly contributing to this progression via unknown mechanisms. Here the authors use a mouse SMM model, VkMYC mice, to show that treatments with butyrate or the commensal, Prevotella melaninogenica, suppress Th17 and cancer progression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/efb834e770274d48031d910950944fb99e68ddd2" target='_blank'>
              Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
              </a>
            </td>
          <td>
            L. L. Cogrossi, Anna Policastro, Paola Zordan, Matteo Grioni, Anna Tosi, Nathalie Rizzo, Benedetta Mattorre, Marco Lorenzoni, Greta Meregalli, Sofia Sisti, F. Sanvito, A. Palmioli, Cristina Airoldi, Aurora Maurizio, Marta Chesi, Leif Bergsagel, Nicola Clementi, A. Rosato, Matteo Bellone
          </td>
          <td>2025-11-24</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Background Human T-lymphotropic virus type 1 (HTLV-1) infects up to ten million people worldwide, and causes severe diseases, including adult T-cell leukemia/lymphoma and HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP). Individuals with HAM/TSP are prone to pulmonary complications (e.g., bronchiectasis). Their bronchoalveolar lavage fluid typically shows increased levels of inflammatory cytokines, chemokines and cell adhesion molecules contributing to chronic inflammation. Results This study assessed the impact of HTLV-1 infection on lung inflammation by analyzing the alveolar transcriptome of A549 epithelial cells following exposure to HTLV-1. Co-culture with HTLV-1-infected MT-2 cells caused transcriptomic changes related to viral response, NF-κB activation, and inflammation. RT-qPCR confirmed elevated expression of the chemokine monocyte chemotactic protein-1 (MCP-1/CCL2) and colony stimulating factor 1 (CSF-1) in A549 MT-2 co-cultures. Increased CSF-1 expression was mechanistically linked to NF-κB signaling, using CRISPR/Cas9 RELA knockout. Supernatant from A549 MT-2 co-cultures triggered chemotaxis and macrophage differentiation of THP-1 and primary monocytes. Systems biology analysis revealed enrichment in pathways associated with monocyte infiltration and bronchiectasis. Finally, we validate the in vivo relevance of our in vitro model through multi-cohort multi-omics analysis combining bulk and single-cell transcriptomics, viral interactomics and multi-ancestry GWAS. Conclusions We describe an in vitro co-culture model that recapitulates HTLV-1-triggered lung inflammation, through RELA/NF-kB-dependent release of pro-inflammatory cytokines and chemokines resulting in monocyte chemotaxis, activation and differentiation. Integrated multi-omics analysis confirmed the in vivo relevance of our in vitro model.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f2fcc915bbd12bb88b05e375c5c2d91f60fb7f15" target='_blank'>
              Deciphering HTLV-1-associated Lung Pathology through Integrated in vitro and Multi-cohort Multi-omics Analysis: Inflammation, Monocyte Recruitment and Differentiation Triggered by HTLV-1-exposed Alveolar Epithelial Cells
              </a>
            </td>
          <td>
            Clément J F Heymann, M. Gouwy, Robin Hermans, J. Twizere, Tatiana Assone, J. Casseb, Isaac Racine, Isabelle Cleynen, Edward L. Murphy, Roberta Bruhn, Dominique Schols, E. Vanderlinden, J. V. Weyenbergh
          </td>
          <td>2025-11-24</td>
          <td>Research Square</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Cytomegalovirus is the leading viral cause of congenital infection with neurological sequelae. Effective medical treatments are limited due to an inadequate understanding of the underlying pathogenesis. Here, we applied single-cell transcriptomics to analyze neonatal mouse brains with congenital cytomegalovirus infection (cCMV). We profiled cCMV in 22 cell types and identified neural progenitor cells (NPCs) and monocyte-derived macrophages (MDMs) as the most commonly infected cells. Infected NPCs exhibited dysregulated neurodevelopment-associated signaling pathways, correlating with viral transcript levels that indicate viral replication levels. Genes associated with phagocytosis and antigen presentation were downregulated exclusively in infected MDMs but remained largely unaffected in microglia and barrier-associated macrophages regardless of infection status. Analysis of intrinsic and induced interferon-stimulated gene expression revealed great heterogeneity across cell types but no direct correlation with cCMV susceptibility. Furthermore, our findings indicate that interferon type II is crucial for the control of cCMV and consequent cortical damage and calcification in the neonatal brain. This study advances our understanding of cCMV tropism and the molecular details of cCMV-induced neurodevelopmental impairment, cerebral immune response, and brain pathology.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/37e868bb50c4bf02ba4bc61b84aaec7d5968b07e" target='_blank'>
              Molecular features of congenital cytomegalovirus infection in neonatal mouse brain at single-cell resolution
              </a>
            </td>
          <td>
            Meng-Jie Mei, Yue-Peng Zhou, Yu-Ting Pan, Jin-yan Sun, Wen-Bo Zeng, Tong Wu, M. McVoy, William J. Britt, Wen Zhou, Bo Yang, Xuan Jiang, Simon Rayner, Han Cheng, Min-Hua Luo
          </td>
          <td>2025-11-17</td>
          <td>Acta Neuropathologica Communications</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="Secreted phosphoprotein 1 (SPP1+) macrophages are a recurrent and functionally critical immune cell subset across multiple cancer types. They drive adverse clinical outcomes by promoting immunosuppression, tumor invasion, metastasis, and therapy resistance. Given their prevalence and pivotal role, SPP1+ macrophages have become a major focus in cancer immunology and a promising target for therapeutic development. SPP1+ macrophages have been identified in a wide range of human malignancies through single-cell RNA sequencing and spatial transcriptomics studies. Their differentiation and maintenance are strongly influenced by reciprocal cellular interactions and hypoxic conditions within the tumor microenvironment (TME). Within the tumor microenvironment (TME), SPP1+ macrophages promote tumor progression by interacting with cancer-associated fibroblasts (CAFs) and helping to form a physical barrier that restricts immune cell infiltration into the tumor core. Specifically, they impair the recruitment of CD8+ T cells and promote T cell exhaustion (TEX). In this review, we focus on recent advances in understanding the differentiation of SPP1 macrophages in hypoxic tumor microenvironment and the role of SPP1+ macrophages in immunosuppression and their therapeutic implications in cancer. Targeting this subset of macrophages has emerged as a highly promising therapeutic strategy, with several approaches demonstrating encouraging results in preclinical models.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7c7489149a391c5b3e442dad42f10334718f488" target='_blank'>
              SPP1+ macrophages in tumor immunosuppression: mechanisms and therapeutic implications
              </a>
            </td>
          <td>
            Juanjuan Wang, Ya Wang, Yuqing Liu, Rongcun Yang
          </td>
          <td>2025-12-05</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Lung cancer remains the leading cause of cancer-related mortality globally, with metastasis and recurrence as the primary determinants of poor prognosis. Despite advances in immunotherapy, intrinsic and acquired resistance to immune checkpoint inhibitors (ICIs) underscores the need to explore alternative immunomodulatory strategies. Emerging evidence highlights the critical yet dual roles of innate and adaptive immune cells within the tumor microenvironment (TME) in either restraining or facilitating metastatic dissemination. Adaptive immunity, dominated by T and B cells, orchestrates context-dependent antitumor responses or immunosuppression, while innate immune dysregulation fosters metastatic niches. We highlight translational opportunities, such as natural killer (NK) cell activation, macrophage reprogramming, and dendritic cell (DC)-based vaccines, alongside prognostic biomarkers like peripheral NK activity and tryptase+ mast cell infiltration. This review summarizes the interplay of immune cell subsets, including T and B lymphocytes, macrophages, DCs, NK cells, and mast cells, in lung cancer progression. By synthesizing preclinical and clinical insights, this review identifies unresolved challenges and proposes targeting innate immunity as a promising avenue to augment current therapies and mitigate metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/42946b2788d2e767cb68fa124579a584984286cc" target='_blank'>
              Targeting innate and adaptive immunity to suppress lung cancer metastasis
              </a>
            </td>
          <td>
            Rong Qin
          </td>
          <td>2025-11-27</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Immunotherapy has transformed cancer treatments, but the majority of cancer patients would inevitably develop resistance to immunotherapy. Th17 cells play complex but crucial roles in anti-cancer immune response, although their therapeutic potential remains underutilized. Segmented filamentous bacteria (SFB) function as prototypical commensal bacteria that can induce intestinal Th17 cells and impact host immune response. In this study, we investigated how SFB antigen-mediated immune responses modify the tumor microenvironment and enhance anti-tumor efficacy through a coordinated gut–lung immunological axis. We engineered B16F1 melanoma cells to express either the SFB3340 epitope (B16-3340, an I-Ab-restricted epitope derived from SFBNYU_003340 and recognized by 7B8 TCR) or a control vector (B16-MEM) to evaluate SFB antigen effects on tumor immunogenicity. We found that expression of the SFB epitope in cancer cells decreased the number of lung tumor nodules, and SFB colonization further reduced tumor growth in a lung metastasis model. In addition, Th1, Th17, and CD8+ Tc1 cells were all increased in the lungs of the B16-3340 tumor-bearing mice compared with B16-MEM control tumor-bearing mice without triggering a compensatory expansion of immunosuppressive Tregs. Interestingly, SFB triggers systemic metabolic changes and an increase metabolites from aromatic amino acid degradation pathways, providing biochemical evidence for a functional gut–lung conduit, which integrates innate microbial detection with adaptive tumor-specific immunity. Our research provides evidence to further investigate and develop novel cancer immunotherapies that utilize microbial antigens and microbiome modifications to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c5429a38be4e5ce2d81f913e703a35d6e85fa2f2" target='_blank'>
              Commensal bacteria antigen-mediated immune response enhances anti-tumor immunity
              </a>
            </td>
          <td>
            Jessica Tzu-Chieh Lee, Soo Ngoi, Brian Deng, Megan Hill, Kai He, Yi Yang, Bei Liu
          </td>
          <td>2025-12-24</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Immune checkpoint blockade (ICB) therapy can restore T cell function in tumors, but not all patients benefit, and the mechanisms behind this remain unclear. In this study, we used patient-derived organotypic (PDO) cultures from metastatic melanoma to examine transcriptomic and cellular changes following ex vivo T cell stimulation. Genomic and transcriptomic features were preserved during PDO formation, capturing melanoma heterogeneity. PDOs from ICB-responsive patients showed rapid T cell expansion upon T cell stimulation, unlike those from ICB-resistant tissue. Resistant tissue harbored T cells lacking activation and checkpoint markers, suggesting non-tumor-reactive T cells. A T cell-specific transcriptomic score, activated in responsive PDOs, correlated with improved overall and relapse-free survival in metastatic melanoma patients treated with ICB. These findings demonstrate that ex vivo analysis is a viable tool to investigate mechanisms of ICB response and may help identify predictive biomarkers for patient outcome.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4ed50cf99fb67ea8136c8c566f1253db09fe9441" target='_blank'>
              Modeling anti-tumor immune responses using patient-derived melanoma organoids
              </a>
            </td>
          <td>
            Kamila Kaminska, B. Phung, Jacob Karlström, M. Lauss, K. Harbst, Teresa Svensson, Kristian Pietras, Kari Nielsen, Ana Carneiro, Henrik Ekedahl, K. Isaksson, G. Jönsson
          </td>
          <td>2025-12-23</td>
          <td>Cancer Immunology, Immunotherapy : CII</td>
          <td>0</td>
          <td>35</td>
        </tr>

        <tr id="Background CD8+ T cells play a critical role in controlling Plasmodium infection. CD103, an integrin composed of αE and β7 subunits, is widely recognized as a cell surface marker for tissue-resident memory T (TRM) cells and tumor-infiltrating lymphocytes (TILs). Methods In this study, a Plasmodium infection model was constructed by intraperitoneally injecting 106 infected red blood cells (iRBCs) into C57BL/6 mice. CD45+ cells in the spleen of naïve and infected mice were sorted and subjected to single-cell RNA sequencing (scRNA-seq). The content, activation, and function of CD103+CD8+ T cells were detected using flow cytometry. qPCR and dual-luciferase reporter assays were performed to find the key transcription factor. Results Here, we identified a substantial subset of CD103+CD8+ T cells in the spleen of naïve mice, whose proportion and count declined rapidly following Plasmodium yoelii NSM infection. Compared to CD103−CD8+ T cells, in both naïve and infected mice, CD103+CD8+ T cells exhibited higher CD62L expression and lower levels of CD44, CD69, and TIGIT, and they rarely secreted IFN-γ or granzyme B upon PMA plus Ionomycin (PI) stimulation. Single-cell RNA sequencing revealed that differentially expressed genes (DEGs) were enriched in pathways related to “cytoplasmic translation” and “ribosome biosynthesis”, suggesting that these cells are in a pre-activation preparatory state. Bioinformatics predictions and dual-luciferase reporter assays indicated that the transcription factor LEF1 may regulate Itgae transcription by binding to its promoter sequence. Conclusions Collectively, our findings demonstrate that splenic CD103+CD8+ T cells express fewer activation and function-associated molecules, which may contribute to their limited role in the course of P. yoelii NSM infection in C57BL/6 mice, and implicates LEF1 in the regulation of CD103 expression.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/26c65e436b43e2a39c5306b49d6e606b3474d43e" target='_blank'>
              Characteristics of CD103+CD8+ T cells in the spleen of Plasmodium yoelii NSM-infected mice
              </a>
            </td>
          <td>
            Xingfei Pan, Feihu Shi, Shanni Tang, Meiling Liu, Li Pan, G. Liang, Lu Li, Hongyan Xie, Shan Zhao, Jun Huang
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Cellular and Infection Microbiology</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Brain metastasis is a major contributor to mortality in patients with lung cancer. The unique microenvironment of the brain plays a critical role in the initiation and progression of brain metastases (BM), yet the molecular mechanisms underlying tumor-microenvironment interactions remain poorly understood. Here, we demonstrate that upregulation of lipocalin-2 (LCN2) in tumor cells promotes brain metastatic progression by orchestrating crosstalk among metastatic tumor cells, astrocytes, and macrophages. Brain metastatic tumor cells secrete LCN2, which binds to SLC22A17 on astrocytes, activating JAK2/STAT3 signaling and inducing astrocyte activation and chemokine secretion, thereby facilitating macrophage recruitment. In turn, macrophages secrete IL-1β, which further upregulates LCN2 expression in tumor cells. Prophylactic administration of the IL-1 receptor antagonist anakinra inhibits BM formation, whereas therapeutic administration alone is ineffective. However, treatment with the STAT3 inhibitor SH4-54, either alone or in combination with anakinra, significantly suppressed tumor growth in the BM. Furthermore, tumor-secreted LCN2 can bind to SLC22A17 on tumor cells, activating JAK2/STAT3 signaling and promoting VEGF-A expression and release, which enhances tumor neovascularization. Inhibition of this axis with SH4-54, bevacizumab, or their combination effectively reduces the tumor burden in BM-bearing mice. These findings underscore the central role of LCN2 in driving brain metastasis and highlight a potential therapeutic strategy for targeting brain metastatic lung cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29f281e09a6235d0b0b2baf53693c1b005b871ad" target='_blank'>
              Lipocalin-2 drives brain metastatic progression through reciprocal tumor-microenvironment interactions in lung cancer
              </a>
            </td>
          <td>
            Yixiang Zhu, Jian Zhang, DanMing He, Hongqing Cai, Yan He, Li Yuan, Si-Shang Li, Yucheng Dong, Zhuang Wei, Zhijie Wang, J. Duan, Xue Zhang, Zixiao Ma, Hua Bai, Jie Wang
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Background Acute myeloid leukemia (AML) is characterized by a complex interplay between genomic alterations, aberrant hematopoiesis, and immune evasion. The aryl hydrocarbon receptor (AHR) pathway is a critical player in this phenomenon determining the fate of stem cell differentiation as well as dictating immune cell development and function. Despite this critical connection, little is known about how AHR regulates the immune microenvironment in AML. Methods We performed a retrospective study examining the pre-treatment effect of immune cell numbers (T and NK cells) in the bone marrow and their impact on overall survival in AML patients undergoing 7+3 induction chemotherapy. Utilizing flow cytometry and both bulk and single-cell RNA sequencing of AML patient samples, we characterized the immune signature of blast cells and the influence of AHR on the immune microenvironment. Lastly, we performed functional studies to determine impact of pharmacological and genomic AHR inhibition on NK cell function. Results Higher bone marrow NK cell percentage in ND-AML correlated with poorer OS and expression of HLA-E on leukemic blasts. AHR upregulation was associated with HLA-E expression on blasts and an innate immune resistant signature defined by upregulation of key cytokine pathways, interferon gamma (IFN-g) pathway, and MHC class I/II as well as impaired NK cell profiles. High AHR expression in AML was associated with monocytic maturation and discrepant MHC class I/II profiles. Pre-treatment of blasts with an AHR inhibitor (AHRi) prior to NK cell killing assay downregulated key checkpoint molecules, including HLA-E, and key IFN-g signaling transcription factors (STAT1, IRF1) and led to enhanced NK cell killing among multiple FAB subsets in AML. Conclusion The data support targeting the AHR pathway as a dual tumor intrinsic and immune targeting therapeutic strategy for AML, particularly in combination with NK cellular therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7893eab44f440eeeac15c67dc9e41e9217e3fc7f" target='_blank'>
              The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor
              </a>
            </td>
          <td>
            Jennifer N Saultz, D. Bottomly, Faith Burns, K. Byrd, Yoko Kosaka, Bernhard Alber, Daniel J Chandra, Stephen Kurtz, Guang Fan, A. Kaempf, Nicola Long, Marta Sanchez-Martin, Lei Wang, Karen McGovern, D. S. Kaufman, Shannon K. McWeeney, B. Druker, Jeffrey W. Tyner, Evan F. Lind
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>127</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bb706d249cfb2775d83ca53d2e8588e8894f0cf6" target='_blank'>
              Dual Transcriptional Drivers of Immune Suppression in SACC: NOTCH1 for Cellular and MYB for Humoral Immunity
              </a>
            </td>
          <td>
            Guoliang Yang, Xudong Wang, Tian Ye, Tingyao Ma, Youmei Chen, Fang Nan, Qian Chen, Lu Kong, Xiao-hong Chen
          </td>
          <td>2025-11-17</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Nasopharyngeal carcinoma (NPC) exhibits a heterogeneous tumor immune microenvironment (TIME) shaped by chemokine signaling, yet the functional roles of tumor-derived chemokines remain elusive. This study integrates single-cell RNA sequencing (scRNA-seq) of NPC tissues with validation in 109 primary patient samples, revealing CXCL10 and CCL20 as tumor-secreted chemokines localized to distinct malignant epithelial subpopulations with antagonistic roles. CXCL10 correlates with prolonged progression-free survival (PFS) and enriches an immune-active TIME by recruiting CD8+ T cells and CD20+ B cells, whereas CCL20 associates with poor prognosis and immunosuppression through preferential recruitment of regulatory T cells (Tregs). Functional validation via in vitro chemotaxis assays and in vivo xenograft models demonstrates that CXCL10 overexpression suppresses tumor growth by enhancing effector immune cell infiltration, while CCL20 promotes Treg accumulation without impeding tumor progression. Mechanistically, Tregs in NPC exhibit elevated expression of co-inhibitory molecules (CTLA4, TIGIT) and engage B cells via CTLA4-CD86 signaling, potentially impairing antigen presentation. Multi-omics analysis of bulk RNA-seq, immunohistochemistry, and cell-cell communication further delineates the antagonistic interplay between CXCL10-driven immune activation and CCL20-mediated immunosuppression. Our findings establish CXCL10 and CCL20 as dual regulators of TIME polarization in NPC, offering prognostic biomarkers and therapeutic targets to rebalance antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b7ab7c111c33778576a3a9efa3929d5f7845ac13" target='_blank'>
              Tumor-Derived CXCL10 and CCL20 Polarize the Immune Microenvironment in Nasopharyngeal Carcinoma via Competitive Recruitment of Effector T Cells and Tregs
              </a>
            </td>
          <td>
            Benjian Zhang, Xiaotian Yuan, L. Meng, Yunqing Liu, Yaxuan Wang, Zirong Chen, Haoxiang Zeng, Xinyue Zhang, Z. Peng, Hua Zhang, Weihong Jiang
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Medical Sciences</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Lymph nodes, brain, bone, and liver are recognized as the four most common metastatic sites for lung adenocarcinoma (LUAD). Metastasis to these locations exhibits some common features, such as immune suppression, and distinct tumor microenvironment (TME) heterogeneity involving differentiation of immune cells, impacting treatment efficacy and prognosis. Lymph node metastases are characterized by immune suppression with exhausted CD8+ T cells, expanded regulated T cell (Tregs), M2-polarized macrophages, and high programmed death ligand-1 (PD-L1) expression. Brain metastases display an “immune desert” phenotype due to blood–brain barrier constraints, reduced T-cell infiltration, and microglia-mediated immunosuppression. Bone metastases involve osteoclast activation, RANKL/OPG pathway dysregulation, and metabolic reprogramming, while liver metastases show Kupffer cell-driven PD-L1/ programmed death 1(PD-1) axis suppression and elevated Treg infiltration. Key biomarkers across all types of metastases include PD-L1, cytokine profiles, immune cell ratios, and metabolic markers. Therapeutic strategies focus on combination therapies such as immune checkpoint inhibitors (ICIs) with metabolic modulators, localized drug delivery, and biomarker-guided approaches. Challenges in this field encompass spatial heterogeneity, dynamic TME evolution, and clinical translation barriers. Future research directions highlight spatial transcriptomics, microbiome interactions, and organoid models to optimize personalized immunotherapy. This article aims to provide a comprehensive review of regarding TME alterations across these four main metastatic locations of LUAD. It will also discuss relevant TME biomarkers and their clinical significance on therapeutic response and prognosis. We expect this article to serve as a source of evidence and inspiration for the future development of treatment strategies based on LUAD TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8eac0fc7ba7c67303e9257f2a2d91aba7b28ddab" target='_blank'>
              Unraveling the alterations and biomarkers in the tumor microenvironment in lung adenocarcinoma metastases and their indications for therapeutic response and prognosis
              </a>
            </td>
          <td>
            Chao Guan, Xiangmin Li, Xiaoshan Zeng, Zhenguang Du, Zhicheng Zhou, Jungang Zhao, Lele Song, Li Yu
          </td>
          <td>2025-12-01</td>
          <td>Therapeutic Advances in Medical Oncology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ac65d0a777c8fee565b72f8796585bc82b593d9b" target='_blank'>
              Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness.
              </a>
            </td>
          <td>
            Onur Eskiocak, Joseph Gewolb, Vyom Shah, James A Rouse, Saria Chowdhury, E. O. Akyildiz, Inés Fernández-Maestre, Jacob A. Boyer, A. Filliol, Alexander S Harris, Raditya Utama, Guangran Guo, Carolina Castro-Hernández, Emmanuella Nnuji-John, C. Chung, Arianna Anderson, Sara Flowers, Jill Habel, P. Romesser, Ross L. Levine, Scott W. Lowe, Michel Sadelain, Semir Beyaz, Corina Amor
          </td>
          <td>2025-11-25</td>
          <td>Nature aging</td>
          <td>3</td>
          <td>30</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dc6a28b4224c2b2503480a6b2e0edc6bbd8d9c3" target='_blank'>
              Innate antiviral readiness drives the expansion of protective T stem cell memory against influenza
              </a>
            </td>
          <td>
            Ivan Tomic, David J Ahern, J. Tomalka, Alba Escalera, T. Aydillo, Matthew D. Pauly, Nadine G Rouphael, S. Lakdawala, Naseem Sadek, E. Clutterbuck, Nisha Singh, P. Aley, H. Robinson, S. Marinou, Stephanie Hao, Matthew Fish, Helder Nakaya, Claudia Monaco, Adolfo García-Sastre, Andrew J Pollard, Adriana Tomic
          </td>
          <td>2025-12-10</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Intratumoral microbiota, once considered passive bystanders, are now recognized as active modulators of the tumor immune microenvironment (TIME)—the complex network of immune cells, stromal components, and signaling molecules within tumors—and ultimately shape immunotherapy outcomes in lung cancer. This review aims to elucidate the exact roles of intratumoral microbiota in lung cancer immuno-therapy responses and the potential mechanism, offering novel perspectives for overcoming resistance. We conducted a narrative review of the literature using a PubMed and Web of Science search of articles written in English from inception to November 2025. We summarize current evidence on the characteristics of intratumoral microbiota in lung cancer and their associations with patient outcomes following immune checkpoint inhibitor (ICI) treatment. We discuss how intratumoral microbes, their metabolites, and extracellular vesicles influence and remodel TIME, thereby either promoting or counteracting ICI efficacy. Furthermore, we explore the potential of microbial signatures as predictive biomarkers and highlight microbiota-targeted strategies—including probiotics, engineered bacteria, and rational antibiotic use—to overcome resistance and enhance clinical benefits. Collectively, available data support intratumoral microbiota as crucial modulators and promising therapeutic targets in lung cancer, and decoding their multifaceted interactions may inform precision microbiota-targeting strategies to improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2006fdd2f61405d8e1cfadd1dbfd7f850047381" target='_blank'>
              Intratumoral Microbiota in Lung Cancer: Emerging Roles in TME Modulation and Immunotherapy Response
              </a>
            </td>
          <td>
            Xue Yang, Liyuan Yin, Zhuoying Tian, Qing-xia Zhou
          </td>
          <td>2025-12-25</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background Bone metastasis (BM) drives therapeutic resistance and mortality in nasopharyngeal carcinoma (NPC). Tumor metabolites are crucial for NPC metastasis; however, the mechanisms by which these metabolites synergistically alter the immune microenvironment to promote BM remain unclear. Methods In this study, limited immune infiltration was observed in the NPC BM tumor microenvironment. Multiomics analysis has identified sphingosine kinase 1 (SPHK1) as a pivotal mediator driving BM and immune evasion in NPC, orchestrating the production of 1-phosphorylated sphingosine (S1P), which is critical for NPC pathogenesis. Results The aberrant buildup of lipid metabolites, along with immune microenvironment shifts, serves as a critical driver of NPC BM. Mechanistically, S1P enhanced osteoclast recruitment via S1PR3 binding and activated the Hippo pathway, worsening bone colonization and facilitating immune evasion by expanding the exhausted CD8+ T cell population. Conclusions The synergy between the SPHK1 inhibitor PF543 and anti-programmed cell death protein 1 therapy amplified treatment effectiveness beyond standalone approaches. Overall, the SPHK1/S1P pathway advances NPC growth and aids in suppressing immune defense. Regulation of lipid metabolism may be a therapeutic target against BM in NPC and may improve the effectiveness of immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7f5767ecd0ec511f2027d46eb857b0d775229ca9" target='_blank'>
              Aberrant lipid metabolism reshapes the immune landscape in bone metastasis of nasopharyngeal carcinoma
              </a>
            </td>
          <td>
            Yuanyuan Feng, Hongmei Wang, Ziyan Zhu, Wenxiang Deng, Xiaoyue He, Yingying Yao, Miao Song, Xiaohong Peng, Yanling Lin, Longmei Cai
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Prostate cancer remains one of the most prevalent solid tumors in men worldwide and poses a major therapeutic challenge due to its immunologically “cold” tumor microenvironment (TME), which is characterized by low T cell infiltration, limited antigen presentation, and high levels of immunosuppressive factors. While chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies, it has yielded limited success in solid tumors such as prostate cancer. Macrophage-based CAR (CAR-M) therapies have emerged as promising alternatives, owing to macrophages’ natural tumor-infiltrating capacity, phagocytic activity, and ability to modulate the TME. However, conventional CAR-Ms exhibit limited capacity to prime adaptive immunity due to insufficient co-stimulatory signaling. To address this limitation, we engineered two novel NKG2D-targeted CAR constructs for macrophages: one containing the intracellular Fc receptor common γ chain (FcRγ) alone (CAR-M), and another incorporating both FcRγ and the intracellular domain of the co-stimulatory molecule CD86 (CD86-CAR-M). These constructs were expressed in Raw264.7 macrophages or and evaluated for antigen-specific phagocytosis, tumor cell cytotoxicity, cytokine secretion, and T cell activation in vitro. In vivo efficacy and safety were assessed using both xenograft and syngeneic mouse models of prostate cancer, including combination therapy with anti-PD-L1 checkpoint blockade. Both CAR-M and CD86-CAR-M exhibited robust, antigen-specific phagocytosis and cytotoxicity against NKG2D ligand-expressing prostate cancer cells in vitro. CD86-CAR-Ms demonstrated enhanced M1 polarization, higher expression of CD86 and superior activation of cytotoxic T lymphocytes, accompanied by increased secretion of IFN-γ and TNF-α. This interaction triggers the phosphorylation of ERK, a central mediator of M1 macrophage polarization and inflammatory responses. In vivo, CD86-CAR-Ms achieved greater tumor suppression and survival benefit than CAR-Ms in immunocompetent models and significantly enhanced the efficacy of anti-PD-L1 antibody therapy without systemic toxicity. The improved anti-tumor effect was associated with increased T cell, NK cell infiltration and macrophages MHC-II expression, indicating TME reprogramming from cold to hot one. This study presents the first demonstration of CD86-enhanced CAR-macrophages targeting NKG2D ligands in prostate cancer. By integrating innate and adaptive immune activation, CD86-CAR-Ms represent a novel and potent strategy for overcoming immunosuppression and improving the therapeutic efficacy of immune checkpoint inhibitors in solid tumors.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a92502fd070af58b4a67230d880201dd22ee2fc7" target='_blank'>
              CD86 costimulation enhances the antitumor activity of NKG2D CAR-Macrophages and synergizes with Anti-PD-L1 therapy to suppress prostate cancer progression
              </a>
            </td>
          <td>
            Abdulrahman Ibrahim, Zihao Liang, Wan Liu, Xiaofei Di, Lawan Rabiu, Rong Li, Pengchao Zhang, M. A. Saliu, Maoxuan Liu, Guizhong Zhang, Xiaochun Wan, Dehong Yan
          </td>
          <td>2025-11-25</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Staphylococcal enterotoxins (SE) crosslink the MHC‐II on antigen‐presenting cells (APC) with the T‐cell receptor, inducing a polyclonal T‐cell response. Although APCs are the initial targets of SE and are critical in shaping subsequent T‐cell activation, the effects of SE on APC function remain poorly understood. This study investigates the immunomodulatory effects of staphylococcal enterotoxin A (SEA) on monocytes and their differentiation into monocyte‐derived dendritic cells (moDC) or macrophages (MDM). Transcriptomic analyses of human monocytes via RNA sequencing revealed SEA‐induced enrichment of gene pathways associated with inflammation, infection, and dermatitis, effects that were amplified in the presence of T cells. Phenotypic and functional characterization showed that SEA‐primed monocytes differentiated into MDM with an altered polarization, deviating from classical M1/M2 pathways. SEA‐primed MDM exhibited downregulation of key markers, including HLA‐DR, CD80, CD86, and PD‐L1. Functional assays demonstrated that SEA‐primed MDM pushed hyperinflammatory T‐cell responses, with significantly enhanced proliferation and IFN‐γ secretion. In contrast, following SEA‐priming, moDC retained robust antigen‐presenting capabilities and displayed enhanced expression of molecules involved in T‐cell interactions. These findings provide mechanistic insights into SEA‐mediated immune modulation, illustrating how SEA reprograms MDM functions and amplifies proinflammatory T‐cell responses. This advances our understanding of superantigen‐driven immune interactions, offering a foundation for developing therapeutic strategies to mitigate superantigen‐mediated immune conditions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/31b8b3bf0438451c3b982c5f615c660d9c3ce361" target='_blank'>
              Staphylococcal Enterotoxin A Shapes Monocyte Transcription and Macrophage Polarization: Implications for Immune Responses in Infection and Inflammation
              </a>
            </td>
          <td>
            C. Arasa, Khaleda Rahman Qazi, David Brodin, Manuel Mata Forsberg, E. Sverremark-Ekström
          </td>
          <td>2025-12-01</td>
          <td>European Journal of Immunology</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Human epidermal growth factor receptor 2 (HER2) -positive breast cancer exhibits aggressive clinical progression and unfavorable outcomes. While HER2-directed agents and immune checkpoint inhibitors have transformed clinical management, persistent challenges include suboptimal response rates and acquired resistance. These limitations underscore the critical need for alternative therapeutic approaches. Our investigation, leveraging single-cell transcriptomic data derived from both healthy and neoplastic breast tissues, sought to elucidate the specific cellular subsets and regulatory pathways that contribute to the aggressive characteristics of HER2 + breast cancer. Subsequent validation of these findings was achieved through the incorporation of bulk transcriptomic datasets from various breast cancer cohorts, alongside spatial transcriptomics data pertaining to HER2 + breast malignancies, and comprehensive multiplex immunohistochemistry examinations. We identified a marked elevation of SPP1 + macrophages, displaying an M2-like immune-suppressive phenotype, within the tumor microenvironment. These particular macrophage populations were deeply implicated in modulating T cell activities and consistently correlated with adverse patient outcomes. At a mechanistic level, we ascertained that SPP1 + macrophages bolster the immune-suppressive capacity of Tregs via engagement of the CD86-CTLA4 axis, thereby facilitating the advancement of the tumor. Furthermore, the strong association between SPP1 + macrophages and both unfavorable prognosis and advanced disease stages was corroborated in an independent, in-house HER2 + breast cancer patient group. Our work uncovered the pro-tumorigenic capabilities and underlying molecular mechanisms of SPP1 + macrophages in HER2 + breast cancer, suggesting these cells represent a promising new therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/360fa2e94ffa34ef9dfde744e04829860bffbcf7" target='_blank'>
              SPP1 + macrophage and Treg interaction mediates immunosuppression and adverse survival in HER2 + breast cancer
              </a>
            </td>
          <td>
            Hao Gao, K. Shen, Luhong Chen, Chao Huang, Jie Ji, Xiaochao Zhu
          </td>
          <td>2025-11-26</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Cellular senescence is a hallmark of cancer and induces senescence-associated inflammatory responses in the tumor microenvironment (TME). CDKN1A, an important cellular senescence marker, plays significant roles in cell proliferation, invasion, migration, and apoptosis. Previous studies have implied its drug resistance role in certain cancer types. However, its impact on immunotherapy efficacy in advanced LUAD remains unclear. Using TCGA and SU2C-MARK cohorts, we investigated CDKN1A’s biological features in advanced LUAD, analyzing pathway regulation, immune infiltration, and immunotherapy associations. Single-cell RNA sequencing (GSE148071) validated TME and cellular communication differences between CDKN1A high/low expressing tumors in advanced LUAD. CDKN1A expression was positively associated with immunosuppressive environment including extracellular matrix, cancer-associated fibroblasts (CAFs) and myeloid-derived suppressor cells (MDSCs) in advanced LUAD for both TCGA and SU2C-MARK cohorts (P < 0.05). CDKN1A showed significantly positive correlations with many senescence genes in advanced LUAD (P < 0.05), which were also positively associated with endothelial cells, epithelial cells, fibroblast cells and macrophages, but negatively associated with immune cells (P < 0.05). In multivariable cox regression, patients with high CDKN1A expression had worse OS (HR = 2.74, 95% CI = 1.31–5.73, P = 0.007) and PFS (HR = 1.78, 95% CI = 1.01–3.11, P = 0.045) than those with low CDKN1A expression when treated with immunotherapy. In contrast, the high CDKN1A expression was not associated with PFS and OS in the TCGA cohort, in which the LUAD patients received standard chemotherapy, suggesting the immunotherapy predictive role instead prognostic role of CDKN1A. Moreover, single-cell analysis revealed that CDKN1A highly expressed tumors were accompanied by an enrichment of stromal and endothelial cells within the tumor microenvironment, along with enhanced activity of SMAD3/4, the downstream transcription factors of TGFB signaling. These tumors exhibited increased cell–cell communication with stromal cells (COL1A1/COL1A2-ITGA1/ITGB1/SDC1) and endothelial cells (NAMPT-ITGAS/ITGB1/INSR). CDKN1A expression was associated with cellular senescence, immunosuppressive environment and exhibited resistance to immunotherapy in advanced LUAD, suggesting a potential combination strategy with senolytic or senomorphic therapies to overcome immunotherapeutic resistance in the future.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a7f34f805e0422258abbde7dbe983d9c6f010ed5" target='_blank'>
              CDKN1A and cellular senescence are associated with immune resistance in advanced lung adenocarcinoma
              </a>
            </td>
          <td>
            Wang Shen, Feidie Duan, Shuiting Fu, Peng Cui, Yezhen Shi, Lei Zhang, Xiao Mi, Yu Xu, Guoqiang Wang, S. Cai, Xuebing Li, Xiaojun Tang
          </td>
          <td>2025-11-18</td>
          <td>Clinical and Experimental Medicine</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Within the tumor microenvironment (TME) of solid malignancies, tumor-infiltrating antibodies, have been identified as significant modulators of tumor progression and immune response. Tumor-infiltrating antibodies predominantly secreted by plasma cells but also including a small proportion of cancer-derived antibodies. This review aims to elucidate the multifaceted roles of tumor-infiltrating antibodies in the immunology of solid tumors, focusing on their dualistic nature within the TME. This review outlines the mechanisms of B cell activation, antibody class switching, plasma cell differentiation and antibody production, with a focus on their contributions to tumor immunity in solid cancers. Additionally, we discuss the emerging potential of tumor-infiltrating antibodies as both therapeutic targets and diagnostic biomarkers, offering insights that may inform future strategies in cancer treatment. Collectively, antibody functions are shaped by their isotypes: IgG is often associated with improved prognosis in various solid tumors. IgG1 and IgG3 generally mediate anti-tumor responses via antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), while IgG4 may impair immune effector functions and associate with immune tolerance. IgM, as an early humoral responder, enhances tumor surveillance through complement dependent cytoxicity (CDC), phagocytosis, and apoptosis induction. IgA predominantly promotes tumor progression through immune suppression. IgE exhibits context-dependent pro- and anti-tumor activities, though current evidence is limited, whereas the function of IgD remains largely unknown. Additionally, tumor-derived IgG promotes tumor growth, metastasis, and immune evasion. These findings may open new avenues of research to develop targeted therapies that modulate tumor-infiltrating antibodies, potentially improving the efficacy and safety profiles of current immunotherapeutic approaches. Overall, this review focuses on tumor-infiltrating antibodies in solid tumors and does not encompass hematological malignancies, aiming to provide a more precise understanding of antibody-mediated regulation within the solid tumor microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8616bf287135d120e92e4c09a4ba7ac972e65717" target='_blank'>
              Unraveling the dual roles of tumor-infiltrating antibodies in solid tumors: friend or foe in the tumor microenvironment?
              </a>
            </td>
          <td>
            Lingrui Miao, Run Zhou, Longfei Zhang, Linlu Feng, Yiao Wang, Pan Song, Dong Lv, Tai-Min Shen
          </td>
          <td>2025-11-21</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Simple Summary Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with profound heterogeneity. While standard immunochemotherapy is curative for the majority, treatment failure in 30–40% of patients due to refractory or relapsed disease remains a significant clinical challenge, emphasizing the need for better prognostic markers. We investigated the interplay between tumor glycolytic metabolism and the tumor immune microenvironment. We identified four distinct glycolysis-related patterns that were associated with three immune subtypes (known as immune-inflamed, immune-excluded, and immune-desert). Importantly, these patterns stratified clinical outcomes and predicted chemotherapy sensitivity. For example, tumors with an immune-inflamed subtype were more sensitive to doxorubicin. Collectively, our findings propose a metabolism- and immune-based classification framework for DLBCL that may facilitate more precise risk stratification and treatment optimization.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e894f2d6a04501c694424859815514794b12befc" target='_blank'>
              Glycolysis-Driven Immune Subtypes in the Tumor Microenvironment Determine Clinical Outcomes in Diffuse Large B-Cell Lymphoma
              </a>
            </td>
          <td>
            Ying Du, Zhenyu Liu, Chuanyan Liu, Yining Yuan, Mengkun Fang, Tong Zhou, Mengge Pan, Weilu Xu, Xu Liu, Peipei Xu
          </td>
          <td>2025-12-25</td>
          <td>Cancers</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Bacillus Calmette-Guérin (BCG) remains the standard treatment for non-muscle invasive bladder cancer (NMIBC), yet approximately 30% of patients fail to respond. To enhance therapeutic efficacy, we developed rBCG-LTAK63, a recombinant BCG strain, as a novel immunotherapeutic candidate. In vitro, rBCG outperformed BCG in MB49 cell/splenocyte co-cultures by enhancing T cell activation and improving spheroid growth control. In vivo, rBCG demonstrated superior antitumor efficacy, significantly reducing the growth of subcutaneously implanted MB49 tumor cells. Immune profiling revealed that rBCG uniquely promoted systemic activation of both CD4⁺ and CD8⁺ T cells, alongside stronger activation of NK and dendritic cells in the spleen. Within the tumor microenvironment, rBCG increased immune cell infiltration, enhanced activation of CD8⁺ T cells and dendritic cells, and decreased the frequency of regulatory T cells, fostering a less immunosuppressive environment. Unlike parental BCG, rBCG-LTAK63 sustained a potent immunostimulatory profile, marked by robust activation of dendritic cells and effector T cells. Similar results were also observed in the orthotopic model, suggesting a translational potential of rBCG-LTAK63. Collectively, our findings demonstrate that rBCG outperforms conventional BCG and represents a promising strategy for improving NMIBC treatment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e4e9e8703be24629b575d1f1ca3d777b67f2abfa" target='_blank'>
              rBCG-LTAK63 Outperforms BCG in Bladder Cancer Immunotherapy: Dendritic and T Cell Coordination Drives Superior Tumor Control in a Mouse Model
              </a>
            </td>
          <td>
            Matheus Ferreira de Almeida, Bruna Gennari Rosa, Daniela Delechiave, Lucas Francisco Annequin, Lázaro M Marques-Neto, M. Trentini, Johanna Christine van Vliet, Isabelle Carolina Cotrim Gozzi, Ana Carolina de Oliveira Carvalho, Dunia Rodriguez, L. R. Pereira, G. Gaboardi, Luís Carlos de Souza Ferreira, Luciana Cezar de Cerqueira Leite, Ana Carolina Ramos Moreno
          </td>
          <td>2026-01-01</td>
          <td>International Journal of Biological Sciences</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) play a crucial role in fostering an immunosuppressive tumor microenvironment, promoting cancer progression, contributing to immune evasion and resistance to immunotherapy. However, the mechanisms by which TAMs exert these effects in gastric cancer (GC) remain unclear. Human TAMs were isolated from GC patients through magnetic sorting for RNA sequencing. THP-1 cell line and mice bone marrow-derived macrophages (BMDMs) induced TAMs were applied for functional assays. Two in-house tumor microarrays were utilized for validation: the Zhongshan Cohort, comprising 135 patients, and the Zhongshan Flow Cytometry (ZSFC) Cohort, which included 60 patients. In this study, we identified a significant accumulation of TREM2+ TAMs in GC tissues, correlating with poor prognosis. Functional assays revealed that targeting TREM2+ TAMs suppressed GC progression both in vitro and in vivo. Mechanistically, TREM2 stabilized signal transducer and activator of transcription 1 (STAT1) by preventing its ubiquitination mediated by Tripartite Motif Containing 21 (TRIM21), while simultaneously promoting STAT1 phosphorylation via spleen-associated tyrosine kinase (SYK), leading to upregulation of CCL8 and PD-L1, fostering an immunosuppressive tumor microenvironment. Furthermore, depletion of TREM2+ TAMs significantly enhanced the efficacy of anti-PD-L1 immunotherapy in GC allograft models. Collectively, our findings establish TREM2+ TAMs as key drivers of GC progression and immune evasion. Targeting TREM2+ TAMs represents a promising therapeutic strategy to overcome resistance to anti-PD-L1 therapy and reshape the tumor immune microenvironment.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8985d5e81195d7a32a0b9d10528627f6d589bb35" target='_blank'>
              TREM2 facilitates gastric cancer progression and immune evasion via inhibiting TRIM21-mediated STAT1 degradation in tumor-associated macrophages
              </a>
            </td>
          <td>
            Zihao Zhang, K. Yu, Yifan Cao, Peiyi Xie, Leihao Wang, Zhenbin Shen, Jing Qin
          </td>
          <td>2025-11-18</td>
          <td>Cell Death & Disease</td>
          <td>1</td>
          <td>18</td>
        </tr>

        <tr id="ABSTRACT Chronic persistent viral infections can lead to significant spleen damage, thus disrupting the host humoral immune response; however, the underlying mechanisms remain unclear. In this study, we employed a Lymphocytic choriomeningitis virus (LCMV) chronic infection model to investigate the effects of virus infection on spleen damage. Mice infected with Lymphocytic choriomeningitis virus clone 13 (LCMV-CL13) presented a series of pathological features, such as white pulp atrophy and reduced germinal center diameter, length, and area in the spleen. More importantly, we observed a diminished GC response alongside a weak antibody response in the chronic infection model. Single-cell RNA sequencing (scRNA-seq) further revealed the dysregulation of gene expression, including Bbc3, Atf3, and Ptpn6, which inhibit B-cell differentiation during chronic viral infection. We verify that the upregulation of Bbc3 or Atf3, respectively, can promote apoptosis in BaF3 cells. Immune repertoire (IR) analysis revealed that the molecular diversity of the BCR repertoire after LCMV-CL13 infection, specifically manifested in BCR clonal diversity, IGHV gene segment usage preference, and CDR3 sequence changes. In conclusion, this study demonstrated that chronic LCMV-CL13 infection interrupted the development of splenic B cells by increasing the expression of apoptosis genes, thus enhancing our understanding of the underlying mechanisms of B-cell development interruption during chronic viral infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/9b7874d18fa09f3125fcaf4e38c682df442d0201" target='_blank'>
              Chronic viral infections impaired the growth process of splenic B cells by upregulating Bbc3 and Atf3 in LCMV-CL13 infected mouse model
              </a>
            </td>
          <td>
            Zhe Li, Wei Yang, Fangzhou Cai, Dan-ping Li, Qian Chen, Yiteng Zhang, Jiarui Cui, Wei Wang
          </td>
          <td>2025-12-02</td>
          <td>Virulence</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, characterized by an immunosuppressive microenvironment. To address the immune desert in GBM, immunocytokine, an innovative recombinant fusion protein that combines antibodies and cytokines, has been proposed. This molecule, targeting tumor cells while stimulating immune cells, effectively enhances the anti-tumor response. Developing a novel immunocytokine presents a promising strategy for GBM. In this study, we developed a novel immunocytokine, αBC-IL15, composed of a bispecific T cell engager (BsTCE) fused to the interleukin-15 receptor alpha-sushi domain/interleukin-15 complex (IL-15/IL-15Rα). To analyze its affection on immune cells, we co-cultured it with peripheral blood mononuclear cells in vitro. To investigate whether it enhances the cytotoxicity of T cells compared to B7-H3 BsTCE, we performed cytotoxicity assays on cell lines and spheroids in vitro. Moreover, we assessed its efficacy in vivo and analyzed the tumor microenvironment using flow cytometry and bulk sequencing. Our study assessed the bioactivity and efficiency of αBC-IL15. In vitro, αBC-IL15 effectively bound to tumor cells and T cells, inducing immune cell activation, cytokine release, and cytotoxicity toward tumor cells. In vivo, αBC-IL15 connects cytotoxic immune cells with tumor cells, leading to effective immune cell infiltration and potent redirected lysis. Overall, we developed a novel bispecific immunocytokine, αBC-IL15, which targets tumor cells while enriching and activating effector immune cells. This agent significantly enhanced anti-tumor effects both in vitro and in vivo, highlighting its potential to overcome the immunosuppressive microenvironment in GBM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/04303ca0c55b928916530495ef259008c917a0c2" target='_blank'>
              A novel immunocytokine promotes T cell– and cytokine-induced killer cell-mediated antitumor immunity via a non-MHC-restricted mechanism in glioblastoma
              </a>
            </td>
          <td>
            Xiaoke Zhang, Nian Yang, Xin Tang, Nanxi Liu, Qizhong Lu, Zongliang Zhang, Long Xu, Lu Jiang, Honglin Ge, Huaqing Lu, Yongdong Chen, Mingbin Bao, Aiping Tong, Liangxue Zhou
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="The role of CARD9 in the pathogenesis of various chronic fungal infections has been established; however, the precise mechanisms underlying the pathobiology of these infections remain unclear. We aimed to investigate the specific cellular mechanisms by which CARD9 deficiency contributes to the pathogenesis of chronic fungal infections. Using single-cell RNA sequencing (scRNA-seq), we analyzed the immune cell profiles in skin lesions from both murine and human samples. We focused on macrophage differentiation and signaling pathways influenced by CARD9 deficiency. We found that CARD9 deficiency promotes the differentiation of TREM2high macrophages following fungal stimulation, impairing their antifungal functions and inducing exhaustion-like T helper 1 (Th1) cells. Mechanistically, the NF-κB pathway activation was restricted in CARD9-deficient macrophages, leading to enhanced CREB activation, which in turn exerted a positive regulatory effect on Trem2 expression by activating C/EBPβ. Notably, targeting TREM2 enhanced the antifungal immune response in vivo and in vitro, thereby alleviating the severity of CARD9-deficient subcutaneous dematiaceous fungal infection. Our findings highlight the important role of CARD9 in regulating cutaneous antifungal immunity and identify potential targets for immunotherapy in chronic dematiaceous fungal infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/47861f8fc6669fbadd445c7c3b125ff47ae444ce" target='_blank'>
              CARD9-dependent macrophage plasticity regulates effective fungal clearance.
              </a>
            </td>
          <td>
            Lu Zhang, Zhichun Tang, Yi Zhang, Wenjie Liu, Haitao Jiang, Li Yu, Kexin Lei, Yubo Ma, Yang-xin Fu, Ruoyu Li, Wenyan Wang, Fan Bai, Xiaowen Wang
          </td>
          <td>2025-12-02</td>
          <td>The Journal of clinical investigation</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Mesenchymal stem cells (MSCs) offer a promising therapy for rheumatoid arthritis (RA). However, their therapeutic potential is hindered by initial trapping in lung capillaries, which may reduce efficacy and increase risks of complications, such as unwanted differentiation and malignancy. Additionally, engineering MSCs to enhance therapeutic effects introduces further safety concerns and regulatory challenges for clinical approval. In this study, we generated enucleated human umbilical cord-derived MSCs overexpressing CCR2 and IFN-γ (En-MSCsC/I), which retained essential organelles and exhibited immune regulatory, paracrine, and homing capabilities. Intravenous administration of either MSCs or En-MSCsC/I alleviated synovitis in a male rat model of RA by modulating immune and inflammatory processes of fibroblast-like synoviocytes and myeloid cells, as revealed by single-cell RNA sequencing analysis. En-MSCsC/I promoted the secretion of factors such as SEMA3E, potentially contributing to synovitis amelioration and cartilage regeneration. Compared to MSCs, En-MSCsC/I demonstrated superior migration to injured joints and unique regulatory signature for cartilage regeneration. Our study suggests that En-MSCsC/I may offer enhanced therapeutic effects for RA-related cartilage damage while maintaining favorable safety profiles. Engineering enucleated MSCs to co-express CCR2 and IFN-γ enhances joint homing and synovial immune regulation, promoting cartilage regeneration and offering a safer, targeted therapeutic strategy for rheumatoid arthritis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c8966151255eda4efe9d5b217917248767e0250" target='_blank'>
              Engineering CCR2/IFN-γ overexpression in enucleated mesenchymal stem cells enhances therapy for rheumatoid arthritis
              </a>
            </td>
          <td>
            Yue Sui, Zixi Pu, Naixue Yang, Yifei Luo, Yalian Sa, Qi Qi, Li Tan, Yaping Yan, Wei Si
          </td>
          <td>2025-11-27</td>
          <td>Communications Biology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Most neuroendocrine cancers lack caspase 8 protein expression. While this feature was thought to facilitate escape from extrinsic apoptosis, its cancer-regulatory function has remained unexplored. Here, we devise a mouse model of small cell lung cancer (SCLC) recapitulating the lack of expression of caspase 8 seen in humans and uncover an unexpected role for necroptosis-fueled pre-tumoral inflammation resulting in reprogramming towards a neuronal progenitor cell-like state and increased metastatic disease. Notably, transcriptional signatures of this cellular state are enriched in relapsed and metastatic human SCLC. Mechanistically, caspase 8 loss within the pre-tumoral niche promotes inflammation marked by increased recruitment of regulatory T cells (Tregs) which are responsible for the promotion of metastatic disease. Importantly, inactivation of the necroptosis executioner MLKL reverses pre-tumoral inflammation, decreases metastasis as well as neuronal-like reprogramming. Taken together, our findings suggest that pre-tumoral inflammatory cell death contributes to neuronal progenitor mimicry, immunosuppression and increased metastasis in SCLC. Caspase 8 protein expression is largely absent in small cell lung cancer (SCLC) patients. Here, the authors generate a caspase 8 deletion SCLC mouse model and show that it promotes a neuronal progenitor-like cell state and pre-tumoral immunosuppression triggered by necroptosis that promotes metastasis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/51116aff6d9c1d775ef35df82108582297dade1e" target='_blank'>
              Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression
              </a>
            </td>
          <td>
            Ariadne Androulidaki, Fanyu Liu, Christina M. Bebber, Ilmars Kisis, V. Sakthivelu, Pascal Hunold, L. Koerner, Alina Dahlhaus, F. I. Yapici, Christina Grimm, Alicja Pacholewska, Sofya Tishina, Franka Doskotz, Lucia A Torres Fernández, J. Stroh, Ali T. Abdallah, Julia Beck, Lejla Mulalić, A. Schmitt, Holger Grüll, T. Persigehl, Alexander Quaas, M. Peifer, J. Brägelmann, H. C. Reinhardt, P. Nieper, Robert Hänsel-Hertsch, Roman K. Thomas, Julie George, M.-R. Schweiger, Manolis Pasparakis, Filippo Beleggia, S. von Karstedt
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>59</td>
        </tr>

        <tr id="Despite advancements in cancer therapies, bacterial complications remain a major challenge, delaying treatment and worsening outcomes. While immunosuppressive therapies and prolonged hospitalizations contribute, they do not fully explain the elevated infection risk in cancer patients. Here we show that tumors producing high levels of granulocyte colony-stimulating factor (G-CSF) promote the persistence of Gram-negative pathogens in head and neck squamous cell carcinoma due to neutrophil reprogramming. Mechanistically, we identify tumor-driven activation of the G-CSF / nicotinamide phosphoribosyltransferase (NAMPT) signaling axis in neutrophil progenitors, resulting in impaired antibacterial functions, such as phagocytosis and neutrophil extracellular traps formation, and development of tissue-damaging neutrophil subsets. This disrupts lung tissue integrity and facilitates bacterial persistence. Importantly, targeting the G-CSF/NAMPT pathway prevents the generation of dysfunctional neutrophils and improves bacterial clearance in vivo. Our findings reveal tumor-induced, NAMPT-dependent neutrophil reprogramming as a central driver of compromised antimicrobial defenses in cancer. Therapeutic strategies aimed at modulating G-CSF/NAMPT signaling could enhance infection control and survival for cancer patients. Cancer patients are at increased risk for severe bacterial infections due to immune dysfunction. Here, the authors show that chronic tumor-derived G-CSF drives NAMPT/NAD-dependent neutrophil dysfunction from the progenitor stage, and that targeting this pathway restores infection control.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/989ea783a50fee5cffb3981c7881623972aa98d2" target='_blank'>
              G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients
              </a>
            </td>
          <td>
            E. Pylaeva, Lea Tollrian, Jana Riedesel, Olga Shevchuk, Ilona Thiel, Irem Ozel, Nastassia Kabankova, Hannah Voss, B. Siebels, Hartmut Schlüter, Corinna Haist, Helmut Hanenberg, Stefan Mattheis, C. Kürten, M. Sperandio, J. Kehrmann, D. Engel, Stephan Lang, Jadwiga Jablonska
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3443903af73c8ea2603fc42506194395d5951dde" target='_blank'>
              Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
              </a>
            </td>
          <td>
            Chien-Huan Weng, Anais Assouvie, Lauren Dong, JC Beltra, S. Budhu, L. Mangarin, Yacine Marouf, Lucia Morgado-Palacin, Cailian Liu, Sébastien Monette, Jonathan F. Khan, Isabell Schulze, Dmitry Zamarin, Linda Hamadene, Fadi Samaan, Daniel Hirschhorn, S. Pourpe, David Schröder, R. Zappasodi, Pamela M. Holland, N. Anandasabapathy, E. Wherry, J. Wolchok, T. Merghoub
          </td>
          <td>2025-11-17</td>
          <td>Nature Immunology</td>
          <td>0</td>
          <td>170</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2dfa1103b42fb7aad2cf0d81519ef11fa1c555b5" target='_blank'>
              Proteomic profiling of the neuroblastoma secretome identifies extracellular vesicles as drivers of T cell suppression
              </a>
            </td>
          <td>
            Josephine G. M. Strijker, Ronja E. van Berkum, Elisavet Kalaitsidou, Arjan Boltjes, Naima Hiddink Verberne, Mirjam A. Damen, F. van den Ham, Liselotte E. Baaij, John Anderson, Jan J. Molenaar, Wei Wu, J. Wienke
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>15</td>
        </tr>

        <tr id="Besides its robust antiviral activity, type I interferon (IFN-I) also exerts immunomodulatory effects and can even drive pathology during chronic viral infections. Mechanisms that regulate IFN-I induction during virus infection, thus strongly affecting the outcome of disease, remain to be defined. Here, using the lymphocytic choriomeningitis virus (LCMV) Docile strain, we identified acid ceramidase (aCDase, Asah1) as a critical lipid-metabolic regulator of endosomal, nucleic acid-driven IFN-I responses and disease outcome during chronic virus infection. aCDase is highly expressed in plasmacytoid dendritic cells (pDCs) and required for robust early IFN-I production. aCDase deficiency resulted in ceramide accumulation, blunting IFN-α/β induction, impairing IFN-I-dependent upregulation of programmed death-ligand 1 (PD-L1) on antigen-presenting cells and preventing the exhaustion of virus-specific CD8+ T cells, leading to severe immunopathology. This pathology is abrogated by CD8+ T-cell depletion or by adoptive transfer of IFN-I-induced PD-L1-expressing macrophages. Conversely, limiting ceramide production in acid sphingomyelinase (Asm)-deficient mice prevented ceramide accumulation, and pDCs showed accelerated IFN-I induction. Mechanistically, ceramide abundance regulated IFN-I production by altering endosomal signaling microdomains. Collectively, our findings reveal ceramide homeostasis as a key determinant of IFN-I-driven CD8+ T-cell exhaustion and immunopathology during chronic viral infection and highlight aCDase as a potential therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3347a83451be199ba4cf611d6ba58e4cec09e11d" target='_blank'>
              Acid ceramidase regulates CD8+ T-cell exhaustion via type I interferon-mediated upregulation of PD-L1
              </a>
            </td>
          <td>
            Zhongwen Hu, Hossam Abdelrahman, Abdelrahman Elwy, F. Kuang, Swati Dhiman, Shafaqat Ali, Marcel Marson, Lisa Holnsteiner, Thamer A Hamdan, J. Friebus-Kardash, Elisa Wiebeck, W. Hansen, S. Scheu, Erich Gulbins, P. Lang, K. Lang, Judith Lang
          </td>
          <td>2025-12-09</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are central constituents of the tumor microenvironment (TME), recruited from circulating monocytes through chemotactic signals, and they execute complex, multifaceted functions throughout tumor progression. Functionally heterogeneous, TAMs are broadly classified into distinct subtypes that display a dynamic duality, capable of shifting between tumor-suppressive and tumor-promoting states, though the pro-tumorigenic functions tend to dominate across multiple cancer types. The polarization of TAMs is modulated by diverse cytokines and signaling networks within the TME. Key pro-tumor mechanisms include activating proliferative signaling pathways, enhancing invasive and metastatic potential, establishing an immunosuppressive TME through immune cell interactions, and conferring therapy resistance. The spatial heterogeneity of TAMs further underscores the predictive relevance. Translational research increasingly focuses on TAM-targeting strategies such as inhibiting recruitment, depleting subsets, or reprogramming function. Emerging approaches, including nanomedicine-based targeting, macrophage-mediated therapies, and novel drug formulations, highlight the importance of combining conventional treatments with immune checkpoint inhibitors (ICIs). Such combinations help overcome therapeutic resistance and improve clinical outcomes. This review systematically summarizes recent advances in TAM biology and plasticity, biomarkers from single-cell and spatial analyses for distinguishing TAM subsets, and their prognostic relevance in immunotherapy. It also discusses TAM-targeting strategies and their synergistic potential with existing therapies. Together, these insights lay the foundation for next-generation cancer treatments that precisely target TAMs to overcome therapy resistance and improve patient survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/364fbf1a7e99dd37bbe5b81db733d5ee958dbfae" target='_blank'>
              Tumor-associated macrophages in cancer: from mechanisms to application
              </a>
            </td>
          <td>
            Wan Tang, Xin Wang, Bing Han, Shuheng Jiang, Hongshi Cao
          </td>
          <td>2025-12-01</td>
          <td>Molecular Biomedicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Sepsis is a life-threatening infectious syndrome that lacks targeted pharmacological therapies and poses major challenges in reducing mortality and long-term complications such as disability and frailty. Early and intensive intervention is critical to improving prognosis and preventing multiorgan dysfunction. However, alternative treatment strategies are urgently needed for patients who do not respond to guideline-based resuscitation, such as those outlined in the Surviving Sepsis Campaign. Natural killer (NK) cells are key effectors of the innate immune system, and their balanced activity may be crucial in preventing the progression of sepsis. Given conflicting evidence on whether NK cell activity (NKA) is protective or harmful, we investigated NKA in a murine model of intra-abdominal sepsis, assessing activating and inhibitory NK receptors (NKRs), as well as NK cell subsets in whole blood, bone marrow, lymph nodes, spleen, and liver. C57BL/6 mice underwent cecal ligation and puncture (CLP) to induce mid-grade (MGS, 30% 7-day survival) or high-grade sepsis (HGS, 0% 7-day survival), with sham-operated mice as controls. Blood and immune-related organs were collected on days 1, 3, and 7 post-surgery (MGS: days 1, 3, 7; HGS: days 1, 3; Sham: day 7). Flow cytometry was used to analyze CD11b and CD27 expression to define maturation-associated cytolytic and cytokine-producing NK cell phenotypes. CD3⁻NK1.1⁺ NK cells were purified by FACS for RT-PCR of activating (Ly49D, Ly49H) and inhibitory (Ly49C, Ly49G2) NKRs, and ELISA was performed for granzyme B and IFN-γ. Our experiments consistently showed that in MGS, NKA—initially suppressed—was significantly restored by day 7 after CLP. This recovery was characterized by increased expression of activating NKRs, decreased inhibitory NKRs, expansion of terminally differentiated cytotoxic NK subsets (CD11b+/CD27−), higher total NK cell counts, and elevated granzyme B levels. In contrast, HGS, associated with high lethality, was marked by persistent suppression of NKA. The sustained impairment of NK cell phenotype is associated with lethal outcomes in sepsis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/eb614be98eef8a13c18c0dbd20e696b039440c98" target='_blank'>
              Dynamic changes of natural killer cell immunophenotypes and receptors according to the mortality in the intra-abdominal murine sepsis model
              </a>
            </td>
          <td>
            Sang Hoon Han, Yeon-Mi Hong, Dayeong Kim, Eun Hwa Lee, Hye Seong
          </td>
          <td>2025-11-19</td>
          <td>Intensive Care Medicine Experimental</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/64b7654a627cfa3016dfa9aa3fca88b428d94206" target='_blank'>
              Daily HIV pre-exposure prophylaxis enhances monocyte activation and effector function and reprogrammes cellular metabolism
              </a>
            </td>
          <td>
            G. Jameson, D. Murphy, Isabella Batten, Sarah A. Connolly, Adam H. Dyer, Annmarie White, Sarah Cochrane, D. Murphy, Laura Quinn, Emma Devitt, Giovanni Villa, S. Basdeo, Liam Townsend
          </td>
          <td>2026-01-09</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="The tumor microenvironment (TME) orchestrates tumor growth, immune evasion, and therapeutic response in head and neck squamous cell carcinoma (HNSCC). Current immune checkpoint inhibitors (ICIs) target the programmed death receptor-1/programmed death-ligand 1 (PD-1/PD-L1) axis and improve survival in recurrent, metastatic, and locally advanced HNSCC. Tumor cells produced exosomes directly suppress cytotoxic T-lymphocytes activity by modulating immune checkpoint pathways and disrupting T-cell receptor signaling. Cancer-associated fibroblast-derived exosomes (CAF-Exos) function indirectly by conditioning immune escape and tumor growth. Together, these exosomal populations cooperate to create an immunosuppressive niche that hinders the efficacy of immunotherapies. CAF-Exos induce TME changes that exclude CD8+ T-cells, promote regulatory T-cells (Tregs), and upregulate PD-L1 expression in tumor cells. The bidirectional transfer of microRNAs (miRNAs) between tumor cells and CAFs enhances epithelial–mesenchymal transition (EMT), suppresses cytotoxic lymphocytes, and undermines ICI efficacy. This review article summarizes recent publications about plasma-derived exosomes from HNSCC patients. These exosomes carry tumor and immune checkpoint markers, reflect tumor burden and treatment response, and strongly modulate immune cells by suppressing T- and B-cell activity and promoting immunosuppressive macrophages. We encourage functional and biomechanistic future studies in the field of HNSCC that examine how CAF subtypes exosomes achieve an immunoresistant TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/045447a931fd77543654643276c8475e775846e3" target='_blank'>
              Cancer-Associated Fibroblasts-Derived Exosomes as Mediators of Immunotherapy Resistance in Head and Neck Squamous Cell Carcinoma
              </a>
            </td>
          <td>
            Julia Federspiel, J. Dudas, B. Hofauer, B. Wollenberg, T. Steinbichler
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="The gene expression uncovering the molecular mechanism of liver transplantation (LT) rejection and immune tolerance remains unclear. The mice orthotopic LT rejection and tolerance models were established. Liver sections were obtained for transcriptome sequencing. A total of 2560 DEGs were identified in the rejection group. The major enrichment pathways included graft‐versus‐host disease, Th17 cell differentiation, T cell receptor signaling pathway and cytokine‐cytokine receptor interaction. The screened top 10 hub genes, including Ctla4, Ifng, Gzmb, Pdcd1, cd28, cd8a, Tbx21, and Lag3, were associated with T cell cytotoxicity and exhaustion. The gene expression levels of functional characteristics of T cell exhaustion, including Il2ra, Tnf, and Ifng were all significantly decreased in the tolerance group. Flow cytometry confirmed the significantly higher expression of TIM‐3 and PD‐1 in CD8+ T cells. Immunohistochemical staining of liver tissues also showed remarkably increased granzyme‐B‐positive cells in the rejection group. A comprehensive molecular profiling of the immune alterations was observed, especially the dynamic change of CD8+ T cell‐mediated cytotoxicity and exhaustion. This provides new insights into the molecular mechanism of LT rejection and immune tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/b85c5e46dbc443562971a29c0594086be37e3410" target='_blank'>
              CD8+ T Cell Cytotoxicity and Exhaustion Underlie Liver Allograft Rejection: Insights From a Murine Transcriptomic Atlas
              </a>
            </td>
          <td>
            Yi-Zhou Jiang, Guangpeng Zhou
          </td>
          <td>2025-11-24</td>
          <td>The FASEB Journal</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="Non-tuberculous mycobacteria (NTM) infections are difficult to cure completely with current treatments, and no specific drugs are available. However, recent reports have indicated that immune checkpoint inhibitors may effectively treat pulmonary NTM infections. In this study, we investigated the expression of immune checkpoint molecules in macrophages, the host cells of NTM, and assessed their impact on the microenvironment of infected lesions. Bulk-RNA sequencing and western blot analyses revealed that macrophages infected with Mycobacterium avium, an NTM species, exhibited a pro-inflammatory phenotype and increased PD-L1 expression. Additionally, immunostaining of an NTM-infected mouse model and human tissues showed that increased PD-L1 expression in macrophages was associated with decreased T cell infiltration and increased T cell exhaustion (upregulated PD-1 expression) within infected lesions. These findings suggest that NTM infections evade cellular immunity by enhancing PD-L1 expression in macrophages. Therefore, PD-L1 inhibition may be a promising therapeutic strategy against NTM infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ac4e6d1c3dbb18bdbd00c3822726e374ee76d3e" target='_blank'>
              Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape
              </a>
            </td>
          <td>
            H. Yano, Yukio Fujiwara, R. Mito, C. Pan, Katsuhiko Ono, K. Imamura, T. Niidome, Tomohiro Sawa, Masahiro Yamamoto, T. Sakagami, Yoshihiro Komohara
          </td>
          <td>2026-01-09</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>52</td>
        </tr>

        <tr id="Despite effective viral suppression, a subpopulation of people living with HIV (PLWH) receiving combination antiretroviral therapy (ART) experience a suboptimal immunological response, failing to restore CD4+ T‐cell counts to levels deemed indicative of good immune recovery. Innate immune cell dysregulation, particularly in mucosal‐associated invariant T (MAIT) and natural killer (NK) cells, is increasingly recognized as a key contributor to immune reconstitution. However, the dynamic changes, interactive crosstalk, and potential roles of these immune cells in immune reconstitution remain poorly understood. A total of 89 participants were enrolled, including 29 healthy controls and 60 HIV‐infected individuals, who were classified as immune responders (IRs, CD4 ≥ 500 cells/µL; n = 34) and suboptimal immunological responders (SIRs, CD4 < 500 cells/µL; n = 26) on the basis of immune recovery status. Longitudinal flow cytometric analysis was performed to assess the phenotypic changes in MAIT and NK cell subsets in peripheral blood mononuclear cells (PBMCs) before treatment (T0) and after 4 years of ART (T4). Correlation analysis was conducted to explore their associations with CD4+ T‐cell recovery. After 4 years of ART, both IRs and SIRs exhibited persistent depletion of total MAIT and invariant natural killer T (iNKT) cells, whereas pretreatment‐diminished CD56bright and CD56dim NK cell subsets increased significantly. MAIT cells also underwent phenotypic remodeling in both groups, with decreased CD4−CD8+ and increased CD4−CD8− subsets. Notably, these cell subset proportions and quantitative changes correlated significantly with CD4+ T‐cell counts in IRs but not SIRs. In IRs, CD4+ T‐cell recovery positively correlated with baseline CD4−CD8− MAIT and CD56bright NK cell numbers, but negatively with baseline CD4−CD8+ MAIT cell numbers. Correlation networks revealed distinct MAIT–NK interactions across ART stages. LASSO models integrating MAIT and NK subsets achieved high predictive accuracy, highlighting the dynamic role of CD4−CD8+ MAIT cells in immune reconstitution. Our study highlights the dynamic correlations between and within MAIT and NK cell subset proportions in PLWH, revealing that phenotypic remodeling rather than absolute cell counts plays a key role in immune reconstitution. CD4−CD8+ MAIT cells show time‐dependent predictive shifts, reflecting functional adaptation. These findings identify MAIT and NK subset dynamics as potential biomarkers and therapeutic targets for enhancing immune recovery of PLWH during ART.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8a98d3cfcae4bc3d9e7d0f462e62d60ace1750c6" target='_blank'>
              Subset Remodeling of MAIT and NK Cells Correlates With Immune Reconstitution in People Living With HIV Following Four Years of Antiretroviral Therapy
              </a>
            </td>
          <td>
            Zhuoya Deng, Xin Zhang, Aiwei Zhu, Xiao-dong Yang, Qiuyue Zhang, Hongxia Yan, Hao Wu, Tong Zhang, Christiane Moog, Bin Su
          </td>
          <td>2025-11-29</td>
          <td>Journal of Medical Virology</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Monocyte-derived cells, including osteoclasts, dendritic cells, and macrophages, are key components of the immunosuppressive tumor microenvironment in multiple myeloma (MM). However, the mechanisms linking monocyte dysfunction to immune evasion remain incompletely understood. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood (PB) and bone marrow (BM) monocytes was performed from healthy donors (HDs) and MM patients to generate a comprehensive single-cell transcriptional map. Although PB and BM monocytes displayed comparable cellular compositions, MM monocytes exhibited marked transcriptional alterations, most prominently within the type I interferon (IFN) signaling pathway. Trajectory analyses revealed IFN-driven disruptions in monocyte differentiation and developmental trajectories in both PB and BM compartments. Functional co-culture assays demonstrated that activation of the type I IFN pathway enhanced MM cell proliferation, suggesting that IFN-mediated monocyte reprogramming facilitates tumor progression. In an independent validation cohort, longitudinal sampling before and after induction therapy confirmed that anti-myeloma treatment alleviated the excessive IFN response of BM monocytes. Collectively, these findings uncover a mechanistic link between aberrant IFN activation and monocyte dysregulation in MM, providing new insights into immune dysfunction and highlighting the IFN pathway as a potential therapeutic target to restore anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c95b600545a3e90a13c96978be5b8e9b2126411" target='_blank'>
              Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.
              </a>
            </td>
          <td>
            Jian Cui, Jingwei Wang, Xiaoyun Li, Lina Wang, X. Mao, Rui Lyv, Wenqiang Yan, Jingyu Xu, Jieqiong Zhou, C. Du, S. Deng, Mu Hao, Yan Xu, S. Yi, D. Zou, Tao Cheng, Xin Gao, Lugui Qiu, Gang An
          </td>
          <td>2025-11-30</td>
          <td>Advanced science</td>
          <td>0</td>
          <td>21</td>
        </tr>

        <tr id="Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and often adopt an M2-like immunosuppressive phenotype that promotes tumor growth. Reprogramming TAMs toward an M1-like pro-inflammatory state is an attractive therapeutic strategy. Tumor Treating Fields (TTFields), an FDA-approved, electric-field–based therapy, has recently been suggested to modulate immune responses in addition to its established anti-mitotic activity. Here, we investigated the direct effects of TTFields on macrophage activation and function. Murine bone marrow–derived macrophages (BMDMs) were polarized toward a pro-inflammatory M1-like phenotype or an anti-inflammatory M2-like phenotype and exposed to TTFields. TTFields rapidly activated guanine nucleotide exchange factor-H1 (GEF-H1), and downstream nuclear factor kappa B (NF-κB) and activator protein-1 (AP-1, via c-Jun N-terminal kinase [JNK]) signaling. Functionally, TTFields reprogrammed M2-like macrophages by increasing major histocompatibility complex class II (MHC-II) and cluster of differentiation 80 (CD80); reducing arginase-1 (Arg1); and elevating secretion of chemokine (C-X-C motif) ligand 1 (CXCL1), interleukin-6 (IL-6), IL-1β, and IL-12 subunit p70 (IL-12p70). In interferon gamma (IFN-γ)-primed macrophages, TTFields provided a secondary signal, driving myeloid differentiation primary response 88 (MyD88)-dependent expression of inducible nitric oxide synthase (iNOS). In vivo, TTFields reduced tumor burden in an orthotopic murine lung cancer model and increased iNOS expression in both M1-like and a subset of M2-like TAMs. These findings demonstrate that TTFields directly reprogram macrophages toward a pro-inflammatory phenotype, suggesting a novel immunomodulatory mechanism that may enhance anti-tumor immunity in the TME.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/db7963f819719f5d174aa6e308c691c9523b680d" target='_blank'>
              Pro-Inflammatory Macrophage Phenotype Skewing Induced by Tumor Treating Fields (TTFields)
              </a>
            </td>
          <td>
            T. Kan, Y. Barsheshet, Tharwat Haj Khalil, B. Brant, T. Voloshin, K. Ben-Meir, Simona Zisman Rosen, M. Giladi, U. Weinberg, Y. Palti
          </td>
          <td>2025-12-01</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>36</td>
        </tr>

        <tr id="Immunocompromised hosts (ICHs) face elevated risks of severe respiratory infections and mortality. Glucocorticoids, commonly used to treat underlying conditions in ICHs, may further impair immune defenses, but the underlying mechanisms remain unclear. Retrospective analysis of peripheral blood immune cell profiles was conducted in pneumonia patients with ICHs. Prospective immunophenotyping of PBMCs by Cytek flow cytometry was performed to compare immune cell subsets in survivors versus deceased patients. To explore glucocorticoid effects on ICH immune mechanisms, we used a murine model of severe pneumonia (MRL/lpr mice) and an in vitro ICH infection mimic model. Glucocorticoid effects on immune cell populations and function were examined in these models. Focusing on key immune cells, we observed that ICH patients with severe pneumonia exhibit a reduction in classical monocyte subsets. Mechanistically, glucocorticoids downregulated CCL2 expression in the lung via GR/STAT3, thereby inhibiting the PA-LPS/TLR4/PI3K/AKT/STAT signaling pathway and diminishing pulmonary CCL2 and Ly6C+CCR2+ monocyte levels. Importantly, exogenous recombinant CCL2 administration restored monocyte function, reduced lung injury, and enhanced survival. These findings uncovered a critical immunosuppressive mechanism by which glucocorticoids, via GR/STAT3-mediated suppression of the CCL2-CCR2 axis, impair monocyte-driven antibacterial responses in severe pneumonia, highlighting the need for targeted immunomodulation in ICH patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d9b4bf1673b01f4644488331e3a225c1f792b5eb" target='_blank'>
              Glucocorticoid-mediated suppression of the CCL2-CCR2 axis drives monocyte dysfunction in severe pneumonia among immunocompromised hosts
              </a>
            </td>
          <td>
            Zhongshu Kuang, Yue Luo, Yao Chen, Yilin Yang, Chen Chen, Feixiang Xu, Yumei Chen, Yannan Zhou, Yongqi Shen, Li Yuan, Hua Su, Chaoyang Tong, Zhenju Song
          </td>
          <td>2025-11-26</td>
          <td>Respiratory Research</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Glioblastoma (GBM) is characterized by fast progression, infiltrative growth pattern, and a high relapse rate. A defining feature of GBM is the existence of spatially and functionally distinct cellular niches, where malignant cells engage in paracrine crosstalk with cell types comprising the tumor microenvironment. Here, we identify pericytes as the most active paracrine signaling hub within the tumor parenchyma. Their depletion through genetic engineering results in accelerated tumor progression and shortened survival. Mechanistic studies reveal that pericyte deficiency remodels the endothelium and impacts the immune cell landscape, exacerbating tumor cell invasion and immune suppression. Specifically, the pericyte-deprived endothelium recruits perivascular, tumor-associated macrophages polarized towards an immune-suppressive phenotype. The recruited macrophages express Hepatocyte Growth Factor, which reinforces activation of its receptor tyrosine kinase MET on GBM cells harboring a pronounced mesenchymal subtype driven by the key phenotypic regulator Fosl1. Indeed, orthotopic implantation of MET-expressing GBM cells corroborates their superior tumor-initiating and invasive capabilities. Thus, pericytes represent critical modulators of GBM development by orchestrating a tumor-suppressive microenvironment, highlighting the importance of their preservation in therapy. Improved understanding of the tumor ecosystem in glioblastoma is critical for developing new treatment strategies for the disease. Here, the authors identify pericytes as an active paracrine signaling hub within the tumor parenchyma that orchestrates a tumor-suppressive microenvironment, suggesting pericyte preservation as a key feature of future therapeutic regimens for glioblastoma.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c09a05790107e087a632df06714ceec3176e20b4" target='_blank'>
              Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma
              </a>
            </td>
          <td>
            S. Braun, P. Bolivar, C. Oudenaarden, J. Sjölund, M. Bocci, K. Harbst, Mehrnaz Safaee Talkhoncheh, B. Phung, E. Cordero, R. Rosberg, E. Johansson, G. Jönsson, A. Pietras, Kristian Pietras
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3bd3a5ca45d24cd8b7d6b837756f7e1569a107b" target='_blank'>
              A Glycosylation-Dependent Checkpoint Restrains Intestinal Intra-Epithelial Lymphocyte Activation
              </a>
            </td>
          <td>
            Liqing Cheng, Niccolò Bianchi, Hadrien Soldati, Ludivine Bersier, Maximilien Evrard, Aurelie Caillon, A. Chawla, B. Nakken, Peter Szodoray, Elien De Bousser, N. Festjens, T.V. Petrova, Sylvain Lemeille, Laura K. Mackay, Nico Callewaert, Mahima Swamy, Simon M. G. Braun, Simone Becattini
          </td>
          <td>2026-01-02</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Acute myeloid leukemia (AML) is primarily driven by leukemic stem cells (LSCs), the main cause of relapse and therapy resistance. Here, we discover that LSCs are predominantly small and mechanically soft. These mechanical properties enable their selective isolation using microfluidic chips. Single-cell RNA-sequencing of primary human AML bone marrow identifies enrichment of LSCs within the FSClow ALDH1A1+ subpopulation, which exhibits long-term stemness in functional assays. Notably, inhibiting ALDH1A1 in these cells promotes F-actin polymerization and increases cellular stiffness, reducing their stemness while enhancing their susceptibility to natural killer (NK) cell-mediated cytotoxicity. In AML patient-derived xenograft models, the combination of ALDH1A1 inhibition with NK cell therapy markedly suppresses leukemia progression. These findings suggest that targeting the mechanical properties of LSC offers a promising strategy to overcome AML treatment resistance, providing insights into stem cell mechanobiology and paving the way for combining targeted therapies with immunotherapy to improve clinical outcomes. Leukemic stem cells (LSCs) drive relapse and therapy resistance in acute myeloid leukemia (AML). Here, the authors show that increasing the stiffness of LSCs reduces their stemness and enhances their susceptibility to natural killer cell-mediated immunotherapy in AML.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/bd4d9af75a4b85e67dee8555546e74be5696efd1" target='_blank'>
              Targeting leukemic stem cell biomechanics suppresses stemness and enhances NK cell-mediated immunotherapy
              </a>
            </td>
          <td>
            Mingming Zhu, Haoxiang Yang, Kailong Qiu, Beibei Huang, Tingting Liang, Yan Wang, Huan Li, Mingming Wu, Xinru Liu, Na Zhao, Xian Song, Xuxu Zhao, Mengqing Gao, Yue Zhao, Xiangting He, Rui Zhao, Lili Qian, Qinhua Liu, Changcheng Zheng, Xiaoyu Zhu, Hongyuan Jiang, Fang Ni
          </td>
          <td>2025-12-01</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Introduction Sepsis leads to expansion of myeloid-derived suppressor cells (MDSC) and their subtypes. These normally transitory MDSCs suppress T cell activation and alter T cell cytokine production while simultaneously promulgating systemic low-grade inflammation. Immune metabolism can shape cell responses, regulate immune suppression, and enhance effector activity. Although MDSC metabolism has been extensively studied in cancer, the metabolic phenotype of this heterogeneous population in sepsis remains unclear. Our goal was to assess metabolic flux in blood MDSCs during and after sepsis and to stratify these patients’ clinical features and outcome with differences in metabolic flux that may guide treatment decisions. Methods Peripheral blood mononuclear cells (PBMC) from healthy subjects and sepsis patients at 4 days, 2-3 weeks, and 6 months underwent CD66b+ or CD3+ enrichment, followed by assessment of metabolic flux, flow cytometry, mRNA sequencing, and chromatin accessibility. Results Mitochondrial basal oxygen consumption rates (OCR) and maximal oxygen consumption rates (SRC, spare respiratory capacity) were decreased in MDSC from septic patients at 4 days after infection and persisted for up to 6 months after sepsis onset. Sepsis was not associated with differences in glycolysis. In contrast, oxidative metabolism in CD3+ T cells was similar between sepsis patients and healthy subjects. Reduced MDSC oxidative metabolism was linked to adverse clinical outcomes. The decline in oxygen consumption from MDSCs in septic patients was also associated with significant reductions in MDSC mitochondrial content. Transcriptomic analysis of CD66b+ cells isolated from PBMC of healthy participants and patients with sepsis at 4 days, 2-3 weeks, and 6 months revealed 19 differentially expressed genes and three long non-coding RNAs as potentially responsible for this decline in mitochondrial mass. Specifically, NR4A3, NR4A2, and TAMLIN/NR4A1 expression, all critical for mitochondrial biogenesis, were persistently decreased with reduced chromatin accessibility indicative of gene silencing. Discussion After sepsis, blood CD66b+ cells present with reduced mitochondrial mass and oxidative metabolism that continue at least 6 months after sepsis. These changes in mitochondrial function result from a reduced content of these organelles. We have also identified gene silencing, reduced gene expression of key transcription factors that regulate mitochondrial biogenesis, as well as increased long non-coding RNA as potential drivers of this unique metabolic phenotype. These results highlight the potential benefit of targeting metabolism in sepsis to promote immune homeostasis and recovery.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/48dac9de2c81b45da57ef12b64fdabc04b31fc63" target='_blank'>
              Prolonged Loss of Oxidative Phosphorylation and Mitochondrial Mass Characterize CD66b+ Leukocytes from Patients with Sepsis
              </a>
            </td>
          <td>
            Christine Rodhouse, Evan L. Barrios, Leilani Zeumer-Spataro, Leandro Balzano-Nogueira, Ruoxuan Wu, Xuanxuan Yu, Guimei Tian, Jason O. Brant, Marie-Pierre L. Gauthier, Jing Chen, Miguel Hernandez-Rios, Valerie E. Polcz, Whitman Wiggins, Angel M. Charles, M. Dirain, Ricardo F. Ungaro, J. Rincon, Tyler Loftus, Feifei Xiao, Guoshuai Cai, L. Moldawer, Robert Maile, Michael P. Kladde, Philip A. Efron, Clayton E. Mathews
          </td>
          <td>2025-12-18</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Sepsis is a systemic inflammatory response syndrome induced by infection, characterized by high morbidity and mortality, and responsible for over 11 million deaths worldwide annually. Recent studies have demonstrated that immune dysfunction represents a core element in the pathophysiology of sepsis, in which cluster of differentiation 8–positive (CD8+) T cells, as key executors of cellular immunity, play a critical role in immune dysregulation. This review systematically elaborates on the quantitative changes, functional status, and molecular regulatory mechanisms of CD8+ T cells in sepsis, including abnormalities in metabolic reprogramming, cell death pathways, transcriptional regulation, and intercellular communication. Additionally, it explores potential therapeutic strategies targeting CD8+ T cells, such as immune checkpoint modulation, cell death intervention, and metabolic regulation, and offers an outlook on future research directions, aiming to provide novel insights for immunotherapy in sepsis.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/99e991f9e6f9946dff0ca3eb21a47f7eaa4959b8" target='_blank'>
              The Role and Research Progress of CD8+ T Cells in Sepsis
              </a>
            </td>
          <td>
            Xianwen Wang, Qihang Huang, Zhihong Zuo, Zhanwen Wang, Lina Zhang, Zhaoxin Qian
          </td>
          <td>2025-11-27</td>
          <td>Biomedicines</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0d70a7f410d7273941b555f5d38eb406c7358fb4" target='_blank'>
              Distinct cytotoxic cell subsets underlie protective and non-protective immunity to African swine fever virus
              </a>
            </td>
          <td>
            D. Marín-Moraleda, A. Tort-Miró, E. Ezcurra, S. Montaner-Tarbes, J. Muñoz-Basagoiti, E. Coatu, M. J. Navas, M. Muñoz, P. Monleón, J. González-Oliver, L. Pailler-García, S. Pina-Pedrero, F. Accensi, F. Rodríguez, J. Argilaguet
          </td>
          <td>2025-12-03</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Interleukin-2 (IL2) has potent anticancer properties but its clinical use is limited by severe dose-dependent side effects, notably capillary leak syndrome (CLS) - a life-threatening condition marked by vascular barrier disruption and multi-organ dysfunction. Despite extensive efforts to engineer IL2 variants with improved pharmacokinetics or reduced toxicity, none of the 45 IL2-based agents currently under investigation across 139 trials have secured regulatory acceptance for cancer or autoimmune applications, largely due to unresolved safety concerns and limited efficacy, suggesting an incomplete understanding of IL2-induced CLS pathogenesis. Here, we describe the development of an immune-competent in vitro model of IL2-induced CLS comprising human primary endothelial cells co-cultured with donor-derived peripheral blood mononuclear cells (PBMCs) that recapitulates IL2 dose-dependent endothelial barrier loss. We demonstrate that neither IL2 alone nor cytokines released from IL2-stimulated PBMCs are sufficient to impair barrier integrity and show that direct cell-cell proximity is required for barrier loss and endothelial activation. Proteomic profiling identified key IL2-induced inflammatory, adhesion, and matrix remodeling pathways and pharmacological inhibition of selected targets mitigated IL2-mediated vascular dysfunction. This platform recapitulates key hallmarks of IL2-induced CLS, provides a mechanistically relevant, human-specific tool to study CLS pathogenesis and supports the development of safer IL2-based therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7242c15b7c8257703280c378aa7cb6c4b182baf0" target='_blank'>
              An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights and evaluation of mitigation strategies
              </a>
            </td>
          <td>
            Tamara Zimmermann, Edith Philipp, Sabine Marget-Muller, Gabrielle Leclercq-Cohen, S. Golling, Juliane Siebourg-Polster, A. Augustin, Remi Villenave
          </td>
          <td>2025-12-06</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="Background and aims Atherosclerosis is a chronic immunometabolic disease driven by lipid accumulation and immune cell infiltration. Macrophages and T cells play key roles throughout plaque development. Galectin-1 (Gal-1), a glycan-binding protein, modulates immune functions in these cells and has been reported to attenuate atherosclerosis, though its mechanisms remain incompletely understood. Here, we investigated the effects of Gal-1 on macrophages and T cells during plaque formation. Methods Effects of Gal-1 on atherosclerosis, macrophages and T cells during lesion formation were studied in Apoe−/− mice treated with recombinant Gal-1. Complementary mouse peritoneal foam cell and in vitro macrophage and T cell cultures experiments were performed to study T cell differentiation, macrophage function, polarization end energy metabolism. The impact of Gal-1 on human macrophages was further evaluated in endarterectomy specimens. Results Gal-1 treatment reduced lesion size and increased circulating IL-10 levels, inversely correlating with plaque burden. Unexpectedly, IL-10 neutralization also mitigated atherosclerosis, indicating that its action is at least partially IL-10–independent. In plaques, Gal-1 promoted anti-inflammatory macrophage phenotypes, mirrored by a quiescent metabolic and anti-inflammatory profile in foamy macrophages ex vivo. The use of the Gal-1E71Q variant revealed that these effects were only partly dependent on glycan binding. Beyond IL-10, Gal-1 reshaped cytokine profiles by increasing IL-17, IL-22, and IL-23, consistent with a macrophage-driven regulatory Th17 response, alongside higher frequencies of IL-10–producing and regulatory T cells. Conclusion Gal-1 protects against atherosclerosis associated with reprogramming macrophages and tuning T cell immunity through glycan-dependent and –independent pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2bb689064d23f64e92df5e88983aeac0866276a1" target='_blank'>
              Galectin-1 induces macrophage immunometabolic reprogramming, modulates T cell immunity and attenuates atherosclerotic plaque formation
              </a>
            </td>
          <td>
            Ya Li, J. Leberzammer, X. Blanchet, R. Duan, M. Lacy, V. Triantafyllidou, Veit Eckardt, Eva Briem, A. S. Jung, R. Su, Joel Guerra, Y. Jansen, Michael Hristov, W. Enard, J. Bernhagen, C. Weber, D. Atzler, Alexander Bartelt, Yvonne Doring, D. Santovito, Herbert Kaltner, Anna-Kristin Ludwig, P. von Hundelshausen
          </td>
          <td>2025-11-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. The OSM receptor was predominantly expressed on nonhematopoietic bone marrow (BM) stromal cells. OSM reprogrammed these cells via STAT3 and induced the secretion of cytokines connected to T-cell exhaustion, including IL-6 and MCP-1. Compared with control mice, OSM-overexpressing mice presented reduced T-cell numbers, increased levels of inhibitory receptors on T cells, and elevated lactic acid production by BM stromal cells. OSM induced the expansion of myeloid cells which suppressed T cells. Conversely, genetic deletion of Osm in a JAK2 p.V617F-driven polycythemia vera mouse model reduced polycythemia, BM fibrosis, inflammatory cytokine levels and the expression of inhibitory markers on T cells. Transcriptomic analyses of T cells from OSM-overexpressing mice revealed enrichment of IL6–JAK–STAT3 and inflammatory signaling pathways. Additionally, pharmacological inhibition of OSM reduced disease activity and cytokine production. These findings establish OSM as a key mediator linking oncogenic STAT5 activation to remodeling of the microenvironment and immune suppression. Targeting OSM signaling therefore represents a promising therapeutic strategy to alleviate disease progression in myeloproliferative neoplasms and related malignancies.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3d49eb0cd9f9aa70be266360e0a4941b4deb7497" target='_blank'>
              Oncostatin M induced by STAT5-activating oncogenes promotes disease progression in hematologic malignancies
              </a>
            </td>
          <td>
            Michael Rassner, T. Müller, Kirstyn Anne Crossley, G. Andrieux, Sabina Schaberg, Cornelia Endres, Lena Jakob, Teresa Poggio, N. Köhler, J. Kolter, Gerhard Müller-Newen, Katharina Schönberger, N. Cabezas-Wallscheid, I. González-Menéndez, Leticia Quintanilla-Martinez, Melissa Zwick, Driti Ashok, T. N. Hartmann, Olaf Groß, O. Gorka, M. Follo, A. Illert, M. Boerries, R. Zeiser, J. Duyster
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>27</td>
        </tr>

        <tr id="Cancer stem cells (CSCs) represent a small subset of tumor cells populations characterized by their ability to self-renew and differentiate. These cells are often considered resistant to chemotherapy, radiotherapy, and immunotherapy, playing a crucial role in driving tumor progression and metastasis. To evade immune attacks, CSCs utilize various genetic and epigenetic strategies that diminish immune recognition, enhance tolerance to immune-induced cytotoxicity, and foster the development of a protective immunosuppressive microenvironment. This microenvironment is shaped by a group of key immunosuppressive cells, particularly myeloid-derived suppressor cells (MDSCs), which not only directly inhibit effector T cells and natural killer (NK) cells, facilitating the immune escape of CSCs, but also significantly contribute to the maintenance of tumor cell stemness and promote their metastasis. Conversely, the developmental signals of MDSCs are also regulated by CSCs. This complex interplay between MDSCs and CSCs adds layers of complexity to the cancer-immune cycle and the associated tumor treatment strategies. Therefore, understanding the detrimental interdependence between MDSCs and CSCs to effectively impede tumor progression has become heated topic in tumor immunology. In this review, we provide a timely summary of the latest studies on the reported characteristics of CSCs and MDSCs, discuss their interconnection during tumor progression, and evaluate various immunotherapeutic strategies targeting these cell populations.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5f6883e12fe0f725487279c796b8b972017bb7c9" target='_blank'>
              Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy
              </a>
            </td>
          <td>
            Bo Wang, Xiaoguo Zhao, Shuxin Han, Yuekang Xu, Jinyao Li
          </td>
          <td>2025-11-24</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/7eec5092ca04ca50d54f7a273e3e46cdc98efcc8" target='_blank'>
              Aging increases ovarian cancer growth, metastasis, and immunosuppression that can be alleviated by inhibiting hedgehog signaling
              </a>
            </td>
          <td>
            Asha Kumari, M. H. Elbahoty, Resha Rajkarnikar, Khushi Sureja, M. Monavarian, L. Quintero, K.C. Fuh, Daniel J. Tyrrell, L. Shevde, Camilla Margoli, Karthikeyan Mythreye
          </td>
          <td>2025-12-27</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>45</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/02d1f577ff573db5c6fa1e5a829b978c4c5a4e28" target='_blank'>
              Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application
              </a>
            </td>
          <td>
            Yao Zhang, Yuting Lei, Yanzhao Huang, Yan Gao, Rong Liu, Kaiyun Guo, Chunlian Zhao, Ming Lei
          </td>
          <td>2025-12-03</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="The induction of immune responses in tissues and mucosa has emerged as one of the most promising strategies for the development of more effective vaccines and immunotherapies. In this context, CD8+ resident memory T cells (CD8+ TRM) have arisen as key players in local immune surveillance, acting persistently within non-lymphoid tissues. These cells represent a new and promising frontier in local immune responses and as potential clinical tools. CD8+ TRM are being extensively investigated as therapeutic targets against viral infections and cancer, although their clinical applications have yet to be fully established. Understanding the molecular signals that regulate their generation, differentiation, maintenance, and activation is crucial for the precise targeting of their immune functions. This review explores the main mechanisms involved in the formation and maintenance of CD8+ TRM, from the strength of MHC: TCR interactions to the coordinated role of cytokines, chemokines, and transcription factors in tissue retention and the expression of markers such as CD69, CD103, and CD49a. By integrating this knowledge, we discuss strategies to manipulate these pathways with the goal of developing more effective vaccines and personalized therapies based on resident memory T cells. We also examine how these molecular signals and pathways, either independently or in combination, can be explored both in the fight against viral infections and cancer, and in identifying CD8+ TRM predictive biomarkers for response to anticancer immunotherapies across various tumor types.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7a54040a23911cb44878186479043eac242cce4" target='_blank'>
              Keeping it local: how CD8 TRMs regulate viral and cancer immunity
              </a>
            </td>
          <td>
            Luiz Rodrigues Junior, Cristina Bonorino, Alisson F. Haubert, Marvin Paulo Lins, Gabriel Pozo Pereira, Pedro R. Torres Romao, Barry T. Rouse
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2c6fe00ac255b835c6c00b785eaad310b786023e" target='_blank'>
              Interferon-alpha 2b (IFNα2b) enhances monocyte-derived dendritic cell maturation and Th1-skewed anti-tumor immunity in non-small cell lung cancer
              </a>
            </td>
          <td>
            Soham Bindu, Oishi Mukherjee, Roshni Bibi, Melvin George, Koustav Sarkar
          </td>
          <td>2025-12-06</td>
          <td>Molecular Biology Reports</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Intestinal stem cells (ISCs) promote tissue repair after genotoxic or immune-mediated injury. However, ISCs are particularly sensitive to various stressors and primary targets of overwhelming immune responses, such as interferon γ (IFNγ)-mediated killing. In mouse models of radiation therapy-induced gut damage and in biopsies from patients who underwent allogeneic hematopoietic stem cell transplantation, we observed IFNγ expression by intestinal Treg cells. Treg cells leverage combined IFNγ and interleukin 10 (IL-10) stimulation of ISCs to nurture the growth of intestinal organoids through the activation of the mTORC1 and Myc pathways. Similarly, Treg cells or the combined addition of recombinant IFNγ and IL-10 promoted the regeneration of organoids after irradiation, and both cytokines were essential for ensuring epithelial regeneration following acute intestinal tissue injury in vivo. The exposure of organoids to growth factor-free culture conditions revealed distinct EGF-like properties of IFNγ and Wnt-like properties of IL-10. While IFNγ rapidly induced epithelial proliferation, it depleted the pool of ISCs in vitro. Only the combination of IFNγ and IL-10 led to epithelial proliferation and organoid growth while simultaneously ensuring ISC maintenance over time. Our results reveal a context-dependent role of inflammatory signaling in ISCs, through which Treg cells promote epithelial repair following therapy-induced injury.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d94b1c2ecbf09b8eb96b76cf6ccb45e0eb507208" target='_blank'>
              Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury
              </a>
            </td>
          <td>
            J.C. Fischer, Sascha Göttert, Maximilian Giller, Paul Heinrich, Kaiji Fan, Omer Khalid, C. Walther, Maria Drießlein, S. Nefzger, Gabriel Eisenkolb, V. R. Timnik, S. Jarosch, Lena Klostermeier, T. Engleitner, Nicholas Strieder, C. Gebhard, Sarah Diederich, Nicole A. Schmid, Laura Lansink Rotgerink, Laura Joachim, Sakhila Ghimire, E. Vonbrunn, M. Büttner-Herold, Marianne Remke, Katja Steiger, R. Öllinger, R. Rad, Daniel Wolff, Markus Feuerer, Petra Hoffmann, Matthias Edinger, Michael Rehli, Markus Tschurtschenthaler, O. Kepp, Guido Kroemer, Erik Thiele Orberg, Stephanie E. Combs, Wolfgang Herr, Florian Bassermann, Dirk H. Busch, Ernst Holler, S. Heidegger, H. Poeck
          </td>
          <td>2025-11-26</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>123</td>
        </tr>

        <tr id="Apoptosis, a form of programmed cell death, is crucial for keeping homeostasis during and after infections. Cellular FLICE-inhibitory protein (c-FLIP) is an inhibitor of death receptor-mediated apoptosis, of which three isoforms have been characterized so far. While the isoforms c-FLIPlong and c-FLIPshort are well characterized, the function of c-FLIPR remains poorly understood. To study the role of c-FLIPR in influenza A virus (IAV) infection, we employed vavFLIPR transgenic mice that constitutively express murine c-FLIPR in all hematopoietic cells. Upon IAV challenge, vavFLIPR mice showed an altered viral dynamic with a higher viral load than wild-type mice, coinciding with a higher number of Natural Killer (NK) cells. IAV directly infected murine NK cells, but viral particles produced by NK cells did not infect other target cells. While NK cells from vavFLIPR and control mice were equally able to kill tumor cells in vitro, we detected reduced degranulation of c-FLIPR transgenic NK cells from infected mice compared to wild-type counterparts. Furthermore, TNFα and IFNg expression was reduced in c-FLIPR transgenic NK cells. We conclude that c-FLIPR impairs NK cell activity during IAV infection. Constitutive expression of the anti-apoptotic c-FLIPR in hematopoietic cells increases IAV titers. Accumulation of NK cells in vavFLIPR mice during IAV infection. IAV infects NK cells in a non-productive manner. IAV infection of NK cells impairs their function. Constitutive expression of the anti-apoptotic c-FLIPR in hematopoietic cells increases IAV titers. Accumulation of NK cells in vavFLIPR mice during IAV infection. IAV infects NK cells in a non-productive manner. IAV infection of NK cells impairs their function.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2201ed3d7dca3eff038218bf0fd445634039c961" target='_blank'>
              The cell death regulator c-FLIPR impairs natural killer cell responses during influenza a virus infection
              </a>
            </td>
          <td>
            André Carmo-Fernandes, Neda Tafrishi, Clara Bessen, Konstantinos Katsoulis-Dimitriou, Marina C. Greweling-Pils, D. Bruder, C. Plaza-Sirvent, Ingo Schmitz
          </td>
          <td>2025-12-26</td>
          <td>Journal of Molecular Medicine (Berlin, Germany)</td>
          <td>0</td>
          <td>37</td>
        </tr>

        <tr id="Stem-like CD8⁺ exhausted T cells (Tex) sustain antitumor immunity, whereas TGFβ signaling acts as a major immunosuppressive pathway. In patients with colorectal liver metastases, we observe that elevated TβRI expression in peri-metastatic hepatocytes correlates with poor prognosis. We therefore investigate whether disrupting hepatocytic TGFβ signaling can reinvigorate stem-like CD8⁺ Tex cells to restrict liver metastasis. In support of this hypothesis, mice with hepatocyte-specific TβRI depletion exhibit reduced liver metastatic burden across multiple tumor models. Mechanistically, hepatocytic TβRI blockade suppresses Galectin-9 secretion, which reshapes the transcriptional program of intra-tumoral CD8⁺ T cells. This reprogramming promotes a phenotypic transition from terminal exhaustion toward stem-like and effector states, yielding T cell subsets with enhanced metastasis-control capacity. Importantly, this axis functions independently of macrophages and CD4⁺ T cells. Furthermore, therapeutic delivery of Galunisertib using choline-modified lipid nanoparticles synergizes with αPD-1, fostering the conversion of exhausted CD8⁺ T cells into responsive Ly108⁺CX3CR1⁺ subsets and suppressing liver metastases. Collectively, our results identify hepatocyte TGFβ signaling as a targetable checkpoint against liver metastases. How TGF-β regulates liver metastasis remains further investigation. The authors here find that TβRI blockade in hepatocytes decreases liver metastatic progression via revitalizing stem-like CD8⁺ Tex subsets, and an LNP encapsulated with the TβRI inhibitor Galunisertib synergizes with αPD-1 to ameliorate liver metastasis">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8539be173ace8a0b4d35310e7d3ebf922993bf40" target='_blank'>
              Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets
              </a>
            </td>
          <td>
            Hao Wang, Yan Zhou, Yuanyu Tu, Junxiong You, Baogui Gao, Kun Yuan, S. Zhong, Changjie Huang, Q. Han, Yuntao Dai, Ye Ma, Qingyuan Zhang, Xinyi Yan, Junjiang Wang, Xiaorui Wang, Liang Zhao, Xuegang Sun
          </td>
          <td>2025-11-27</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Psychosocial stress impacts immune system and brain function, yet mechanisms linking peripheral immune dysregulation to major depressive disorder remain unclear. Here, we demonstrate that a specific subset of T cells, the stem cell-like memory CD8+ T (TSCM) cells, is elevated in patients and stress-susceptible mice. CD8+ TSCM cells from patients display unique transcriptional programs and correlated with depression severity. Adoptive transfer of stress-derived CD8⁺ TSCM cells induced depressive-like behavior and neuroinflammation in recipients, without brain migration. Employing a whole-body immunolabeling technology, we discover CD8+ TSCM cells migrated to intestine via the interaction of pro-platelet basic protein and C-X-C motif chemokine receptor 2. CD8+ TSCM cells decrease the abundance of tyrosine-metabolizing bacteria to reducing homovanillic acid production, triggered neuroinflammation and depressive symptoms. Thus, our findings uncover a complex interplay between CD8+ TSCM cells and gut microbial metabolism, shedding light on potential mechanisms underlying depression and suggesting avenues for therapeutic intervention. Major depressive disorder has been linked to peripheral immune dysfunction. Here, the authors identify elevated stem cell-like memory CD8⁺ T cells in patients and in a murine stress model show migration to the intestine via PPBP-CXCR2 and suggest gut CD8 cells modulate tyrosine metabolizing bacteria and homovanillic acid potentiating neuroinflammation and depressive phenotype.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/35b60060166ee9a2ca47646aac614361b170bc9e" target='_blank'>
              Migration of CD8 + TSCM cells into intestine via PPBP–CXCR2 axis increases host stress susceptibility by inhibiting gut microbiome-derived homovanillic acid
              </a>
            </td>
          <td>
            Yuan Zhang, Minzi Ju, Suzhen Chen, Wendi Yang, Yang Cai, Xiaoyu Yu, Gang Chen, Zhongxia Shen, Ying Bai, Hui Ren, Yinghui Li, Ling Shen, Junxu Li, Peng Shi, Yonggui Yuan, Bing Han, Honghong Yao
          </td>
          <td>2025-11-19</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>13</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/954805b24a989a5a800c8a228d8a6b54b8ed322d" target='_blank'>
              Cooperative Interaction Between IL-4 Signaling and FLT3 in Multipotent Progenitors Restore Lymphopoiesis in Inflammation and Aging
              </a>
            </td>
          <td>
            Jingfei Yao, Yuting Wang, Yi Zhang
          </td>
          <td>2025-12-22</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Introduction We have recently shown that the DNA hypomethylating agent decitabine (DAC) rescues lung allografts from acute rejection. This involves a mechanism that is dependent on host CD4+ FoxP3+ T cells for maximal benefit. DAC treatment also reduces host T-cell IFN-γ production. We therefore hypothesized that DAC may also reduce host macrophage activation. Our objective was to determine if an effect on macrophages contributes to the beneficial effects of DAC in transplantation. Methods In murine orthotopic lung transplant, hosts were treated on post-op day 3-8 with Clodronate (n = 5), DAC (n = 9), or DMSO (n = 11). Results Partial macrophage depletion (clodronate) improves allograft gross and histologic integrity. DAC-mediated allograft rescue was associated with reduced host macrophage recruitment into allograft airways, reduced activation of recruited macrophages, and regeneration of donor resident alveolar macrophages. Discussion These findings suggest that infiltrating host macrophages promote allograft rejection. They also suggest that donor alveolar health is indicative and/or promoting of allograft tolerance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1c63160c7629dcafa8b9f8bf95ff593b261fc72b" target='_blank'>
              The role of macrophages in the mitigation by decitabine of acute allograft rejection
              </a>
            </td>
          <td>
            W. Daccarett-Bojanini, Manuel Sollmann, Kristine Yarnoff, Nicola M. Heller, J. Dodd-o
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Transplantation</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Radiation‐induced heart disease (RIHD) is a serious complication of radiotherapy and a major contributor to non‐cancer mortality. This study employs single‐cell RNA sequencing technology to investigate the dynamic immune landscape following radiation‐induced cardiac injury, uncovering potential mechanisms of RIHD and providing strategies for its prevention and treatment. We identified nine immune cell types, totaling 24,683 leukocytes. Macrophages accounted for the largest proportion (78.45%). Over time following irradiation, the proportion of macrophages decreased, while monocytes, T cells, and dendritic cells (DCs) increased. B cells and natural killer cells showed a slight decrease on day 7 but peaked on day 35. Neutrophils reached their highest levels on day 7. We observed a significant increase in pro‐inflammatory subpopulations on day 7 post‐irradiation, along with elevated expression of pro‐inflammatory genes. By day 35, the proportions of apoptosis‐ and proliferation‐related subpopulations had significantly risen, with corresponding upregulation of apoptosis‐ and proliferation‐related genes. We also observed two specific subpopulations: IFN+ macrophages and mregDCs. We identified a fibrosis‐associated macrophage subpopulation, MHCII+_Ccr2 macrophages, and found that the SPP1 pathway was significantly expressed in this subpopulation 7 days post‐irradiation. We further hypothesize that the SPP1‐CD44 pathway may be closely associated with cardiac fibrosis. Thus, this study provides a comprehensive immune atlas of the mouse heart post‐irradiation, revealing significant shifts in immune responses at different time points.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/6d8b083b9df998ebe7e318abea7ba774d57dceef" target='_blank'>
              Immunological landscape of radiation‐induced cardiac injury
              </a>
            </td>
          <td>
            Huan Liu, Dan Ou, Han Zhao, Ran Wu, Keman Liao, Jianyi Zhao, Zhou Li, Zhe Xu, Yuerui Wang, Lu Cao, Yingying Lin, Jia-yi Chen
          </td>
          <td>2025-11-18</td>
          <td>View</td>
          <td>1</td>
          <td>4</td>
        </tr>

        <tr id="Monocyte exhaustion is a dysfunctional state characterized by prolonged pathogenic inflammation and immune suppression, commonly observed in chronic infections and sepsis. However, the mechanisms underlying the generation and propagation of exhausted monocytes remain poorly understood. In this study, we investigate the impacts of exhausted monocytes on neighboring naïve monocytes, endothelial cells, and T cell function. Using an in vitro co-culture system, we demonstrate that exhausted monocytes induced by prolonged LPS stimulation propagate the exhaustion phenotype to neighboring naïve monocytes. Meanwhile these exhausted monocytes can promote endothelial apoptosis, upregulate adhesion molecules ICAM-1 and VCAM-1, and enhance monocyte transmigration, contributing to endothelial dysfunction. Pharmacological inhibition of CD38, a key marker of monocyte exhaustion, significantly mitigates these effects, highlighting its critical role in monocyte-driven endothelial alterations. Furthermore, we show that exhausted monocytes suppress T cell proliferation and activation, a process reversed by CD38 inhibition. We also identify mTOR signaling as a key regulator of monocyte exhaustion and its propagation, with mTOR inhibition partially restoring monocyte functionality by downregulating exhaustion markers and STAT1/STAT3/S6K signaling. Collectively, our findings highlight the CD38-mTOR axis as a central driver of monocyte exhaustion and its pathological consequences, offering potential therapeutic targets for reversing immune dysfunction in inflammatory diseases. The inhibition of CD38 can alleviate monocyte exhaustion through suppressing the sustained mTORC1-STAT1 activation. Upon LPS stimulation, TLR4 signaling is activated through the TRAM-TRIF adaptor complex, leading to the phosphorylation of Src. This activation promotes mTORC1 signaling, characterized by the recruitment of Raptor and the activation of S6K. mTORC1 activation subsequently drives STAT1/3 signaling, which further induces CD38 expression and forms a sustained positive feedback loop. Elevated CD38 levels contribute to monocyte exhaustion by depleting NAD⁺, a key metabolic cofactor. NAD⁺ depletion negatively impacts mTORC2 signaling, leading to impaired Akt phosphorylation, resulting in diminished expression of PGC1α/β, CREB and CD86, both of which are associated with exhausted monocyte immune suppression. The CD38 inhibitor 78c disrupts this exhaustion pathway, offering a potential therapeutic strategy to mitigate monocyte dysfunction during monocyte exhaustion.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/339d48c34c821d9297b2f89fa7a33fe439da7b15" target='_blank'>
              Propagation of monocyte exhaustion memory and underlying mechanisms
              </a>
            </td>
          <td>
            Jing Wang, Blake A. Caldwell, Yajun Wu, Babak Razani, Liwu Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Communication and Signaling : CCS</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Radiofrequency ablation (RFA) has been one of the most promising local treatments for colorectal liver metastases. However, tumor progression after RFA still severely affects patient prognosis, and its molecular mechanisms remain to be further explored. Here, we show that heat-stressed residual tumor cells following insufficient RFA (iRFA) can lead to lung metastases. Specific Cd177hiPad4hi neutrophils are found as the main pro-tumor phenotype in iRFA conditions, and neutrophil extracellular traps are produced to accelerate lung metastasis via the MEK/ERK signaling pathway. Mechanistically, PPARγ-triglyceride (TG) synthesis in residual tumor cells activates the P38 signaling pathway and CXCL5 secretion, contributing to Cd177hiPad4hi neutrophil infiltration. Furthermore, the specific CD36hi-EM (epithelial-mesenchymal) - circulating tumor cells (CTCs) with activated lipid metabolism characteristics are found to assist in early identification of residual tumor cells. This study not only provides specific targets for improving the efficacy of iRFA but also realizes its early identification and intervention. A relatively high proportion of patients relapse following radiofrequency ablation. Here, authors show that neutrophils with high expression of CD177 and PAD4 promote progression of residual tumors after incomplete radiofrequency ablation via PPARγ-related lipid metabolism adaptation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ce396293aed26c6525d0be11decc31973022a1b8" target='_blank'>
              Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177hiPAD4hi neutrophils
              </a>
            </td>
          <td>
            N. Huang, Yisheng Fang, Siting Zheng, Jianhua Wu, Genjie Huang, Xinyue Deng, Yijin Guan, B. Liang, Dongqiang Zeng, Beibei Xu, Yuanwen Huang, Xiaoxiang Rong, Chunlin Wang, J. Bin, Yulin Liao, Zuqiang Wu, Min Shi, Wangjun Liao
          </td>
          <td>2025-12-02</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="The tumor microenvironment (TME) is a complex ecosystem where interactions between tumor cells, immune cells, and microbes notably influence cancer progression and response to therapy. Tumor-associated macrophages (TAMs), which are crucial components of the TME, exhibit remarkable plasticity, adapting their functions in response to signals from both the tumor and its microbiota. Microbes—including bacteria, viruses, fungi, and their metabolites—modulate multiple aspects of TAM biology, from polarization and metabolism to immune modulation, thereby influencing tumor progression and immune evasion. This review focuses on the mechanisms through which microbes shape TAM responses, particularly in the context of cancer immunotherapy. Emerging therapeutic strategies leverage these microbe–TAM interactions using engineered microbes, oncolytic viruses, and microbial nanomaterials to reprogram TAMs and enhance antitumor immunity. Although formidable challenges remain, including spatial and temporal heterogeneity, mechanistic complexity, and safety concerns, these innovative approaches hold the potential to revolutionize cancer treatment. By targeting the microbe–TAM axis, this therapeutic strategy offers a promising avenue for overcoming resistance and improving the effectiveness of cancer immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8d35035aaaac9820113403b52fedea9b4aaf5d8f" target='_blank'>
              Targeting Microbe-Mediated Macrophage Education: A Novel Paradigm in Cancer Immunotherapy
              </a>
            </td>
          <td>
            Rongwei Xu, Xinyuan Zhao, Xu Chen, Huixi Zhou, Li Cui
          </td>
          <td>2025-11-18</td>
          <td>Biomaterials Research</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="The tumor microenvironment (TME) constitutes a highly complex and dynamic ecosystem wherein diverse leukocyte subsets engage in intricate cross-talk that ultimately dictates the balance between tumor progression and suppression. This review provides a comprehensive analysis of the dualistic functions of key immune cell populations-including natural killer (NK) cells, effector T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs)-within this milieu. Particular emphasis is placed on the Nigerian context, where unique genetic backgrounds, such as the high prevalence of sickle cell trait, and environmental factors, including endemic infections, significantly shape immune phenotypes and cancer pathogenesis. We explore how cutting-edge single-cell technologies are revolutionizing our understanding of the spatial architecture, functional plasticity, and cellular heterogeneity of these leukocytes in patient cohorts, revealing mechanisms of both immune surveillance and tumor-promoting immunosuppression. The paradoxical roles of these cells elucidate the variable clinical outcomes observed with immunotherapies and underscore the critical need for precision medicine strategies that are tailored to individual immune landscapes. Finally, we discuss emerging therapeutic modalities aimed at selectively depleting pro-tumor subsets like Tregs or MDSCs while activating anti-tumor effectors such as NK cells, which hold substantial promise for reshaping the TME and improving oncology outcomes both in Nigeria and across the globe.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/85d4138591bf3dda987df758be78f378fdcee1f4" target='_blank'>
              Leukocyte Subset Dynamics in the Tumor Microenvironment: Dual Roles, Single-Cell Insights, and Implications for Cancer Immunotherapy in Nigeria
              </a>
            </td>
          <td>
            Okluchi Hartumu
          </td>
          <td>2025-11-25</td>
          <td>Hematological Disorders in the Single-Cell Era</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="HIV persists in diverse tissues, with distinct cellular reservoirs presenting a major barrier to a cure and requiring targeted therapeutic strategies to address this heterogeneity. Here, we develop tissue models of HIV latency using human tonsillar, intestinal and cervicovaginal tissues. These models reveal differential HIV infection across CD4+ T-cell subpopulations, with ART partially restoring CD4+ T cells and reducing intact HIV DNA. T follicular helper cells (TFH CD69+ CCR7-) are the primary inducible reservoir in tonsils, while tissue-resident memory cells (TRM CD69+ CD49a+) dominate in the intestine. Identification of markers for inducible reservoirs shows that CD69, CD45RO, and PD-1 are shared across tissues, while CXCR5 in tonsils and CD49a in the intestine act as tissue-specific markers. Furthermore, using different latency reversal agents (LRAs) demonstrates that Histone Deacetylase Inhibitors (HDACis) fail to induce HIV in any tissue, the SMAC mimetic AZD5582 is effective only in a resident-memory CD4+ T-cell subpopulation in the intestine, and IL-15 exhibits the broadest reactivation potential across tissues and CD4+ T-cell subsets. These models provide insights into the inducible reservoir’s composition in different tissues and inform strategies for its elimination. HIV’s persistence in diverse tissue reservoirs poses a challenge to cure efforts, necessitating targeted approaches. Here, the authors develop human tissue models of HIV latency and find that inducible reservoirs differ across tissues and CD4⁺ T-cell subsets, highlighting tissue-specific markers and IL-15 as the most effective latency reversal agent.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f5d4113257cf548bebb44b19b15a33724ee123ce" target='_blank'>
              Identification of inducible HIV reservoirs in tonsillar, intestinal and cervical tissue models of HIV latency
              </a>
            </td>
          <td>
            A. Gallego-Cortés, N. Sánchez-Gaona, C. Mancebo-Pérez, O. Ruiz-Isant, A. Benítez-Martínez, S. Landolfi, J. Castellví, F. Pumarola, N. Ortiz, I. Llano, J. Lorente, L. Mañalich-Barrachina, JG. Prado, E. Martín-Gayo, V. Falcó, M. Genescà, MJ. Buzon
          </td>
          <td>2025-11-24</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>16</td>
        </tr>

        <tr id="Trained immunity is reshaping our understanding of host defense by demonstrating that innate immune cells once thought to lack memory can be reprogrammed to mount heightened responses to subsequent challenges. Unlike tolerance, differentiation, or priming, trained immunity relies on epigenetic and metabolic rewiring of resident myeloid cells, particularly in mucosal barriers such as the skin, gut, and lungs, where these cells provide continuous protection against toxins and pathogens. Here, we review recent advances showing how an initial stimulus endows monocytes and macrophages with long-lasting functional changes that can be either protective or maladaptive upon re-exposure. We highlight therapeutic opportunities that harness trained immunity to boost vaccine efficacy and discuss strategies to modulate this program in cancer and hyper-inflammatory disorders. Finally, we propose new directions for enhancing or dampening trained immunity to promote human health.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/57f6e83421893f19b268537080a2332361f2582c" target='_blank'>
              Innate immune memory: The evolving role of macrophages in therapy
              </a>
            </td>
          <td>
            Payal Damani-Yokota, Kamal M. Khanna
          </td>
          <td>2025-11-14</td>
          <td>eLife</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="B cell follicles in secondary lymphoid tissues are major sites of HIV expression in untreated people living with HIV (PLWH), but whether lymphoid B cells promote HIV expression in CD4+ T cells is unknown. Using a tonsil model and flow cytometry, germinal center B cells induced HIV expression in follicular helper CD4+ T cells (TFH) in a concentration-, contact-, and major histocompatibility complex class II (MHC-II)-dependent manner. Non-naïve tonsil B cells also induced HIV expression in nonTFH CD4+ T cells that was MHC-II restricted. In situ hybridization and immunofluorescent staining of lymph node sections from six PLWH on long-term antiretroviral therapy (ART) and six ART-naïve PLWH demonstrated most HIV RNA-expressing (vRNA+) cells were adjacent to at least one B cell. In both groups, vRNA+ cells per mm2 were elevated in B cell follicles, particularly after adjusting for CD3+CD4+ frequencies. TFH (PD-1+BCL6+) were a minority of vRNA+ cells in all PLWH. In contrast to ART-naïve PLWH, most vRNA+ cells in PLWH on ART resided outside follicles, and were preferentially adjacent to extrafollicular B cells. Thus, B cells upregulate HIV expression largely through cognate interactions in vitro and are linked to HIV expression in secondary lymphoid tissues.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3794a47de574dfccbbd2a0ad1e02e04d0a55b25c" target='_blank'>
              Lymphoid B cells upregulate HIV-1 ex vivo and are linked to its expression in vivo
              </a>
            </td>
          <td>
            M. Ollerton, J. Folkvord, Veronica Bush, David A Parry, Amie L Meditz, Martin D McCarter, Fred Yost, Cecilia M Shikuma, E. Connick
          </td>
          <td>2025-12-01</td>
          <td>PLOS Pathogens</td>
          <td>0</td>
          <td>46</td>
        </tr>

        <tr id="One barrier to developing an HIV-1 cure is viral reservoirs persisting within B cell follicles of lymphatic tissues, partly due to failure of HIV-specific cytotoxic cells to express the follicular-homing receptor CXCR5. We evaluated HIV-specific CAR/CXCR5 NK cells armored with IL-15 and a PD-1 knockout for in vitro functionality. The safety and efficacy of these NK cells were assessed in vivo by treating ART-suppressed, HIV-infected-humanized-DRAGA mice following ART interruption. In vitro, CAR and control NK cells proliferated and killed HIV-Envelope-expressing cells. In vivo, there were no adverse health outcomes associated with cell infusions. CAR NK-treated animals had, on average, 1.88 times higher NK cell levels, and cells persisted up to 2 weeks longer than control NK-treated animals. At 56 days post-treatment, 62.5% of CAR NK-treated and 50% of control NK-treated groups had viral loads below the detection limit compared to 0% of the saline control group. Importantly, animals that had undetectable viral loads at 56 days post-treatment had earlier viral rebound post-ART interruption that coincided with high levels of NK cells, suggesting that timing of treatment with viral recrudescence was key to efficacy. This study demonstrates the promise of NK therapies for treating HIV infections.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/da12b9f97b1e80c3918f80d558932e33ac6cf097" target='_blank'>
              NK cell immunotherapy administered at the time of HIV recrudescence is associated with viral control
              </a>
            </td>
          <td>
            Liliana K. Thron, P. Pumtang-on, Jae Woong Chang, Maxwell E. Cantor, Ian Gorrell-Brown, Kelsie L. Becklin, Zoe E. Quinn, Ahmad F. Karim, Aaron K. Rendahl, M. Pampusch, Sofia A. Casares, V. Vezys, B. Moriarity, Pamela J. Skinner
          </td>
          <td>2025-11-19</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>34</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c872e20ed96ce9671cd91e8697d416593c662410" target='_blank'>
              Cellular stress, cell death, and extracellular vesicles: redefining the therapeutic landscape of rheumatoid arthritis.
              </a>
            </td>
          <td>
            Barathan Muttiah, A. Wahab
          </td>
          <td>2025-12-24</td>
          <td>Clinical rheumatology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Glucocorticoid-Induced TNFR-related protein (GITR) is a costimulatory molecule involved in the proliferation and effector functions of CD8 + and CD4 + T-cells. Recently, it has gained attention as a novel target for HIV immunotherapy. However, reports on its expression in people living with HIV (PLWH), as well as functional studies of GITR ligands effects in the context of HIV remain scarce. Here, we performed a thorough immune characterization of GITR expression in PLWH following HIV peptide stimulation. We found a prevalence of an effector memory phenotype on HIV-specific GITR-expressing CD8 + T-cells that correlated with viral control. Costimulation with a hexameric GITR ligand (GITRL) showed a modest improvement on antiviral function. Characterization of CD4 T-cells revealed an association between GITR expression among regulatory T-cells and viral control, as well as the prevalence of a central and effector memory T-cell phenotype. Remarkably, GITRL costimulation enhanced viral transcription without increasing the reservoir size, positioning GITR as an interesting target for the development of novel latency reversal agents.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/78545ddf84fd594bec744d6ebf23dd9435e72671" target='_blank'>
              GITR triggering has limited impact on HIV-specific CD8 T-cell function but enhances HIV transcription reactivation from latently infected CD4 T-cells
              </a>
            </td>
          <td>
            A. Czernikier, Lucía Baquero, Paula Benencio, Laura A. Osorio Ocampo, J. Salido, Ana Gun, M. I. Figueroa, N. Laufer, Y. Ghiglione, María F. Pascutti, Gabriela Turk
          </td>
          <td>2025-12-01</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="Many inflammatory stimuli can induce progenitor cells in the bone marrow to produce increased numbers of myeloid cells as part of the process of emergency myelopoiesis. These events are associated with trained immunity and have long-term impacts on hematopoietic stem and progenitor cell (HSPC) development but can also compromise their function. While many cytokines support emergency myelopoiesis, less is known about the mechanisms that temper these events. When mice that lack the cytokine IL-27 were infected with Toxoplasma gondii, there was enhanced generation of monocyte progenitors and increased numbers of inflammatory monocytes. In the bone marrow of infected mice, there was increased production of IL-27 that localized with HSPCs, and a survey of cytokine receptor expression highlighted that HSPCs were uniquely poised to respond to IL-27. Furthermore, the use of in vitro differentiation assays and mixed bone marrow chimeras revealed that HSPCs from IL-27-deficient mice are predisposed toward the monocyte lineage. Additional studies highlighted that after infection, loss of the IL-27R resulted in reduced HSPC fitness that manifested as reduced proliferative responses and a decreased ability to reconstitute the hematopoietic system. Thus, the ability of IL-27 to act on HSPC provides a regulatory brake on differentiation to limit monocyte induction and preserve HSPC stemness.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4296e880a374b1ca1dccbcbdeb368a411cccee06" target='_blank'>
              IL-27 limits HSPC differentiation during infection and protects from stem cell exhaustion
              </a>
            </td>
          <td>
            D. Aldridge, Zachary Lanzar, Anthony T Phan, David A. Christian, Ryan D. Pardy, Booki Min, Ross M. Kedl, Christopher A. Hunter
          </td>
          <td>2025-12-15</td>
          <td>eLife</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Abstract Unconventional T cells expressing the γδ T cell receptor (TCR) are abundant within the intestine and largely function as ‘first responders’ to injury, infection and inflammation. To this end, murine γδ T cells are highly compartmentalized within the intestinal mucosa based on the expression of their Vγ chain and their effector function. The activation status also differs among these γδ T cell populations to ensure a timely and appropriate response within their local microenvironment. In this review, we will examine the role of γδ T cell populations in the epithelium (i.e. intraepithelial lymphocytes), the lamina propria and Peyer's patches and discuss the influence of the gut microbiota on the maintenance and effector function of each compartment. We will also highlight how γδ T cells contribute to the host response to luminal bacteria and how this reciprocal crosstalk is disrupted in the context of inflammatory bowel disease (IBD). An enhanced understanding of how γδ T cells function within distinct mucosal compartments and their regulation by commensal bacteria may lead to the development of novel microbiome-based therapies for IBD.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/05c0bab1b59e7852efa3b798e6fb5e0fbd1f5eaa" target='_blank'>
              Crosstalk between the microbiota and intestinal γδ T cell compartments in health and IBD
              </a>
            </td>
          <td>
            Ananya Parthasarathy, Tingting Li, Karen L. Edelblum
          </td>
          <td>2025-12-29</td>
          <td>Gut Microbes</td>
          <td>0</td>
          <td>22</td>
        </tr>

        <tr id="Tuberculosis (TB) remains a leading infectious cause of morbidity and mortality, and the development of a new, highly effective vaccine would have a tremendous beneficial impact on global health. Although conventional memory CD4 and CD8 T cells will likely be key mediators of long‐lived, vaccine‐elicited protection, a potent T cell–inducing vaccine against TB has been elusive. Protection by Mycobacterium tuberculosis (Mtb)‐specific T cells is mediated primarily through their communication with Mtb‐infected macrophages. Here, we discuss emerging evidence of multiple structural and immunoregulatory factors that limit effective T cell–macrophage interactions in TB granulomas, posing a unique challenge to vaccine‐induced protection. Developing new TB vaccination strategies will require a better understanding of the crosstalk between T cells and infected pulmonary macrophages and strategies to enhance these interactions.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e57a70513267b900083d97f9bbbec632105edc5a" target='_blank'>
              T cell–macrophage interactions in tuberculosis: What we've got here is failure to communicate
              </a>
            </td>
          <td>
            R. Mortensen, C. S. Arlehamn, R. Coler, Michael Y Gerner, Delia Goletti, D. Lewinsohn, Robert L Modlin, Munyaradzi Musvosvi, Jyothi Rengarajan, K. Urdahl, G. Walzl, S. Behar, Daniel L Barber
          </td>
          <td>2025-11-22</td>
          <td>Journal of Internal Medicine</td>
          <td>0</td>
          <td>73</td>
        </tr>

        <tr id="The tumor immune microenvironment plays a critical role in tumor progression and responses to immunotherapy. Nevertheless, its cellular complexity and heterogeneity remain incompletely understood. In this study, we employed high-resolution single-cell RNA sequencing on CD45+ immune cells isolated from ten syngeneic murine tumor models, representing seven distinct cancer types under treatment-naïve conditions, thereby enabling a comprehensive profiling of tumor-infiltrating immune cells. We identified seven principal immune cell populations and provided an in-depth characterization of T cells, NK/innate lymphoid cells, dendritic cells, monocytes/macrophages, and neutrophils. Cross-species analyses further delineated conserved immune cell states and transcriptomic features within the T cell and monocyte/macrophage compartments that are shared across syngeneic models and human tumors. To investigate the functional relevance of the predominant monocyte/macrophage compartment and the notable presence of neutrophils in syngeneic tumors, we evaluated responses to anti-PD-1 therapy across various models and analyzed the enrichment of monocyte/macrophage subsets in tumors that responded to treatment. Furthermore, we conducted neutrophil depletion experiments using anti-Ly6G antibodies, administered both as monotherapy and in combination with PD-1 blockade. Remarkably, an interferon-stimulated gene-high (ISGhigh) monocyte subset was significantly enriched in models responsive to anti-PD-1 therapy. Neutrophil depletion resulted in variable antitumor effects across models but failed to enhance the efficacy of PD-1 blockade. In summary, our single-cell profiling offered a detailed atlas of the immune microenvironment across multiple syngeneic mouse tumor models, thereby enabling rational model selection for immuno-oncology studies. We uncovered an ISGhigh monocyte subset enriched in anti-PD-1 responsive models, and showed the context-dependent effects of neutrophil depletion on tumor immunity and immunotherapy, underscoring the heterogeneity and functional divergence of immune cell sublineages.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8f925e5b4fe351a72672a38a0505d78e0be84e52" target='_blank'>
              Single-cell atlas of the tumor immune microenvironment across syngeneic murine models
              </a>
            </td>
          <td>
            Jia Wang, Bin Jiang, Minjuan Deng, Han Yan, Peilin Zhang, Wei Jin, Zhirong Shen
          </td>
          <td>2025-11-14</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Multiple myeloma (MM) is a refractory hematologic malignancy driven by clonal plasma cell proliferation and a complex bone marrow microenvironment. CD81, a tetraspanin protein, has been implicated in immune regulation and cancer progression, but its role in MM remains unclear. This study investigated the prognostic significance of CD81 expression and its relationship with immune cells in 178 newly diagnosed MM patients. CD81 positivity (60.67%) was associated with reduced overall survival (OS) but not progression-free survival (PFS). High CD81 expression correlated with decreased peripheral CD8 + T cell counts and increased M2 macrophage infiltration (CD206+), both linked to poorer outcomes. Conversely, high CD68 expression (pan-macrophage marker) was associated with improved prognosis, potentially reflecting favorable M1 macrophage activity. These findings highlight CD81 as a prognostic marker in MM, influencing immune cell dynamics and clinical outcomes. The interplay between CD81, M2 macrophages, and CD8 + T cells underscores the complexity of the MM immune microenvironment, suggesting novel therapeutic targets. Further studies are needed to elucidate CD81’s mechanistic role in immune modulation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/69420a9eb5bcba88e30a4b938f4df5f0bb4efe32" target='_blank'>
              The impact of CD81 on immune cells and clinical prognosis in multiple myeloma
              </a>
            </td>
          <td>
            Qian Zhao, Mengyao Lv, Qing Yan, Yanfei Sun, Feng Li
          </td>
          <td>2025-11-27</td>
          <td>Annals of Hematology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="There are multiple reports of elevated inflammation in patients with major depression. It is, however, unclear whether these reported perturbations in immune functions in depression affect the general functionality of the peripheral immune system. Here, using single-cell RNAsequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) extracted from blood samples collected prior to a flu vaccination administration/immunization (at baseline), we found downregulated T cell and B-cell-associated gene expression repertoire coupled with a selectively upregulated plasmablast, CD14 classical monocytes, and natural killer (NK) proliferating cell-associated gene expression in 9 depressed patients (6 females) compared to 5 healthy controls (5 females), as well as in association with depression ratings. Our cell type proportion analysis revealed shifts in immune cell populations, specifically reduced numbers of CD4+ T and CD8+ T proliferating cells, plasmablasts, and NK cells in individuals with depression compared with controls. In contrast, we found increased numbers of CD14 classical and CD16 monocytes as well as doublet cells in depressed individuals compared with controls. Although our baseline and flu vaccine challenge did not show marked differences in peripheral immune markers measured by a multiplex cytokine assay, our results suggest impaired innate and adaptive immune responses at the transcriptomic and cellular population levels in depressed patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2cf073f7c3882ea32b466937ec788669b0a8b86" target='_blank'>
              Immune System Alterations in Depression across Baseline and Flu Vaccine Challenge
              </a>
            </td>
          <td>
            D. Arasappan, Alyssa Marron, Sina Sanei, Mbemba Jabbi
          </td>
          <td>2025-12-05</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>14</td>
        </tr>

        <tr id="Gastric cancer (GC) remains a major global health burden with persistently high mortality despite therapeutic advances. Accumulating evidence highlights the pivotal role of tumor-associated macrophages (TAMs) in orchestrating gastric tumor progression through immune suppression, angiogenesis, extracellular matrix remodeling, and metastasis. Within the tumor microenvironment (TME), TAMs exhibit functional plasticity, often polarizing toward an M2-like phenotype that promotes immunosuppression and tumorigenicity. These cells actively participate in immune evasion via immune checkpoint expression and cytokine-mediated T cell inhibition, while also facilitating lymphovascular invasion and chemoresistance through exosome-mediated crosstalk. The density and phenotype of TAMs have been associated with prognosis and therapeutic response in GC. Recent studies have proposed TAMs as promising targets for therapy, with strategies focusing on depleting M2 subsets, reprogramming toward M1 phenotypes, and blocking TAM-driven oncogenic signaling. Targeted interventions, including MENK, paclitaxel, and NF-κB inhibitors, have shown potential in preclinical models. This review comprehensively discusses the mechanistic roles of TAMs in GC and evaluates emerging TAM-targeted therapeutic strategies that may enhance the efficacy of immunotherapy and improve patient outcomes.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/913bc3f4af4f9d7fed06d178714e6cfa582ea213" target='_blank'>
              Tumor associated macrophages in gastric cancer dual roles in immune evasion and clinical implications for targeted therapy
              </a>
            </td>
          <td>
            Chang Wang, Xu Fan, Xiaomeng Sun, Yi Xu, Yanna Sun, Jidong Liu
          </td>
          <td>2025-12-11</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Background: Hepatocellular carcinoma (HCC) harbors a dynamic tumor microenvironment (TME) in which macrophages are highly abundant and plastic. Under physiological conditions, macrophages switch between inflammatory and resolution/tissue-repair programs to maintain homeostasis; however, during hepatocarcinogenesis these programs are reprogrammed into tumor-associated macrophage (TAM) states that foster immune suppression, angiogenesis, and tumor progression. Purpose: To summarize macrophage heterogeneity and polarization mechanisms in HCC, and to highlight omics-informed therapeutic opportunities for targeting TAMs and improving precision immunotherapy. Research Design: This review summarizes physiological macrophage polarization and the mechanistic basis of macrophage reprogramming in the hepatocellular carcinoma immune microenvironment, integrating evidence from recent advances in single-cell sequencing, multi-omics, and spatial transcriptomics, with a focus on macrophage subset diversity, key regulatory pathways governing polarization and function, and emerging macrophage-targeted interventions and biomarkers. Results: Recent single-cell and spatial multi-omics studies reveal substantial TAM heterogeneity and plasticity in HCC. Macrophage-targeted strategies—including TAM depletion, phenotypic reprogramming, and exosome-mediated drug delivery—show encouraging preclinical efficacy. Macrophage-associated prognostic models and biomarkers may support individualized immunotherapeutic approaches. Conclusions: Macrophage polarization in HCC represents a dynamic continuum that is essential for homeostasis but is co-opted by tumors to drive immunosuppression and tissue remodeling. Advances in single-cell and spatial multi-omics are redefining TAM subsets and actionable pathways, enabling more rational macrophage-targeted therapies. However, challenges remain in standardizing TAM definitions, identifying robust predictive biomarkers, minimizing off-target effects, and optimizing combinations with immunotherapy. Integrating longitudinal multi-omics with AI-based modeling may help predict macrophage state transitions, guide patient-specific regimens, and advance precision medicine in HCC. Plain language summary Hepatocellular carcinoma is a highly aggressive cancer. Studies have found that immune cells within tumors—particularly macrophages—play a crucial role in cancer development and therapeutic response. Macrophages have two main “personalities”: the M1 type, which can kill cancer cells, and the M2 type, which supports cancer growth. They shift between these states in response to signals from the tumor microenvironment. Both liver-resident Kupffer cells and infiltrating macrophages are involved in this process. Various molecules, such as cytokines, enzymes, and exosomes, influence their polarization. This polarized state of macrophages, in turn, affects key tumor processes such as stemness, proliferation, metastasis, and angiogenesis. In recent years, scientists have been exploring drugs that specifically target macrophage polarization to suppress liver cancer, offering new directions for future therapy. Graphical Abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5b9c3d3369daa7c8bd747ff210bf91cca4945570" target='_blank'>
              Macrophage Polarization in the Tumor Microenvironment of Hepatocellular Carcinoma: From Mechanistic Insights to Translational Therapies
              </a>
            </td>
          <td>
            Xiaoqing Fu, Mingquan Pang, Zhixin Wang, Haijiu Wang
          </td>
          <td>2025-11-01</td>
          <td>Cancer Control: Journal of the Moffitt Cancer Center</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is an aggressive malignancy that is often refractory to chemotherapy and immune checkpoint inhibitors. This therapeutic resistance is driven in part by the persistence of cancer stem-like cells (CSCs) and the development of an immune-cold tumor microenvironment. However, the upstream regulators that coordinate these malignant features remain poorly defined. In this study, we identified dysadherin as a novel upstream activator of YAP that promotes both CSC plasticity and immune evasion through the FAK/YAP/TEAD2 signaling axis. Using single-cell transcriptomic analysis, in vitro assays, and multiple in vivo models including a humanized immune mouse system, we showed that dysadherin enhances the expression of pluripotency genes, such as OCT4 and upregulates PD-L1. These changes support stem-like tumor behavior and contribute to T-cell exclusion, fostering an immunosuppressive niche. Notably, genetic knockdown or peptide-based pharmacologic inhibition of dysadherin effectively restored antitumor immune activation, suppressed metastasis and improved therapeutic responsiveness. Our findings reveal a mechanistic link between dysadherin-mediated cell adhesion signaling and the transcriptional regulation of both stemness and immune escape. Collectively, these findings establish the dysadherin/YAP axis as a key driver of HCC progression and resistance, and highlight it as a compelling therapeutic target that could overcome treatment failure in advanced liver cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/29884335d480102826ec8b793e157ba0b7881a1e" target='_blank'>
              Dysadherin/YAP axis fuels stem plasticity and immune escape in liver cancer
              </a>
            </td>
          <td>
            T. Jang, So-El Jeon, H. Yun, Choong-Jae Lee, , Sang Hoon Lee, Dajun Lee, Seungwon Lee, Jungmin Choi, Hyung-Sik Kim, Jeong-Seok Nam
          </td>
          <td>2025-12-01</td>
          <td>Signal Transduction and Targeted Therapy</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Liver fibrosis, characterized by the excessive deposition of extracellular matrix (ECM) driven by hepatic stellate cells (HSCs) activation, remains a critical challenge due to its progression to cirrhosis and hepatocellular carcinoma (HCC). This review clarifies the complex crosstalk between the immune system and HSCs, highlighting key cellular players including macrophages, natural killer (NK) cells, regulatory T cells (Tregs), and their cytokine‐mediated signaling pathways that regulate fibrogenesis and fibrosis resolution. We describe pivotal molecular mechanisms such as transforming growth factor (TGF)‐β, platelet‐derived growth factor (PDGF), Wnt/β‐catenin, and NF‐κB signaling in HSCs modulation, emphasizing their interplay with immune responses. Novel therapeutic strategies targeting this complex immune–HSCs interaction, ranging from immunomodulatory agents, macrophage polarization, and NK cell‐based therapies, to stem cell‐derived exosomes, offer promising opportunities for preventing and reversing fibrosis. We further discuss innovative combination therapies integrating immunotherapies with antifibrotic agents, personalized strategies based on immune profiling, and the challenges of immune heterogeneity in fibrosis management. This review discusses recent advances in molecular interplay of immune system and HSCs, highlighting novel therapeutic targets, and future perspectives for managing chronic liver diseases.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5022b23a68cf2c2cfdfb9468e2f2ae355d75f27a" target='_blank'>
              Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
              </a>
            </td>
          <td>
            Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, F. H. Zahiroh, Aris Muhammad Nurjamil, T. Wargasetia, I. M. Nainggolan, Rizal Azis, Elham Rismani, Dr. Massoud Vosough
          </td>
          <td>2026-01-01</td>
          <td>Journal of Immunology Research</td>
          <td>0</td>
          <td>29</td>
        </tr>

        <tr id="Despite advances in therapy, non-small cell lung cancer (NSCLC) continues to rank among the deadliest cancers worldwide. Targeting immunosuppressive components within the tumor microenvironment (TME) has emerged as a promising therapeutic strategy. Unlike M1 tumor-associated macrophages (TAMs), M2-like TAMs contribute to NSCLC progression by promoting an immunosuppressive tumor microenvironment (TME), highlighting the need for tumor microenvironment remodeling. CL7, a monoclonal antibody that targets the activating receptor CD300c on human monocytes and macrophages, was selected as a therapeutic candidate because CD300c engagement triggers MAPK and NF-κB signaling pathways, promoting M1 macrophage polarization and antitumor immune activation. To evaluate the therapeutic potential of CL7, we established an orthotopic NSCLC model by inoculating LLC-luc cells into the left lung of mice. We administered CL7 intraperitoneally at doses of 5 or 10 mg/kg twice a week. Only representative data from the 10 mg/kg CL7 group are shown to maintain consistency with subsequent analyses (flow cytometry, RT-qPCR, and IHC). Tumor growth was significantly suppressed in the CL7-treated group compared to the PBS control group. CL7 treatment also modulated the tumor microenvironment by increasing the population of M1 macrophages and CD8+ T cells, while decreasing the population of regulatory T cells. Our findings suggest that CL7 exerts antitumor effects in NSCLC by reprogramming the immunosuppressive landscape of the TME and enhancing antitumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/863d3f6179309aee5c3016baab1955820d8c1527" target='_blank'>
              The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma
              </a>
            </td>
          <td>
            Soyoung Kim, IkJoon Han, Suin Lee, Sujin Park, Jae-Won Jeon, Hyunsu Bae
          </td>
          <td>2025-11-25</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="Background Lipocalin-2 (Lcn2) is a sensitive early marker for acute kidney injury, delayed graft function and acute rejection of kidney transplants. We previously showed the renoprotective effect of recombinant Lcn2:Siderophore: Fe3+ (rLcn2) in a mouse kidney transplantation (KTx) model. Here, we investigate the molecular and cellular mechanisms underlying these effects. Methods Male C57BL/6 mice (10–12 weeks) received BALB/c kidney allografts, with or without rLcn2 treatment (250 µg, s.c.). To examine the immunomodulatory function of rLcn2, immune cells from graft, spleen, lymph nodes and blood were analyzed by flow cytometry at post-operative days (pod) 3 and 7. Syngeneic C57BL/6 grafts were used to investigate the impact of rLcn2 on alloimmune-independent tissue injury and inflammation through multiplex signaling assays, functional readouts, cytokine profiling and histopathological analyses. Results rLcn2 treatment markedly reduced frequencies of distinct T cell subsets, including effector memory T cells and their cytotoxic (Tc) and helper (Th) subsets across grafts, lymphoid tissues and blood by pod-7 following allogeneic KTx. In graft infiltrating CD8+ T cells, rLcn2 decreased degranulation capacity and diminished expression of interferon-γ and perforin. rLcn2 also lowered the proportion of NKG2D+ CD8+ T cells, an activating Tc subset, in spleen and blood. In contrast, its impact on innate immune cells was modest and selective, influencing only neutrophils, macrophages in lymph nodes and intermediate mature NK cells in spleen and blood. No significant effect of rLcn2 treatment was observed on alloimmune-independent tissue injury or inflammation in syngeneic kidney grafts. Conclusion rLcn2 selectively modulates T-cell activity after KTx without affecting alloimmune-independent injury pathways.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ed180d49cdbfb39ec89a170f0fe6750f292b2bde" target='_blank'>
              Lipocalin-2 modulates recipients alloimmune responses to the murine kidney transplants
              </a>
            </td>
          <td>
            A. M. Pfefferkorn, R. Fritsche-Guenther, Angelika Kusch, Hubert G. Schwelberger, Shiqian Liu, R. Klopfleisch, Yuhuan Li, R. Catar, Shaokun Liu, Felix Aigner, Johann Pratschke, I. M. Sauer, Muhammad-Imtiaz Ashraf
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>26</td>
        </tr>

        <tr id="The progression of endometrial cancer (EC) is significantly affected by the inflammatory microenvironment (IME), which is essential for facilitating immune evasion and developing resistance to therapeutic interventions. Components that promote immune suppression, such as regulatory T cells (Tregs), macrophages associated with tumors (TAMs), cytokines like interleukin-10 (IL-10) and transforming growth factors-beta (TGF-β), are crucial in establishing a favorable microenvironment for tumor growth. TAMs with a M2-like phenotype promote angiogenesis and inhibit antitumor immunity through the secretion pro-tumorigenic factor. Further, metabolic shifts in the extracellular matrix and structural modifications of the extracellular matrix (ECM) inhibit the infiltration of cytotoxic T lymphocytes (CTLs), thereby strengthening mechanisms of immune evasion. Inflammatory signaling pathways, such as interleukin-6/janus kinase/signal transducer and activator of transcription 3 (IL-6/JAK/STAT3) and NF-κB/tumor necrosis factor-alpha (TNF-α/NF-κB), also stimulate the expression immune checkpoint molecules, such as programmed cell death protein 1 (PD-1). Novel interventions aimed at modulating immune checkpoints, inhibiting TGF-β signaling, and altering metabolic circuits are under investigation and offer potential to counteract immune suppression and enhance therapeutic success. Nevertheless, significant obstacles remain, including intratumoral heterogeneity, fluctuating immune dynamics, and the absence of dependable biomarkers. Advancements in single-cell analysis and spatial transcriptomics are anticipated to unveil actionable molecular patterns and support the development of individualized strategies to interrupt immune evasion and therapeutic resistance in EC. These advances offer promise for personalized immunotherapy approaches that could significantly improve outcomes in endometrial cancer patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/08650738c72d5687a0479b11b8c3deb3610cc229" target='_blank'>
              Inflammation-driven mechanisms in endometrial cancer: pathways from inflammatory microenvironment remodeling to immune escape
              </a>
            </td>
          <td>
            Zhaoping Tan, Binyue Sheng, Lu Chen, Hong Dong, Yaqin Deng, Yunyun Li, Cong Liu, Han Wang, Zi Yang, Ting Xie, Yanming Huang
          </td>
          <td>2025-11-26</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Post-stroke T lymphocytes exert differential effects both at the infarction site and systemically; these are pro-inflammatory cascades, subsequent T cell infiltration into the brain, and persisting interaction of infiltrating T lymphocytes (more specifically a subset of CD4- CD8-double-negative T cells (DNTs)). Moreover, brain-resident microglia cells exacerbate the parenchymal damage. The acute peripheral immune response is characterized by lymphopenia and persisting activation of circulating T lymphocytes. In the temporal course, it is supposed that anti-inflammatory mechanisms in general and especially the anti-inflammatory M2 phenotype of microglia cells help to recover the functionality of brain parenchyma. We assessed the long-term temporal course of peripheral blood T cell activation post stroke as well as the interaction of pan-T cells or DNTs with microglia cells ex vivo. T cell subpopulations (CD4+, CD8+, DNT) and their activation (CD25, CD57, CTLA-4 (CD152) and PD-L1 (CD274)) were analysed in peripheral blood from stroke patients and controls by flow cytometry. Pan-T cells and DNTs were isolated by magnetic beads from stroke patients’ blood 3 days (t1), 1 month (t2), and 3 months (t3) post stroke or once from controls, and they were incubated with or without healthy donor human microglia cells ex vivo. Upon interaction, T cell (HLA-DR) and microglia activation (HLA-DR, CX3CR1, CD32, CD86, CD206 and CD209) was assessed by flow cytometry. Moreover, IL-1β in cell culture supernatants was quantified by ELISA. Post-stroke CD4+ and CD8+ T cell activation (CD25) persisted for 1 month and declined only after 3 months. Inhibitory activation markers CTLA-4 and PD-L1 were upregulated only 3 months after stroke. Co-culture of pan-T cells and microglia had little effect on microglial activation but a strong effect on T cell activation (HLA-DR). Co-culture of DNTs with microglia cells inhibited the M2 phenotype of microglia. Stroke acutely leads to a strong activation (CD25 upregulation) of both CD4+ and CD8+ T cells. This activation persisted in the subacute post-stroke phase and declined at 3 months post stroke, being accompanied by upregulation of PD-L1 and CTLA-4. Both might be involved in terminating chronic T cell activation. DNTs might influence microglia through CX3CR1 and inhibit an M2 state ex vivo, which might contribute to cerebral inflammation post stroke.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a6eeee342578d5c85114ed9491dbdbb4d5e9207f" target='_blank'>
              Lack of Negative Feedback Loops of CTLA-4 and PD-L1 as Key Mechanisms for Post-Acute T Cell Activation Until 3 Months After Ischemic Stroke
              </a>
            </td>
          <td>
            Lars Peglau, J. Ruhnau, Mara Winkelmann, Thomas Krüger, Alexander Dressel, J. Schulze, A. Vogelgesang
          </td>
          <td>2025-11-27</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Long COVID has emerged as a major global health concern, yet the long-term trajectory of immune recovery and its contribution to persistent symptoms remain to be elucidated. Here, we conducted a three-year longitudinal follow-up of the 47 COVID-19 patients and applied single-cell RNA sequencing (scRNA-seq) and multiplex cytokine profiling to comprehensively characterize the peripheral immune landscape during convalescence. We observed persistent immune dysregulation up to three years post-infection, characterized by chronic inflammation and impaired restoration of naïve CD4⁺ T cells, naïve CD8⁺ T cells, and SLC4A10⁺ MAIT cells—features reminiscent of immunosenescence. Notably, Th17 cells, rather than monocytes, emerged as key drivers of chronic inflammation beyond one year. We identified two distinct Th17 subsets: RORC⁺ Th17 cells and LTB⁺ Th17 cells. While RORC⁺ Th17 cells were negatively correlated with inflammatory cytokine levels, LTB⁺ Th17 cells showed proinflammatory features and were positively associated with long COVID symptoms. Sustained elevation of S100A8 and IL-16 in follow-up patients may contribute to the persistent presence of LTB⁺ Th17 cells. Together, our study provides an in-depth longitudinal map of immune remodeling in COVID-19 convalescents, revealing key cellular and molecular drivers of sustained inflammation up to three years post-infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/f682ef5df5972e318b0093c3cf2459508e92d089" target='_blank'>
              T cell-driven sustained inflammation and immune dysregulation mimicking immunosenescence for up to three years post-COVID-19
              </a>
            </td>
          <td>
            Tian Zheng, Ru Gao, Yiwei Liu, Ye-ming Wang, Chao Wu, Li Guo, Lan Chen, Xinming Wang, Yan Xiao, J. Zhong, Rongling Zhang, Ying Wang, Xianwen Ren, Bin Cao, Lili Ren, Jianwei Wang
          </td>
          <td>2025-11-20</td>
          <td>Immunity & Inflammation</td>
          <td>0</td>
          <td>32</td>
        </tr>

        <tr id="Liver metastasis continues to be a leading cause of cancer-related mortality, particularly in colorectal, pancreatic, and breast cancer. The successful establishment of metastatic lesions depends critically on the liver metastatic tumor microenvironment, where reciprocal cellular interactions between disseminated tumor cells and both parenchymal hepatocytes and non-parenchymal cells facilitate tumor cell colonization and outgrowth. Hepatic macrophages that encompass both tissue-resident Kupffer cells (KCs) and monocyte-derived macrophages (Mo-Macs) have emerged as pivotal regulators of liver metastatic progression. This review summarizes recent progress from the following perspectives: (I) Primary tumors recruit macrophages via secretion of cytokines and exosomes, or induce phenotypic alterations in resident KCs and recruited Mo-Macs, thereby establishing a premetastatic niche; (II) Once the premetastatic niche is formed, hepatic macrophages directly interact with tumor cells to mediate their capture, colonization, and subsequent outgrowth; (III) Furthermore, hepatic macrophages regulate phenotypic changes in T cells, NK cells, hepatocytes, and hepatic stellate cells (HSCs) through cytokine/exosome secretion or direct cell-cell interactions, which induce T cell exhaustion, impairment of NK cell cytotoxicity, and activation of HSCs leading to fibrotic microenvironment formation. Additionally, we review advances in macrophage-targeted therapeutic strategies against liver metastasis. By delineating the pivotal roles of hepatic macrophages in metastatic progression and analyzing current clinical limitations of targeting macrophages for liver metastasis therapies, this review provides foundational insights for understanding macrophage biology and developing effective therapeutics.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/ad28500548fcc71d426ab070d872289195a208d5" target='_blank'>
              The hepatic macrophage: a key regulator of liver metastatic tumor microenvironment through cell crosstalk
              </a>
            </td>
          <td>
            Weihua Wang, Ziying Yi, Zeyu Yang, Yinde Huang, Hongdan Chen, Yao Li, Lianghong Jing, Supeng Yin, Fan Zhang
          </td>
          <td>2025-11-21</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Immunity during cancer progression involves critical responses that may be harnessed to augment anti-tumor cytotoxicity. A potent arm of immunity in cancer involves cytotoxic T cells (a key CD8+ T-lymphocyte subset): Anti-tumor responses by such cells optimally involve sensitization and acquired responses to tumor antigens by antigen presenting cells. Many tumor microenvironment (TME) biophysical and functional limitations in carcinomas limit robust achievement of this ideal cellular-immunologic pathway. This is especially challenging in lung carcinoma, on which we focus mechanistically and with an eye to therapeutic translation. Localization of tumor-sensitized and activated CD8+ T cells to tumor “nests” with efficient tumor cytolysis involves many challenging steps. Amplifying and sustaining such responses is also a unique challenge. The variety of homeostatic and immunosuppressive obstacles often becomes overwhelming. Measuring the state of this response during lung cancer progression is also challenging, making it difficult to mount (and/or predict) T-cytotoxic responses in the heterogeneous and dynamic carcinoma antigen landscape. We investigate these challenges herein, while examining strategies to boost T-cytotoxic immunity in lung cancer through novel and emerging immunotherapeutic approaches. Beyond current immune checkpoint blockade approaches that are relatively non-specific with respect to antigen recognition by the T-cell receptor, we highlight ongoing and translational vaccines, cell-therapies, antigen-presenting cell boosting approaches, T-cell therapies, and biophysical considerations with an eye to overcome key barriers of this powerful arm of anti-tumor immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d405cc42ae9819222b3a3a0b50f4e0cc2451158" target='_blank'>
              The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma
              </a>
            </td>
          <td>
            Aditya Dash, Afsheen Banisadr, Donivian Al Dikka, Scott C. Johns, Mark M. Fuster
          </td>
          <td>2025-12-17</td>
          <td>Frontiers in Oncology</td>
          <td>0</td>
          <td>10</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1516695d6b5d42eee01c5283dd2b0d1ed45c9880" target='_blank'>
              Loss of Acid Ceramidase in Myeloid Cells Protects from Chronic Colitis in IL10-Deficent Mice
              </a>
            </td>
          <td>
            Keila S. Espinoza, Brandon K. Dahl, , Ella M. Ryan, Mary R. Gordon, Chelsea L. Doll, Marilyn T. Marron, Cameron A. Beard, Pujarini D. Dey, Richard J. Simpson, Justin M. Snider, Justin E. Wilson, Pawel R. Kiela, Ashley J. Snider
          </td>
          <td>2026-01-06</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="Kaposi’s sarcoma-associated herpesvirus (KSHV) infection is linked with the development of life-threatening malignancies in elderly and immunocompromised hosts, suggesting tight control of the infection by T cell responses. T cells against KSHV, however, are barely detectable in infected individuals, and the mechanisms underlying immune recognition of KSHV-infected cells remain poorly understood. Here, we present publicly available sequences of T cell receptors (TCRs) targeting the KSHV latency-associated nuclear antigen (LANA/ORF73). By using these TCRs transgenically expressed on T cells as identifiers for KSHV-specific cells, we show that despite their failure to recognize KSHV-infected B cells in vitro, activated effector memory differentiated LANA-specific CD4+ T cells accumulate in vivo at infection sites in the preclinical infection model of humanized mice. This suggests more efficient antigen-presentation in vivo than by KSHV-infected B cells in vitro and highlights the possible contribution of CD4+ T cells to the immunosurveillance of latently infected B cells. Karposi’s Sarcoma-associated herpesvirus (KSHV) infection is associated with malignancy in older infected humans. Here the authors characterise antigen presentation using a KSHV-specific CD4+ T cell-derived TCR in a mouse model and show that although KSHV-specific CD4+ T cells are difficult to detect in humans, antigen presentation is effective in vivo suggesting persistence and accumulation of these cells through antigen recognition.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8732f46ab8fbde7b2d707b2048fc5daf4cc8650f" target='_blank'>
              LANA-specific CD4+ effector T cells accumulate at the site of KSHV infection in humanized mice
              </a>
            </td>
          <td>
            Michelle Böni, Shitao Peng, Danusia Vanoaica, Kareem Haal, S. L. Nopper, L. Rieble, Sandra Schmid, Alma Delia Valencia-Camargo, A. Holler, Hans Stauss, Christian Münz
          </td>
          <td>2025-12-05</td>
          <td>Nature Communications</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Background: Colorectal cancer (CRC) frequently metastasizes to the liver (CRLM), where M2-polarized macrophages shape an immunosuppressive pre-metastatic niche. The molecular cues driving this polarization remain unclear. Methods and Results: Using integrated transcriptomics, patient cohorts, and mouse models, we investigated the role of tissue inhibitor of metalloproteinases-1 (TIMP1) in CRLM. TIMP1 was consistently overexpressed in CRC tissues and associated with poor overall survival. CRC cells secreted TIMP1 into the tumor microenvironment, where it induced M2-like macrophage polarization and increased the expression of immunosuppressive mediators such as CSF1 and IRF4. In vivo, TIMP1 overexpression enhanced, whereas its knockdown reduced, liver metastatic burden. Immune profiling and depletion experiments indicated that these pro-metastatic effects were largely macrophage-dependent. Mechanistically, TIMP1 engaged CD63/β1-integrin on macrophages, activating AKT/mTOR signaling and stabilizing the M2 phenotype. Conclusions: CRC-derived TIMP1 remodels liver macrophages via the CD63/β1-integrin–AKT/mTOR pathway to promote a hepatic pre-metastatic niche. Pharmacologic inhibition of this signaling axis with the integrin antagonist cilengitide suppressed macrophage M2 markers and liver colonization in mice, supporting TIMP1–integrin signaling as a potential therapeutic target.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/4e7ffd59e713fcb828787baa3b25c1e2df9f73c8" target='_blank'>
              Integrin-Mediated TIMP1 Signaling Reprograms Liver Macrophages and Accelerates Colorectal Cancer Metastasis
              </a>
            </td>
          <td>
            Jialiang Liu, Liming Zhao, Lin Wang, Guoli Sheng, P. Cheng, Mingyu Han, Guoxin Li, Zhaoxu Zheng
          </td>
          <td>2025-12-23</td>
          <td>Cells</td>
          <td>0</td>
          <td>7</td>
        </tr>

        <tr id="Beta-arrestin 1 (ARRB1) is a multifunctional adaptor protein that regulates diverse signaling pathways beyond its canonical role in G-protein-coupled receptor desensitization. While ARRB1 has been implicated in cancer progression, its role in modulating host immunity against multiple myeloma (MM) remains unexplored. Here, we demonstrate that host ARRB1 deficiency significantly enhances anti-myeloma immunity and prolongs survival in a syngeneic murine MM model. Using Vk*MYC myeloma cells transplanted into wild-type and ARRB1 knockout mice, we show that ARRB1 deficiency in the host microenvironment promotes robust T cell infiltration and activation while reducing immunosuppressive myeloid populations. Notably, ARRB1 knockout mice exhibited markedly decreased programmed cell death protein-1 (PD-1) expression on both T cells and myeloid-derived suppressor cells, indicating reduced immune exhaustion. Furthermore, ARRB1 deficiency conferred protection against myeloma-induced bone disease, suggesting a dual role in immune regulation and bone homeostasis. These findings establish ARRB1 as a critical negative regulator of host anti-myeloma immunity and identify it as a potential therapeutic target for enhancing immunotherapy efficacy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e3458263c03dcd78fb680e514ef2ef3a2d506e7e" target='_blank'>
              Beta-Arrestin 1 Deficiency Enhances Host Anti-Myeloma Immunity Through T Cell Activation and Checkpoint Modulation
              </a>
            </td>
          <td>
            Jian Wu, Xiaobei Wang, Shaima Jabbar, Niyant Ganesh, Emily Chu, V. T. Math, Lindsay Rein, Yubin Kang
          </td>
          <td>2025-11-27</td>
          <td>International Journal of Molecular Sciences</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="The chemokine receptor C-X-C chemokine receptor type 3 (CXCR3) is a key chemoattractant molecule that facilitates the migration of activated T cells to the pancreas, leading to beta cell death. In this study, we investigated CXCR3 responses in B cells during type 1 diabetes progression. Peripheral blood samples were obtained from individuals with recent-onset and long-duration type 1 diabetes, who were age- and sex-matched to non-diabetic donors. We isolated peripheral blood mononuclear cells (PBMCs) and examined changes in CXCR3 expression on lymphocytes from donors, performing multiparameter flow cytometry and functional cell culture assays. Human post-mortem pancreatic tissue was obtained from the Exeter Archival Diabetes Biobank. Immunofluorescence staining was used to assess CXCR3 expression in pancreatic tissues. We observed reduced CXCR3 expression on antigen-experienced B cells in individuals with a long duration of type 1 diabetes, although B cells remained responsive to IFNγ. In individuals who were recently diagnosed, IFNγ treatment resulted in increased CXCR3 expression compared with B cells from non-diabetic donors. B cells in pancreases that were recovered post-mortem from young recent-onset donors lacked CXCR3 expression, but co-staining to detect CD8+ T cells revealed a CXCR3+CD20+CD8+ T cell population, with their circulating counterpart showing increased CXCR3 expression. We conclude that the CXCR3 response in antigen-experienced B cells is dysregulated during the progression of type 1 diabetes. CXCR3 expression is limited in CD20+ B cells in pancreases from recent-onset individuals diagnosed with type 1 diabetes under 7 years of age, but evident on CD8+ T cells that express CD20.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0895fbd19269fbdc4298e324e79791c8a18caebd" target='_blank'>
              CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes
              </a>
            </td>
          <td>
            J. Boldison, P. Leete, E. Robinson, Wendy Powell, Joanne Davies, Conor McMullan, Sophie L Walker, Noel G. Morgan, S. Hanna, F. S. Wong
          </td>
          <td>2025-11-22</td>
          <td>Diabetologia</td>
          <td>0</td>
          <td>19</td>
        </tr>

        <tr id="Hepatocellular carcinoma (HCC) is characterized by an immunosuppressive tumor microenvironment (TME) that critically propels malignant evolution. Sphingomyelin synthase 2 (SGMS2), the pivotal sphingolipid metabolizing enzyme, catalyzes the conversion of ceramide to sphingomyelin. Emerging evidence highlights sphingolipid metabolism as a key regulator of tumor immunity, particularly in shaping macrophage phenotypes within the TME. However, the macrophage-specific contributions of SGMS2 to HCC progression remain unexplored. This study elucidates the critical role of SGMS2 in shaping TME and influencing patient prognosis. Bulk RNA-seq analysis was performed using TCGA-LIHC datasets (n = 371). Single-cell RNA sequencing and spatial transcriptomics were used to identify SGMS2-expressing cell types and evaluate spatial immune interactions. Clinical validation was performed on a cohort of 188 HCC patients (2017–2022) using multiplex immunofluorescence to quantify SGMS2+ macrophages and NR4A3hi NK cells. THP-1 monocytes were transfected with lentiviral SGMS2 overexpression vectors and differentiated into macrophages via PMA induction. Co-culture assays with liver tumor cells were performed in transwell plates for 48 h, followed by tumor cell apoptosis assessment using Annexin V-FITC/PI staining and flow cytometry. High SGMS2 expression in HCC tissues was associated with improved patient prognosis. SGMS2 was mainly expressed in macrophages within the HCC immune microenvironment, promoting their polarization toward the M1-like phenotype. High infiltration of SGMS2+ macrophages significantly prolonged overall survival (OS), recurrence-free survival (RFS), and early RFS. Notably, patients with high infiltration of SGMS2+ macrophages accompanied by low infiltration of SGMS2- macrophages had the most favorable prognosis. Mechanistically, SGMS2+ macrophages secreted CXCL2, recruiting CD56dimCD16highNR4A3high cytotoxic NK cells, enhancing tumor cell apoptosis and improving prognosis. In patients receiving PD-1 therapy, those with high infiltration of SGMS2+ macrophages and CD56dimCD16highNR4A3high NK cells demonstrated superior treatment responsiveness and prolonged survival. SGMS2 could polarize macrophages toward the M1 phenotype. SGMS2+ macrophages secrete CXCL2 to recruit CD56dimCD16highNR4A3high NK cells, thereby enhancing tumor apoptosis. High infiltration of SGMS2+ macrophages and CD56dimCD16highNR4A3high NK cells correlates with superior PD-1 therapy responsiveness and extended survival.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/07729b0162422252368582216157eef717d5ce88" target='_blank'>
              SGMS2+ macrophages enhance NR4A3hi NK cell infiltration to improve prognosis and PD-1 treatment efficacy in hepatocellular carcinoma
              </a>
            </td>
          <td>
            Fansheng Meng, Fulin Nian, Haokang Feng, Zhixue Chen, Qiu-Yu Jiang, Feng Zhang, Lin Xu, Yueying Chen, Hao Zhang, Tao Ye, Biwei Yang
          </td>
          <td>2025-11-28</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>6</td>
        </tr>

        <tr id="The roles of eosinophil extracellular traps (EETs) in cancer have not been investigated. This research aims to unearth the association between EETs and clinical outcomes in pan-cancer. From the Cancer Genome Atlas (TCGA) program, a 28-gene EETs score was constructed. Overall, higher EETs scores indicated shorter overall survival. EETs were significantly correlated to various pro-tumor processes, including extracellular matrix remodeling, IL-17 signaling, M2 macrophage polarization, and Treg differentiation. Immune suppressive M2 macrophages infiltrated more in the tumor microenvironment (TME), while cytotoxic cells (CD8 T and NK cells) were fewer. EETs-gene expression correlated with multiple T cell co-inhibitors. Target molecules of immune checkpoint inhibitors (ICIs) were not in proximity to the EETs disease module. Drugs against IL-5, IL-5RA, CCL-11 and IL-33 scored highly in perturbation of the disease module. Therefore, the EETs formation was coordinated with the adverse clinical outcomes and TME alternations in cancer. The role of EETs and anti-eosinophil therapy in cancer deserve further investigation in the era of immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b598a846eb03bb4801110e2bd62531abd6b5070" target='_blank'>
              Eosinophil extracellular traps formation is correlated with cancer prognosis by tumor microenvironment remodeling
              </a>
            </td>
          <td>
            Jingdai Zhang, Yu Qiu, Yifan Liu, Shengwei Mo, Muwen Nie, Hui Zhang, Xiaohang Liu, Wei Chen
          </td>
          <td>2025-11-17</td>
          <td>Scientific Reports</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e2e717b4466922c6801a12a8f82b0f2c866a33da" target='_blank'>
              PA28γ-containing tumor-derived exosomes promote T-cell dysfunction in head and neck squamous cell carcinoma
              </a>
            </td>
          <td>
            Ying Wang, Shiyu Zhang, Yang Yang, Yimei Wang, Yingxin Zhang, Ming Liu, Xin Zeng, Ning Ji, Silu Sun, Chunjie Li, Yuwei Zhao, Xikun Zhou, Qianming Chen, Jing Li
          </td>
          <td>2025-12-08</td>
          <td>Cellular & Molecular Immunology</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Plasmacytes, the effector arm of humoral immunity, produce sufficient amounts of specific antibodies to provide protection against infection or disease. The durability of this humoral protection depends on the generation of long-lived plasmacytes (LLPC), a specialized population that is capable of secreting antibody over long periods of times - years to decades. Here we investigate the role of constitutively active germinal centers (GCs) in generating the plasmacytes resident in bone marrow, a site critical for vaccine-induced LLPC to provide meaningful protection to infection and resistance to morbidity. In unimmunized B6.S1pr2-Cre mice, we show that a short period of conditional labeling marks 85% of gut-associated GC B cells and their progeny. Frequencies of labeled GC B cells fall over time, but frequencies of labeled bone marrow PC increase to approximately one-third of all bone marrow PC by 70-80 days after pulse labeling. Labeled, GC derived bone marrow PC express the identical isotypic distribution of the unlabeled PC in bone marrow. We conclude that the progeny of gut-associated GC B cells are responsible for most, and perhaps all, bone marrow PC and that under homeostatic conditions, serum antibody reflects exposure to gut antigens. Bone marrow occupancy by these gut-derived PC raises the possibility of competition with more transient, vaccine-induced humoral responses.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/cbb121bf0ac8dd95134fd53dc1a8a140a008ead3" target='_blank'>
              On the carrying capacity of the bone marrow survival niche in mice
              </a>
            </td>
          <td>
            Keisuke Tonouchi, Chen-Hao Yeh, D. Cain, E. Moseman, B. Haynes, K. Wagh, K. Wiehe, Tomohiro Kurosaki, G. Kelsoe, Julie Tellier, J. Weill
          </td>
          <td>2025-11-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>80</td>
        </tr>

        <tr id="Background Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immunotherapy because of its highly immunosuppressive tumor microenvironment. Aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor, has emerged as a key regulator of immune homeostasis and inflammation. However, its systemic immunomodulatory role in PDAC, particularly outside the tumor microenvironment, remains poorly understood. Methods Peripheral blood mononuclear cells (PBMCs) from patients with PDAC and healthy donors were isolated and treated ex vivo with two AHR agonists (Carbidopa and Tapinarof) and one antagonist (BAY 2416964). The samples were stratified into Low and High/Medium AHR expression groups. Flow cytometry (FC), qPCR, ELISA, Luminex assays, and immunofluorescence imaging were used to evaluate immune checkpoint expression, cytokine secretion, monocyte polarization, and subcellular AHR localization. Overall survival analysis was performed based on the baseline AHR expression levels. Results Baseline AHR expression strongly influenced the immunological effects of AHR modulators. In High/Medium AHR PBMCs, Carbidopa increased PD-L1 and soluble PD-1 (sPD-1) levels, while IL10 expression was suppressed. In contrast, BAY significantly reduced PD-1 and sPD-1 levels in Low AHR PBMCs, whereas Tapinarof induced the highest IL10 expression. All modulators reduced the proportion of M2-like monocytes, indicating a shift toward less immunosuppressive phenotypes. Nuclear translocation of AHR protein varied across treatments and expression levels. Kaplan–Meier analysis revealed a non-significant trend toward improved overall survival in the High/Medium AHR group (log-rank p = 0.276). Conclusion Baseline AHR expression critically shapes the immune response to pharmacological modulation in PBMCs from PDAC patients. These findings suggest that AHR profiling may serve as a clinically relevant biomarker for stratifying patients and guiding personalized immunotherapy approaches for PDAC.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/a46524e691b33034f74b47cfc886a57c3dea8c5c" target='_blank'>
              Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients
              </a>
            </td>
          <td>
            Arenida Bartkeviciene, A. Jasukaitienė, Inga Žievytė, Sandra Ivanauskienė, Gabija Stachnevičiūtė, Kornelija Jenceviciute, Gabrielė Karvelytė, Darius Stukas, Agne Sikarske, Daiva Urbonienė, T. Maimets, K. Jaudzems, A. Vitkauskiene, Jason Matthews, A. Gulbinas, Ž. Dambrauskas
          </td>
          <td>2025-11-20</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>30</td>
        </tr>

        <tr id="Immunogenic cell death (ICD) significantly boosts anti-tumor immunotherapy effectiveness; however, the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), driven by factors such as adenosine accumulation and oxygen depletion during ICD, impairs the overall therapeutic outcome as well as facilitates tumor development and metastasis. Recent studies identify CD300ld as a key regulator of PMN-MDSCs recruitment, making it a promising immunotherapeutic target. Here, an innovative strategy is developed to eminently amplify ICD while alleviating PMN-MDSC infiltration upon ultrasound (US) stimulation. A modified generation 5 (G5) poly(amidoamine) dendrimer (G5PBA) was employed to encapsulate hematoporphyrin (GH)—a widely used organic sonosensitizer—and modified the complex with pardaxin peptides (Par) to achieve precise endoplasmic reticulum (ER) targeting, and adsorbed the negatively charged siCD300ld (PGH@siRNA). Under US irradiation, PGH@siRNA precisely accumulates at ER to induce localized reactive oxygen species (ROS) bursts, and effectively silence CD300ld, thereby amplifying endoplasmic reticulum stress (ERS)-mediated ICD and reducing PMN-MDSCs infiltration to reshape the tumor microenvironment. This systematic preclinical evaluations demonstrated enhanced immune activation, suppressed metastasis, and improved therapeutic outcomes. This study introduces a sono-responsive synergistic strategy integrating ER-targeted sonodynamic therapy with gene silencing, offering a novel paradigm for targeting PMN-MDSCs and enhancing triple-negative breast cancer (TNBC) immunotherapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d8ace307e49ce92f9985bbbbae4accb311e36425" target='_blank'>
              Sono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment
              </a>
            </td>
          <td>
            Xuejun Chen, Shaoyue Li, Qing Lu, Yitong Li, Mingrui Zhu, Shen Zhang, Yan Fang, Congjian Wen, Daohui Yang, Peili Fan, Huixiong Xu, Haohao Yin
          </td>
          <td>2025-11-26</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>8</td>
        </tr>

        <tr id="Natural killer (NK) cells exhibit remarkable adaptability within the tumour microenvironment (TME), where dynamic shifts in phenotype, function and metabolism govern their dual roles in antitumour immunity and tumour immune evasion. In the TME, NK cells undergo receptor remodelling, which is characterised by upregulated inhibitory signals and suppressed activating receptors, leading to the formation of dysfunctional subsets, such as exhausted TIM-3⁺ NK cells or tissue-resident CD49a⁺ populations. Immunosuppressive factors within the TME drive a transition from cytotoxic activity to regulatory or senescent-like states, impairing tumour surveillance. Metabolic reprogramming further compromises NK cell effector functions, as nutrient deprivation and metabolic byproducts disrupt energy pathways and suppress immune responses. Therapeutic strategies targeting this plasticity include engineered natural killer (NK) cells with enhanced specificity, metabolic restoration approaches and microenvironment-modulating interventions. However, challenges persist because of TME heterogeneity and persistent dysfunctional states. Understanding these adaptive mechanisms provides a framework for developing NK cell-based therapies that leverage plasticity to counteract tumour resistance.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/910259fba0614bb5440944e1a9be14c37f13989d" target='_blank'>
              Multidimensional plasticity of natural killer cells in tumours
              </a>
            </td>
          <td>
            Xinya Yang, Zhaoyang Song, Ligang Chen, Qingge Jia, Mingyang Li
          </td>
          <td>2025-12-01</td>
          <td>Cell Death & Disease</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/41c90be54d0c8300380663bf0b722bf4b28986ad" target='_blank'>
              Divergent myelopoiesis and macrophage polarization underlie host susceptibility to chronic Chlamydia trachomatis infection
              </a>
            </td>
          <td>
            Naveen Challagundla, Shivani Yadav, Reena Agrawal Rajput
          </td>
          <td>2025-12-13</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="Understanding the tumor microenvironment (TME) requires a comprehensive exploration of the interactions between tumor cells and various stromal and immune cells, as these interactions significantly influence tumor growth and treatment response. Immunometabolism, which examines the relationship between immune cell metabolic processes and their behaviour, has become crucial in determining the effectiveness of anti-tumor immune responses. This review explores the intricate relationship between immunometabolism and TME, highlighting how metabolic changes in immune cells can either enhance or impair their capacity to fight cancer. It specifically investigates the metabolic reprogramming of T cells, macrophages, and dendritic cells within the TME and how these alterations affect their anti-tumor roles. The review also examines how tumors utilise metabolic pathways to establish an immunosuppressive environment that fosters tumor growth. Understanding these processes reveals potential therapeutic targets in immunometabolism to improve cancer treatment outcomes. By emphasising the dual role of immunometabolism in both aiding and inhibiting the immune response to cancer, this review underscores the necessity of integrating metabolic strategies into cancer immunotherapy research, which may lead to novel treatments that maximise the immune system's ability to combat cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8ee6d9003c1d9ef5a52cbc4df38e206a7582a70a" target='_blank'>
              Immunometabolism in the Tumor Microenvironment: Dual Role in Modulating Anti-Tumor Immunity and Tumor Progression.
              </a>
            </td>
          <td>
            Casterland Marbaniang, Lakhon Kma, R. N. Sharan
          </td>
          <td>2025-11-20</td>
          <td>Asian Pacific journal of cancer prevention : APJCP</td>
          <td>0</td>
          <td>3</td>
        </tr>

        <tr id="Purpose Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) exert strong immunosuppressive effects and are associated with poor prognosis in breast cancer. However, the mechanism underlying their differentiation remains unclear. Here, we aimed to elucidate how transforming growth factor-β1 (TGF-β1)/SMAD4 signaling regulates PMN-MDSC differentiation and modulates the breast cancer immune microenvironment. Methods We analyzed neutrophil subpopulation heterogeneity in breast cancer tissues using single-cell RNA sequencing combined with spatial transcriptomics (GSE176078 dataset). A 4T1 mouse breast cancer metastasis model was established, and tumor progression was tracked via in vivo fluorescence imaging. Colony formation and differentiation outcomes following Tgfb1 overexpression or knockdown were assessed in spleen-derived hematopoietic stem cells using flow cytometry. Gene expression profiles and signaling pathways were characterized using RNA sequencing and Western blotting. Results Neutrophil subpopulations in breast cancer tissues exhibited significant heterogeneity, particularly the N3 subset, which showed enhanced intracellular communication and regulatory potential. Tgfb1 was significantly upregulated along the neutrophil developmental trajectory in both spleen tissue and serum of breast cancer mice. In normal mice, the number of metastatic foci significantly correlated with neutrophil proportions. Tgfb1 overexpression promoted PMN-MDSC differentiation, colony formation, and SMAD4 upregulation in normal mice but exerted opposite effects in tumor-bearing mice. Conclusion Our findings implicate TGF-β1/SMAD4 signaling in the differential regulation of PMN-MDSC differentiation in breast cancer models. The TGF-β1 pathway represents a potential therapeutic target for modulating the immune microenvironment in breast cancer, although further validation in clinical settings is required to determine therapeutic efficacy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/384d19c717f6881d268b2cff7245b623f5578409" target='_blank'>
              Differential TGF-β1/SMAD4 Signaling Regulates PMN-MDSC Differentiation and Reshapes the Immune Microenvironment in Breast Cancer
              </a>
            </td>
          <td>
            Jie Cao, Enqi Qiao, Hui Shao, Chunlei Wang, Manzhi Xia, Bo Qin
          </td>
          <td>2025-12-01</td>
          <td>Breast Cancer : Targets and Therapy</td>
          <td>0</td>
          <td>0</td>
        </tr>

        <tr id="Signal regulatory protein alpha (SIRPα) is an important regulator of innate and adaptive immune responses by promoting T cell and macrophage activation and macrophage adhesion (multi-nucleated giant cell formation) while preventing phagocytic cell death to sustain inflammatory responses. We determined whether SIRPα is expressed in sarcoidosis tissue and whether ELA026, a humanized SIRP-blocking Ab, suppresses sarcoidosis granuloma formation by attenuating inflammation, promoting cell death, and suppressing adhesion during granuloma formation. Based upon immunohistochemistry, SIRPα stained in greater abundance in giant cells, monocytes, macrophages and dendritic cells in sarcoidosis lung tissue than in normal lung, lung cancer, non-granulomatous lung diseases and non-sarcoidosis granulomatous diseases. All these differences were statistically significant except for non-sarcoidosis granulomatous lung diseases. We then leveraged an ex vivo human granuloma model, wherein PBMCs from sarcoidosis patients are activated to form granulomas within 7 days, to determine whether ELA026 attenuated granuloma formation, based upon MIPAR image analysis, and associated cytokine responses. A matching isotype antibody (ELA099) that does not bind SIRPs was a negative control; prednisone was a positive control. As hypothesized, pre-treatment (day 0) or post-treatment (day 4) with ELA026 or prednisone (not ELA099) caused dose-dependent suppression of sarcoidosis granuloma formation by day 7. Unexpectedly, ELA026 only modestly reduced TNFα production when used as a pre-treatment and did not suppress IL-1β release or promote cell death, as reflected by no LDH release. SIRPα is robustly expressed in monocyte/macrophage lineages within human sarcoidosis tissues, and inhibition of SIRPs (ELA026) suppresses sarcoidosis granuloma formation by preventing macrophage adhesion/aggregation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/899d8ce7f5589a64da8ac7ef8117c50a5802c943" target='_blank'>
              Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation
              </a>
            </td>
          <td>
            Marc A Judson, M. Julian, L. Foulke, S. Panicker, S. H. Arker, Paul J. Feustel, G. Parry, S. Bicer, E. Crouser
          </td>
          <td>2025-12-05</td>
          <td>Respiratory Research</td>
          <td>0</td>
          <td>40</td>
        </tr>

        <tr id="Chronic hepatitis B virus (HBV) infection progression is closely associated with repeated inflammatory liver injury. Myeloid-derived suppressor cells (MDSCs), known to suppress inflammatory responses during hepatitis, may play a protective role in mitigating liver damage; nevertheless, the precise functional specialization of MDSC subpopulations and the critical regulator in controlling their suppressive capacity remain incompletely understood. This study investigates the immunoregulatory role of IL-21, a pleiotropic immunomodulatory cytokine, in modulating MDSC function and its implications for HBV-associated liver inflammation prognosis. The frequencies of peripheral and intrahepatic MDSCs, along with serum IL-21 levels, in patients with chronic HBV infection were measured with freshly isolated samples. C57BL/6 mice carrying pAAV-HBV1.2 plasmids was established to explore the effect of IL-21 on aminotransferase levels and MDSC function. Patients with chronic HBV infection demonstrated significantly elevated frequencies of circulating MDSCs compared to healthy controls. Of note, the granulocytic MDSCs (gMDSCs) were markedly more abundant in hepatic tissues than in peripheral blood. Strikingly, a significant inverse correlation was observed between circulating gMDSC frequencies and serum ALT levels specifically in patients with elevated serum IL-21 concentrations, whereas this correlation was absent in the low IL-21 subgroup. In vitro functional assays demonstrated that exogenous IL-21 potentiated the immunosuppressive capacity of MDSCs, significantly attenuating IFN-γ production in co-cultured T cells. Consistent with these findings, hydrodynamic injection of IL-21 plasmid in an HBV mouse model resulted in significantly reduced serum ALT levels concomitant with enhanced arginase I expression in hepatic MDSCs. These results reveal that IL-21 enhances MDSC-mediated immunosuppression, implicating this regulatory axis in the attenuation of hepatic inflammation during chronic HBV infection. These findings provide a novel perspective on the involvement of IL-21 in the negative regulation of intrahepatic inflammation and provide a novel perspective on the role of IL-21 in developing immunotherapeutic strategies to optimize available anti-inflammatory treatments in chronic HBV infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/43769e93eb8ada104943a4089afc526ef6d10aa6" target='_blank'>
              IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cells immunosuppressive function in chronic HBV infection
              </a>
            </td>
          <td>
            Xiaoyi Li, Zihan Jin, Meihan Pan, Zheyu Dong, Junling Chen, Zhipeng Liu, Hongjie Chen, Guofu Ye, S. Zhong, Weiying He, Libo Tang, GuiRong Rao, Yongyin Li
          </td>
          <td>2025-12-01</td>
          <td>Journal of Translational Medicine</td>
          <td>0</td>
          <td>12</td>
        </tr>

        <tr id="Cytokine release syndrome (CRS) is the most common and potentially life-threatening toxicity associated with CAR-T cell therapy and is related to a heightened immune effector state. In this work, we identified a novel role of the pro-tumorigenic cytokine B-cell activating factor (BAFF) in its pathophysiology. First, we observed that patients who experienced CAR-T cell-related CRS have elevated serum BAFF levels that coincide with elevated IL-6. Mechanistically, we show that IFN-γ, produced by activated CAR-T cells, stimulates monocytes to release BAFF, which induces the expression of CRS-related cytokines from monocytes. Monocytes derived from CRS patients express BCMA, which is further induced by IFN-γ stimulation. Neutralization of BAFF with belimumab significantly reduces production of various CRS and ICANS-related cytokines without impairing CAR-T cell activation or killing. Overall, we demonstrate that BAFF plays a critical role in CAR-T-cell-related CRS, and its neutralization may be a novel strategy for treating both CRS and ICANS. Graphical abstract">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d7dad4b7999e1dace318b6056bdf111f387b3904" target='_blank'>
              B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome
              </a>
            </td>
          <td>
            Claire Fritz, L. Metheny, David Wald, P. Caimi, Reshmi Parameswaran
          </td>
          <td>2025-11-25</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>17</td>
        </tr>

        <tr id="Currently, colorectal cancer ranks third in terms of global cancer incidence and second in terms of cancer-related mortality, posing a significant therapeutic challenge. However, the efficacy of immunotherapy is limited by the immunosuppressive tumor microenvironment, which is driven in part by T cell exhaustion. Herein, a copper–propranolol nanoplatform (Cu-PN NPs) rationally engineered by coordinating copper ions with propranolol and stabilizing the complex via mPEG-SH self-assembly was initially constructed. This design enables the codelivery of copper ions and propranolol, achieving dual functions: inducing copper-dependent cell death (cuproptosis) and apoptosis to trigger immunogenic cell death (ICD), and blocking ADRB1 on T cells to reverse exhaustion and restore effector function. In vitro studies in CT26 colorectal cancer (CRC) cells and patient-derived organoids (PDOs) confirmed enhanced cytotoxicity and ICD induction compared with those of monotherapy. In vivo, Cu-PN NPs significantly inhibited CRC tumour growth, reshaped the tumour microenvironment (TME) by attenuating T cell exhaustion, increasing cytokine secretion, and promoting dendritic cell maturation and CD8⁺ T cell activation. When combined with anti-PD-1 therapy, Cu-PN NPs markedly improved tumour control. This work introduces Cu-PN NPs as a dual-functional nanoplatform that integrates ICD induction with T cell reinvigoration via ADRB1 blockade, offering a promising strategy to enhance immune checkpoint blockade therapy against colorectal cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/63e63e2dba8fc55c256e0fdd3771cb8d6031632a" target='_blank'>
              Reinvigorating CD8+ T cells through ADRB1 blockade using copper-propranolol nanoparticles for enhanced immune checkpoint blockade therapy
              </a>
            </td>
          <td>
            Binshu Weng, Nan Zhu, Huirong Li, Lishan Ding, Yutong Wu, Ying Chen, Yijie Xi, Lifan Lin, Jiawen Chen, Le Xin, Jinjun Ye, Yanfeng Hu, Guoxin Li, Weihong Guo
          </td>
          <td>2026-01-05</td>
          <td>Journal of Nanobiotechnology</td>
          <td>0</td>
          <td>4</td>
        </tr>

        <tr id="Background Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer in Asian, Caucasian, and Hispanic populations and its aggressive form contributes to significant morbidity and mortality. Chronic ultraviolet B (UVB) exposure is a major environmental carcinogen that drives cSCC initiation, progression, and immune evasion. Regulatory T cells (Tregs) are known mediators of UVB-induced immunosuppression; however, their direct involvement in the establishment of cSCC remains elusive. Methods Flow cytometry was employed to quantify Treg populations in the skin and draining lymph nodes of UVB-exposed and untreated mice. The functional role of Tregs following UVB exposure was examined using a contact hypersensitivity assay, where Treg activity was modulated by anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4, anti-TIGIT, and anti-FR4 antibodies. The capacity of UVB to render mice susceptible to immunogenic cSCC tumor establishment was assessed under different UVB exposure regimens. Treg-modulating antibodies were administered following UVB treatment and prior to tumor implantation to explore whether UV-induced Treg manipulation can prevent cSCC tumor establishment. Results UVB irradiation for 5 consecutive days significantly increased the number of CD4+ Foxp3+ Tregs in both skin and skin-draining lymph nodes. These Tregs were shown to be suppressive in contact hypersensitivity assays. However, suppression was prevented following depletion of Tregs and/or avolition of their function using monoclonal antibodies. Consistently, chronic UVB exposure prior to tumor implantation permitted the establishment and growth of otherwise immunogenic cSCC tumors, which correlated with the expansion and recruitment of Tregs into the skin. Importantly, immunomodulation with anti-CTLA-4 or anti-FR4 after chronic UVB exposure effectively prevented cSCC establishment, indicating that the manipulation of UV-induced Tregs prevented the establishment and growth of immunogenic cSCC tumors. Conclusion Our findings show that the manipulation of UV-induced Tregs prevents early cSCC establishment. Thus, strategies aimed at modulating Treg function or abundance in the skin may represent a feasible therapeutic avenue for the prevention of cSCC tumor emergence in patients.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0e9646d0ae217447d84ed31b1896b1daa87cf40c" target='_blank'>
              Immunomodulation of UVB-induced regulatory T cells prevents the establishment of squamous cell carcinoma
              </a>
            </td>
          <td>
            Shoaib Anwaar, Amina Ashraf, Sarah Jahfali, Joseph Yunis, Jazmina L Gonzalez Cruz, James W. Wells
          </td>
          <td>2025-12-01</td>
          <td>Journal for Immunotherapy of Cancer</td>
          <td>1</td>
          <td>9</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c515ee3e9e86703752ec072206a806bfdf0f76b3" target='_blank'>
              SLAMF1-peptide mediated epigenetic priming reprograms innate immune responses in sepsis
              </a>
            </td>
          <td>
            Sindre Ullmann, Birgitta Ehrnström, Jørgen Stenvik, S. Pinto, Yashwanth Subbannayya, Victor Boyartchuk, I. Mestvedt, Mahamaya Dhaware, Siddhesh S. Kamat, L. Ryan, Hilde Vagle, T. Dahl, B. Halvorsen, J. K. Damås, T. Espevik, Maria Yurchenko
          </td>
          <td>2025-12-29</td>
          <td>bioRxiv</td>
          <td>0</td>
          <td>71</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/72f3e3fb83d6da5da12fbd024325e0282875f616" target='_blank'>
              Single-cell analysis identifies monocyte signatures of disease activity and clinical subtypes in Behcet disease
              </a>
            </td>
          <td>
            E. Carmona, R. Deniz, C. Bes, H. Direskeneli, A. Gul, A. H. Sawalha
          </td>
          <td>2025-12-27</td>
          <td>None</td>
          <td>0</td>
          <td>1</td>
        </tr>

        <tr id="


 Early-onset colorectal cancer (EOCRC), CRC diagnosed before age 50, are rising with the global incidence of EOCRC predicted to double by 2030. Notably, this disease is more common in men and women have better survival outcomes. Changes in immunity with age and between sexes are postulated to contribute to these discrepancies, which warrants further investigation. Therefore, we used single-cell RNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from males and females with CRC. Our analysis revealed reduced proportions of circulating naïve and effector memory CD8+ T-cells in late-onset colorectal cancer (LOCRC) compared to EOCRC. Similarly, genes associated with proliferation were decreased in circulating CD8+ T-cells from LOCRC patients. Hallmark and GO BP pathway analyses revealed that T-cells isolated from patients with LOCRC have decreased transcriptional profiles associated with AKT/MTOR signaling, lymphocyte differentiation, and cell surface/antigen receptor-mediated signaling. Conversely, upregulated pathways were associated with TNF and interferon alpha signaling, apoptosis, DNA damage, oxidative stress, and RNA/protein homeostasis. Regarding NK cells, in LOCRC, the overall frequency of naïve and cytotoxic populations cells was also decreased while interferon-producing NK cells signatures were increased. Notably, pathway analyses revealed almost identical transcriptional immunosuppressive changes in NK and T-cells in LOCRC. Analysis of sex differences in the immune landscape of EOCRC and LOCRC revealed proliferative defects in CD8+ T-cells in males regardless of age. However, NK cells from males with EOCRC appear to be more functional as highlighted by the increased expression of genes associated with cytolysis and more naïve signatures associated with these cells. Conversely, NK cell signatures in females were robust in both the EOCRC and LOCRC, and did not exhibit age-dependent functional declines. Furthermore, in females, NK cells and T-cells in EOCRC had similar decreases in differentiation, intracellular signaling, decreased TNF activation, and apoptosis signatures but signatures associated with metabolism, protein homeostasis, and p53 activation were increased. Compared to females, pathway analyses of NK cells and T-cells from males with EOCRC revealed reduced gene signatures associated with differentiation and intracellular signaling but enhanced signatures associated with inflammation, oxidative stress, RNA processing, MYC activation, G2M checkpoint activation, and apoptosis. In summary, we reveal that circulating lymphocytes from female patients with EOCRC and LOCRC are more functional than those observed in males. Furthermore, T-cells from males with CRC become more dysfunctional with age, potentially due to increased sensing of pro-inflammatory cytokines like TNF and interferon alpha. Therefore, better survival outcomes for women with CRC may potentially be attributed to possessing a more robust immune system that exhibits minimal decline with aging.



 Timothy J. Kopper, Claire E. Pillsbury, Michael Kaufman, Clara Sánchez-Menéndez, María González-Sanmartin, Montserrat Torres, Mayte Coiras, Jose Perea Garcia, Curtis J. Henry. Transcriptional profiling of circulating immune cells from patients with early- and late-onset colorectal cancer reveals sex-specific differences [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers—Knowledge Gaps and Research Opportunities; 2025 Dec 10-13; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(23_Suppl):Abstract nr C012.
">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/18bde8a985e5e049ae833ecf8777d4a97aaf142e" target='_blank'>
              Abstract C012: Transcriptional profiling of circulating immune cells from patients with early- and late-onset colorectal cancer reveals sex-specific differences
              </a>
            </td>
          <td>
            T. Kopper, Claire E Pillsbury, Michael Kaufman, Clara Sánchez-Menéndez, María González-Sanmartín, Montserrat Torres, M. Coiras, Jose Perea Garcia, Curtis J. Henry
          </td>
          <td>2025-12-10</td>
          <td>Clinical Cancer Research</td>
          <td>0</td>
          <td>23</td>
        </tr>

        <tr id="Brain tumors such as glioblastoma remain among the most lethal and immunologically resistant cancers, in large part due to epigenetic programs that sculpt the tumor–immune microenvironment. DNA methylation, histone modifications, and chromatin remodeling do not merely drive tumor-intrinsic changes; they also profoundly reprogram immune responses, shaping antigen presentation, cytokine signaling, and immune cell recruitment. At the center of this regulation are T cells, whose effector functions are suppressed through promoter hypermethylation of antigen-processing genes, silencing of interferon pathways, and the establishment of exhaustion-specific chromatin states. Mutations such as IDH1/2 and H3K27M further reinforce these epigenetic barriers, fostering immune-cold microenvironments that disable cytotoxic T-cell activity. Emerging evidence highlights both CNS-specific adaptations, including microglial and astrocytic epigenetic programs that reinforce immune privilege, and conserved features of T cell exhaustion that mirror those in peripheral cancers. This duality underscores the need for therapeutic strategies that dismantle CNS-specific barriers while leveraging shared exhaustion programs across tumor types. Epigenetic drugs, ranging from DNA methyltransferase and EZH2 inhibitors to BET degraders and CRISPR-based epigenome editors, are beginning to restore antigenicity, reverse T cell dysfunction, and sensitize tumors to checkpoint blockade. Yet these approaches carry the paradoxical risk of disrupting CNS immune tolerance, potentially triggering harmful neuroinflammation or autoimmunity. To our knowledge, this is among the first comprehensive reviews to integrate CNS-specific immune privilege mechanisms with peripheral exhaustion pathways, providing a unified perspective on how epigenetic regulation orchestrates immune dysfunction across central and peripheral contexts. By mapping the continuum between immune evasion and global immunosuppression, we propose a conceptual framework for tailoring epigenetic-immunotherapy combinations to achieve durable antitumor immunity in the CNS.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/2d7202ed1c4ffc9d0ee982c0f1ad42403d845276" target='_blank'>
              Beyond the genome: epigenetic regulation of immune responses and T cells in brain tumors
              </a>
            </td>
          <td>
            Shuo Sun, Yu Han, Haiying Li, Chengyan Wang, Shu Zhou, Xiaowei Zhang, Shuhong Dai, Yao Peng, Zhuoqun Wang
          </td>
          <td>2025-11-18</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Alzheimer’s disease (AD) is a progressive neurodegenerative disorder defined by amyloid-β (Aβ) plaques, tau hyperphosphorylation, and neuroinflammation. Although earlier work emphasized brain-resident glia (microglia and astrocytes), recent studies highlight adaptive immune cells, particularly T and B lymphocytes, as modulators of AD pathology. This review synthesizes animal and human findings from 2022–2025 to provide updated insights into the multifaceted roles and therapeutic potential of adaptive immunity in AD. Infiltration of peripheral T and B cells into the brain parenchyma links peripheral immunity to central nervous system (CNS) pathology. Both infiltrating lymphocytes and resident glia show context-dependent dual effects, either exacerbating neurodegeneration or promoting neuroprotection. Therapeutic strategies under active investigation include modulation of CD4+ T cell differentiation, adoptive transfer of regulatory T cells, and next-generation active vaccines for AD. Overall, selective modulation of discrete immune subsets may enable adaptive-immunity-based treatments, a complex yet promising avenue for AD therapy.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/3b57de078f4e9067551a7f587763ddb6ea70cdf6" target='_blank'>
              Adaptive Immunity and Alzheimer’s Disease: Dual Roles in Neurodegeneration and Neuroprotection with Therapeutic Implications
              </a>
            </td>
          <td>
            You Min Ahn, Min-Kyoo Shin
          </td>
          <td>2025-12-31</td>
          <td>Biomolecules & Therapeutics</td>
          <td>1</td>
          <td>0</td>
        </tr>

        <tr id="Trained immunity (TI) represented a unique state of innate immune activation, characterized primarily by persistent epigenetic modifications in immune cells. This phenomenon was first observed during pathogen infections and vaccinations, where it manifested as enhanced defensive responses in innate immune effector cells—such as those of the mononuclear phagocyte system and natural killer cells—upon re-stimulation. Cancer was a disease with complex mechanisms, marked by the loss of normal growth regulation in cells due to genetic mutations or epigenetic dysregulation, leading to abnormal proliferation and dissemination. With hundreds of subtypes, cancer could arise in virtually any human tissue or organ. The primary cause of cancer-related mortality was metastasis, which referred to the spread of cancer cells from their original site to distant organs and accounted for approximately 90% of cancer deaths worldwide. The induction of TI involved multiple immune components including myeloid cells, natural killer cells, pattern recognition receptors, and various cytokines. Notably, the enhanced response observed during secondary stimulation remained non-specific to particular pathogens. Compared to conventional therapeutic approaches, TI demonstrated superior systemic immune activation. Simple pharmacological stimuli such as β-glucan or Bacillus Calmette-Guérin (BCG) not only triggered innate immune responses but also conferred benefits to adaptive immunity, resulting in more rapid immune activation and enhanced efficacy. TI enhanced the capacity of immune cells to recognize and eliminate cancer cells, playing a critical role in countering metastasis. In this review, we summarized existing knowledge in the field, focusing on the mechanisms underlying TI induction and its significance in combating cancer.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/be50ad019666a2caa18340fc39a316d430799286" target='_blank'>
              The significance of trained immunity in cancer
              </a>
            </td>
          <td>
            Junxing Qu, Xinya Guo, Xinru Wang, Huiwen Meng, Peizhi Li, Zhiheng Sun
          </td>
          <td>2025-12-01</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>5</td>
        </tr>

        <tr id="ABSTRACT The human-specific gammaherpesviruses Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvirus infect >95% of all adults, establish lifelong infections, and are associated with multiple different cancers, including B-cell lymphomas. These viruses naturally infect B cells and drive a unique and robust germinal center response to establish their latent viral reservoir in memory B cells. The unique and robust nature of the virus-driven germinal center response increases the risk for B-cell transformation, which is why many gammaherpesvirus-associated cancers are derived from germinal center or post-germinal center B cells. We have previously reported that both global and T cell-specific host IL-17RA signaling is proviral in the context of gammaherpesvirus infection by promoting the virus-driven germinal center response and establishment of latent viral infection. In this study, we examine the role of B cell-specific IL-17RA signaling in the context of gammaherpesvirus infection, given these viruses’ reliance on B cells to establish and maintain lifelong infection. Similarly, to what we observed in the context of global and T cell-specific IL-17RA signaling, we found that B cell-intrinsic IL-17RA signaling supports the establishment of viral latency and reactivation in the spleen and peritoneal cavity, as well as promotes the virus-driven germinal center response. Our study reveals the proviral role of B cell-intrinsic IL-17RA signaling in supporting the establishment of chronic gammaherpesvirus infection. IMPORTANCE Gammaherpesviruses are lifelong pathogens that are prevalent in over 95% of all adults. These viruses are tumorigenic and associated with multiple cancers, including B-cell lymphomas. They are B-cell tropic viruses that manipulate the germinal center response to establish their latent viral reservoir in memory B cells. This manipulation of the germinal center response is thought to be the target of viral transformation, leading to lymphomagenesis as most gammaherpesvirus-associated cancers are germinal center or post-germinal center derived. In this study, we developed a new mouse model to understand the B cell-intrinsic role of IL-17RA signaling in gammaherpesvirus infection. Previous studies have shown that IL-17RA signaling is proviral in the context of gammaherpesvirus infection, and this study found that while B cell-intrinsic IL-17RA signaling is not the sole factor behind the systemic proviral role of IL-17RA signaling, it plays an important role in the virus-driven germinal center response, the expansion of B-1 B cells, and the establishment of chronic gammaherpesvirus infection. Gammaherpesviruses are lifelong pathogens that are prevalent in over 95% of all adults. These viruses are tumorigenic and associated with multiple cancers, including B-cell lymphomas. They are B-cell tropic viruses that manipulate the germinal center response to establish their latent viral reservoir in memory B cells. This manipulation of the germinal center response is thought to be the target of viral transformation, leading to lymphomagenesis as most gammaherpesvirus-associated cancers are germinal center or post-germinal center derived. In this study, we developed a new mouse model to understand the B cell-intrinsic role of IL-17RA signaling in gammaherpesvirus infection. Previous studies have shown that IL-17RA signaling is proviral in the context of gammaherpesvirus infection, and this study found that while B cell-intrinsic IL-17RA signaling is not the sole factor behind the systemic proviral role of IL-17RA signaling, it plays an important role in the virus-driven germinal center response, the expansion of B-1 B cells, and the establishment of chronic gammaherpesvirus infection.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/1890fb6742f276fac3b4c0609bbeabf5b4059e28" target='_blank'>
              B cell-intrinsic interleukin 17 receptor A signaling supports the establishment of chronic murine gammaherpesvirus 68 infection
              </a>
            </td>
          <td>
            S. T. Majeed, Nicholas P. Huss, Samantha M. Bradford, C. Jondle
          </td>
          <td>2025-12-01</td>
          <td>Journal of Virology</td>
          <td>0</td>
          <td>11</td>
        </tr>

        <tr id="Glioblastoma is one of the most aggressive and therapeutically challenging brain tumors. It is characterized by a highly immunosuppressive tumor microenvironment and poor prognosis, requiring novel treatment strategies. Along this line, ferroptosis has been proposed. To study the impact of ferroptosis on glioblastoma cells and immune cell infiltration, we established a spheroid model using LN229 glioblastoma cells and verified ferroptosis by measuring lipid peroxidation and RNA expression of ferroptosis-related genes. We then co-cultured spheroids with human peripheral blood mononuclear cells to follow the infiltration of distinct immune cell subsets by flow cytometry and immunohistochemistry. T lymphocyte infiltration into ferroptotic spheroids compared to control spheroids became apparent with the notion that ferroptotic cells attracted T cells more efficiently compared to apoptotic or necrotic cells. Mechanistically, ferroptotic glioblastoma spheroids released high amounts of ATP, which caused T cell attraction, while ATP deprivation reduced this effect. Ferroptosis appears to be an interesting therapy approach but might need co-treatments to ensure proper T cell activation.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/0d8f9909cc48b7c49c46b992fe55c08f1c1b4fd5" target='_blank'>
              Ferroptosis Enhances T Lymphocyte Infiltration into Glioblastoma Spheroids
              </a>
            </td>
          <td>
            Anna Schwantes, Yara Shadid, V. M. Guerrero Ruiz, B. Aliraj, Anja Wickert, Megan A. Palmer, S. Meyer, Andreas Weigert, Bernhard Brüne, D. Fuhrmann
          </td>
          <td>2025-11-01</td>
          <td>Antioxidants</td>
          <td>0</td>
          <td>18</td>
        </tr>

        <tr id="None">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/fc692c3e1c7e0729bdb6f8b1c8d623d6f263acd5" target='_blank'>
              The impact of macrophage phenotype during Mycobacterium tuberculosis infection and in host-directed therapeutic interventions
              </a>
            </td>
          <td>
            Shamsuddeen Yusuf Ma'aruf, Suleiman Yusuf, Nelita du Plessis
          </td>
          <td>2025-12-01</td>
          <td>Mycobacteria</td>
          <td>0</td>
          <td>24</td>
        </tr>

        <tr id="Diffuse gliomas remain lethal primary brain tumors. Immune-checkpoint inhibitors have not delivered durable benefit for most patients, reflecting myeloid-dominant immunosuppression and spatially organized immune exclusion. In this mini-review we summarize ligand–receptor multi-omics—single-cell RNA/CITE-seq, single-cell chromatin accessibility, and spatial proteo-transcriptomics—that resolve microglia- and monocyte-derived TAM programs and malignant state continua, and we appraise translational opportunities spanning TAM reprogramming (CSF1–CSF1R), perivascular SPP1–CD44 disruption, and innate–adaptive combinations targeting CD47–SIRPα, CD39–CD73, and PD-1/PD-L1. We also discuss challenges—including ontogeny-aware state definitions, heteromer-aware databases, chromatin gating of receivers (requiring accessible regulatory DNA for the receptor and its program), spatial registration, and limited assay standardization—that temper implementation. By integrating myeloid-informed readouts (SPP1–TAM burden, CD39–CD73 proximity, HMOX1+ IL-10 niches, serum IL-8), emerging strategies aim to restore antigen presentation, enable effector ingress, and remodel vascular–stromal interfaces. Our synthesis provides an appraisal of reproducible communication architectures in glioma and outlines pragmatic reporting standards and trial-ready pharmacodynamic endpoints for myeloid-informed precision immuno-oncology. We hope these insights will assist researchers and clinicians as they design multi-omics pipelines and interventions to convert suppressive ecosystems into responsive ones.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/e39bafbb89665949b18c8b3763ecd3648dcb8152" target='_blank'>
              Mapping TAM–tumor crosstalk in glioma via ligand–receptor multi-omics: mechanisms of immune evasion
              </a>
            </td>
          <td>
            Dong Zhang, Yiming Ma, Daxiong Feng
          </td>
          <td>2025-11-21</td>
          <td>Frontiers in Immunology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Introduction Aging increases vulnerability of the elderly to influenza, but the mechanisms have not been fully understood. Although lethally infected aged mice are frequently used as models of influenza infection in the elderly, they are more suitable for studying mortality rather than the increased disease severity frequently observed in non-lethal infections. Therefore, understanding age-related differences under sublethal infection conditions is crucial. Methods Adult (8–12 months) and aged (22–24 months) mice were infected with a sublethal dose of H1N1 (PR8). Body weight loss, lung viral titers, pulmonary innate immune cell composition, and transcriptional levels of key inflammatory cytokines were assessed. Results Despite similar body weight loss, the aged mice showed significantly higher lung viral titers at day 8. Notably, key innate immune populations, including alveolar macrophages, neutrophils, and eosinophils, showed distinct age-related patterns. In the adult mice, alveolar macrophages negatively correlated with weight loss, whereas no protective immune factor was identified in the aged mice. Moreover, our data showed that persistent viral replication led to distinct innate immune cell composition in the adult and aged mice despite comparable transcription levels of inflammatory cytokines. The numbers and frequencies of both the neutrophils and eosinophils were significantly higher in the virus-persistent adult mice than those in the virus-persistent aged mice. Discussion Our findings reveal skewed acute immune responses to influenza in aged mice, which may partially account for their mild weight loss despite delayed viral clearance and highlight age-related impairments in early antiviral immunity.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5c351ed0e5d3df4fe77cb078ab0d2b65afface5c" target='_blank'>
              Skewed pulmonary innate immune cell composition underlies the delayed influenza clearance in aged mice
              </a>
            </td>
          <td>
            Xiaoyang Cheng, Fang Zhao, Jing Wu, Yanmin Wan, Zhaoqin Zhu, Jialin Jin
          </td>
          <td>2025-12-10</td>
          <td>Frontiers in Microbiology</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Induced pluripotent stem cell (iPSC)-derived pancreatic islets represent a promising therapeutic approach for restoring insulin independence in type 1 diabetes (T1D). However, their clinical success remains critically dependent on overcoming rejection mediated by innate and adaptive immune responses. Current immunosuppressive therapies pose significant long-term risks and only partially control alloimmune and autoimmune reactions. Targeted immunomodulation using monoclonal antibodies is a safer, more precise alternative. Here, we explored the impacts of blocking CD276 (B7-H3) and CD155 (PVR), activating ligands involved in immune recognition and regulation, on the survival and in vivo maturation of iPSC-derived endocrine progenitors (EPs) into functional pancreatic islets. Using a humanized mouse model, we demonstrated that dual blockade of CD276 and CD155 markedly reduced NK cell-mediated graft rejection, prevented CD14+ monocyte activation, and limited overall immune infiltration. In addition, CD155 blockade increased PD-1 levels on activated CD8+ T cells and significantly enhanced regulatory T cell (Treg) expansion and function, thereby promoting graft tolerance. Combined treatment prolonged engraftment and facilitated the maturation of EPs into functional, insulin-secreting cells, as indicated by increased human C-peptide levels and glucose responsiveness 4 weeks post-transplantation. Our findings highlight CD276/CD155 blockade as a novel immunomodulatory strategy to support tolerance and the functional maturation of iPSC-derived pancreatic grafts in T1D.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/99ae440749b98ba4470d804290b5bedbd3a66a2f" target='_blank'>
              Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice
              </a>
            </td>
          <td>
            G. Siracusano, F. Deambrogio, V. Sordi, M. Malnati, L. Piemonti, R. Chimienti
          </td>
          <td>2025-12-01</td>
          <td>Transplant International</td>
          <td>0</td>
          <td>2</td>
        </tr>

        <tr id="Background and Objectives In multiple sclerosis (MS), a variety of immunosuppressive treatments are available. While effective, these approaches often lead to sustained impairment of essential components of the immune system, posing long-term safety concerns. Consequently, there is a growing interest in alternative therapeutic approaches that selectively limit pathogenic B-cell functions while preserving their physiologic roles. In this study, we investigated the therapeutic potential of inhibiting the enzyme Bruton tyrosine kinase (BTK), a key signaling molecule in both B-cell and myeloid cell activation. Methods The effects of the BTK inhibitor evobrutinib were evaluated in various experimental in vivo models of CNS demyelination, each representing different aspects of disease pathology as well as a naïve healthy condition. The impact on disease onset and severity was determined, and phenotypical alterations in different cell populations were assessed via flow cytometry. Furthermore, functional changes in both murine and human myeloid cells induced by BTK inhibition under specific Fc receptor–dependent stimulation were analyzed in in vitro settings using flow cytometry. Results In a naïve, healthy environment, evobrutinib promoted the development of regulatory B-cell properties. In various experimental models of CNS demyelination, BTK inhibition limited the differentiation of proinflammatory B cells while supporting their regulatory properties. Beyond modulating B-cell responses, BTK inhibition also attenuated the activation of myeloid cells after Fc receptor–mediated antigen uptake, a process assumed to be of importance in conditions, such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein–antibody associated disease. In addition, BTK inhibition was shown to suppress the secretion of proinflammatory cytokines and reduce antigen presentation, further dampening pathogenic immune responses. Discussion These findings highlight the potential of BTK inhibition as a selective and sustainable immunomodulatory strategy for both B cells and myeloid cells in the context of chronic CNS inflammation. Despite their efficacy, broad-spectrum immunosuppressive therapies often fail to provide targeted immune modulation. By contrast, BTK inhibition promotes regulatory B-cell properties while leaving other B-cell functions intact, providing the basis for its broad use—potentially in combination with established anti-inflammatory agents.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/d45c864d650e75d6107915d1c803721a2b18f33f" target='_blank'>
              Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease–Driving Inflammation While Promoting Regulatory B Cells
              </a>
            </td>
          <td>
            Sarah Dybowski, Jacqueline Thode, Marie Freier, Darius Saberi, S. Nessler, Anastasia Geladaris, Silke Häusser-Kinzel, M. Ringelstein, Sebastian Torke, Martin S. Weber
          </td>
          <td>2025-11-25</td>
          <td>Neurology® Neuroimmunology & Neuroinflammation</td>
          <td>0</td>
          <td>48</td>
        </tr>

        <tr id="Multiple myeloma (MM) develops in the hypoxic bone marrow (BM) microenvironment, which alters tumor behavior and immune responses. While hypoxia is known to directly suppress immune function, its effect on immunotherapy-relevant antigen expression and the MM secretome remains underexplored. Here, we investigated how hypoxia affects BCMA expression and BCMA-targeted CAR T cell responses. MM cells were cultured under normoxia (21% O₂) or hypoxia (1% O₂). BCMA surface and total expression were analyzed. Anti-BCMA CAR T cells were co-cultured with normoxic or hypoxic MM cells to assess cytotoxicity and cytokine release. Conditioned media and small extracellular vesicles (sEVs) were isolated, quantified, and RNA-profiled. MM cells cultured in hypoxia showed reduced BCMA surface and total protein expression, resulting in reduced CAR-mediated signaling. Importantly, the hypoxic tumor secretome further reduced BCMA levels and significantly impaired CAR T cell killing and cytokine production, which was partially reversible by γ-secretase inhibition. To dissect the suppressive nature of the hypoxic secretome, we identified an increase in small extracellular vesicle (sEV) release under hypoxia. RNA profiling of sEVs revealed a hypoxia-induced RNA signature with potential immunomodulatory roles. This study shows that hypoxia diminishes BCMA expression and enhances secretion of immunosuppressive factors, including sEVs, thereby limiting the efficacy of BCMA CAR T cell therapy in MM.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/32804a5eae759659f84b5610dc79fafee9f0e914" target='_blank'>
              Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma
              </a>
            </td>
          <td>
            Chenggong Tu, A. Van der Vreken, Fien Meeus, Lauren van den Broecke, Jack Brons, K. De Veirman, K. Vanderkerken, E. De Bruyne, Karine Breckpot, E. Menu
          </td>
          <td>2026-01-08</td>
          <td>Experimental Hematology & Oncology</td>
          <td>0</td>
          <td>60</td>
        </tr>

        <tr id="The global demographic shift towards an aging population has amplified the public health challenge posed by immunosenescence, a progressive remodeling of the immune system that compromises host defenses. This age-related decline is characterized by a reduction in adaptive immunity, marked by a diminished pool of naïve T-cells and an increased susceptibility to infections and poor vaccine responses. Simultaneously, it is defined by a paradoxical state of chronic low-grade inflammation, or “inflammaging,” which accelerates age-related pathologies. This review posits “immunopause” as a conceptual framework for a state of severe immune decline, a state often viewed as an inevitable consequence of aging. However, the evidence synthesized herein challenges this view by positioning physical exercise as a potent, non-pharmacological intervention capable of countering this process. The report systematically reviews the cellular, molecular, and systemic mechanisms through which exercise exerts its beneficial effects, including the rejuvenation of T-cell repertoires, the regulation of cytokine networks, and the modulation of multi-organ axes involving myokines and the gut microbiome. By improving the efficacy of existing immune cells and shifting the systemic inflammatory milieu, chronic physical activity promotes a more “youthful” and functional immune phenotype. This synthesis not only underscores exercise’s potential to enhance vaccine efficacy and serve as an adjuvant therapy for age-related diseases but also argues for a paradigm shift: from viewing immune aging as an immutable process to recognizing it as a modifiable state. The report concludes that exercise provides a scientifically validated strategy to extend healthspan and prevent the pathological state of immunopause.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/8d2ef4f654e5c24f33ac1029bbaa1112ea170159" target='_blank'>
              “Immunopause” no more: exercise to counter immunosenescence in aging
              </a>
            </td>
          <td>
            Chen Sun, Jiao Li, Heng Xu, Junying Du, Paramasivam Muthusamy, Kaiyuan Liu, Song Wei, Lulu Zhang
          </td>
          <td>2025-11-22</td>
          <td>Immunity & Ageing : I & A</td>
          <td>1</td>
          <td>1</td>
        </tr>

        <tr id="CD38 is a transmembrane glycoprotein involved in NAD+ metabolism, calcium signaling, and immune cell activation. Its role in the inflammatory response has been studied extensively in innate immune cells; however, its contribution to the activation of memory T lymphocytes under inflammatory conditions is less understood. Additionally, recent studies have shown an age-related increase in the expression of the protein CD38 in various human and murine tissues. Moreover, CD8+ bystander T cells have been shown to contribute to inflammation during the aging process. Given the importance of its potential role in age-related pathologies, we examined the effect of CD38 on bystander activation of CD8+ memory T cells in aged mice following lipopolysaccharide challenge. CD38-deficient mice exhibited attenuated serum cytokine responses (IL-1β, IL-6, IFN-γ, and IL-10) and a distinct CD8+ T cell profile, characterized by a decrease in activated T cells. Wild-type mice displayed a significant expansion of CD69+TCM cells after LPS inoculation, an effect that was absent in CD38-deficient animals. LPS also promoted the expression of CD69 and CD38 in TEM/EFF subsets. Thus, our findings reveal a CD38-dependent mechanism underlying bystander activation of memory CD8+ T cells in aging. Highlighting the potential contribution of CD38 to age-related diseases, such as autoimmunity, and in the face of inflammatory conditions in aged people.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/c2543f635ae92595d3f140c2ea47a35fc4eab9dd" target='_blank'>
              CD38 promotes LPS-induced innate-like activation and proliferation of CD8+ T lymphocytes in aged mice
              </a>
            </td>
          <td>
            Wendolaine Santiago-Cruz, Enrique Espinosa, Jocelyn C Pérez-Lara, Héctor Romero‐Ramírez, Priyadharshini Devarajan, Fabio García-García, J. C. Rodríguez-Alba
          </td>
          <td>2025-12-19</td>
          <td>Frontiers in Aging</td>
          <td>0</td>
          <td>9</td>
        </tr>

        <tr id="Highlights What are the main findings? We find that under inflammatory conditions, B cells from streptococci-infected tonsils and blood of HLA-C*06:02-positive psoriasis patients activate a melanocyte-reactive T-cell receptor from a pathogenic psoriatic CD8+ T cell clone and also have autostimulatory properties for CD8+ T cells. We identify several self-peptides from the complex HLA-C*06:02 immunopeptidomes of B cells that may serve as autoantigens to activate the lesional psoriatic autoimmune response against melanocytes due to T-cell receptor polyspecificity. What is the implication of the main finding? The proinflammatory environment of streptococcal tonsillopharyngitis, as an important trigger for psoriasis, might break the tolerance of pathogenic psoriatic CD8+ T cells to autoantigens presented by HLA-C*06:02 on B cells that subsequently react against melanocytes, inducing psoriasis. The findings open up potential avenues for the development of therapies targeting the pathogenic B-T cell interaction in psoriasis. Abstract Psoriasis vulgaris is a T-cell-mediated skin disease that may involve an autoimmune response against melanocytes. It develops through still unexplained pathomechanisms. Streptococcal tonsillopharyngitis is a major trigger of psoriasis onset and relapses. HLA-C*06:02 is the main psoriasis risk gene. Here we find that B cells isolated from streptococci-infected tonsils or peripheral blood of HLA-C*06:02+ psoriasis patients stimulate an HLA-C*06:02-restricted melanocyte-reactive Vα3S1/Vβ13S1 T-cell receptor (TCR) from a lesional psoriatic CD8+ T cell clone in an IFN-γ-enhanced manner. Patients’ B cells furthermore induce proliferation of autologous blood CD8+ T cells. We identify several HLA-C*06:02-presented self-peptides in the immunopeptidomes we had isolated from four HLA-C*06:02 homozygous B-cell lines that stimulate the Vα3S1/Vβ13S1 TCR and differ from the melanocyte autoantigen recognized by this TCR. These data suggest that the proinflammatory environment of streptococcal tonsillopharyngitis may enable B cells to activate autoreactive CD8+ T cells that, owing to the polyspecificity of T-cell receptors, recognize several B-cell self-peptides presented by HLA-C*06:02 and subsequently cross-react against melanocytes in the skin, thereby triggering psoriasis. The capacity of B cells to stimulate a cross-reactive autoimmune response through HLA class I-presented B-cell peptides is a previously unknown mechanism in the induction of autoimmunity that could explain psoriasis onset and persistence.">
          <td id="tag"><i class="material-icons">visibility_off</i></td>
          <td><a href="https://www.semanticscholar.org/paper/5d7a0f1489f4e873304e188edfedc3bb70c48a78" target='_blank'>
              B Cells Can Trigger the T-Cell-Mediated Autoimmune Response Against Melanocytes in Psoriasis
              </a>
            </td>
          <td>
            Mengwen He, Melissa Bernhardt, Akiko Arakawa, Song-Min Kim, S. Vollmer, B. Summer, Yukiyasu Arakawa, Tatsushi Ishimoto, A. Schlosser, J. C. Prinz
          </td>
          <td>2025-12-01</td>
          <td>Cells</td>
          <td>0</td>
          <td>19</td>
        </tr>

    </tbody>
    <tfoot>
      <tr>
          <th>Abstract</th>
          <th>Title</th>
          <th>Authors</th>
          <th>Publication Date</th>
          <th>Journal/Conference</th>
          <th>Citation count</th>
          <th>Highest h-index</th>
      </tr>
    </tfoot>
    </table>
    </p>
  </div>

</body>

<script>

  function create_author_list(author_list) {
    let td_author_element = document.getElementById();
    for (let i = 0; i < author_list.length; i++) {
          // tdElements[i].innerHTML = greet(tdElements[i].innerHTML);
          alert (author_list[i]);
      }
  }

  var trace1 = {
    x: ['2025', '2026'],
    y: [13, 0],
    name: 'Num of citations',
    yaxis: 'y1',
    type: 'scatter'
  };

  var data = [trace1];

  var layout = {
    yaxis: {
      title: 'Num of citations',
      }
  };
  Plotly.newPlot('myDiv1', data, layout);
</script>
<script>
var dataTableOptions = {
        initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;

                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);

                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';

                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    scrollX: true,
    scrollCollapse: true,
    paging: true,
    fixedColumns: true,
    columnDefs: [
        {"className": "dt-center", "targets": "_all"},
        // set width for both columns 0 and 1 as 25%
        { width: '7%', targets: 0 },
        { width: '30%', targets: 1 },
        { width: '25%', targets: 2 },
        { width: '15%', targets: 4 }

      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  }
  new DataTable('#table1', dataTableOptions);
  new DataTable('#table2', dataTableOptions);

  var table1 = $('#table1').DataTable();
  $('#table1 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table1.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
    }
  });
  var table2 = $('#table2').DataTable();
  $('#table2 tbody').on('click', 'td:first-child', function () {
    var tr = $(this).closest('tr');
    var row = table2.row( tr );

    var rowId = tr.attr('id');
    // alert(rowId);

    if (row.child.isShown()) {
      // This row is already open - close it.
      row.child.hide();
      tr.removeClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility_off</i>');
    } else {
      // Open row.
      // row.child('foo').show();
      var content = '<div class="child-row-content"><strong>Abstract:</strong> ' + rowId + '</div>';
      row.child(content).show();
      tr.addClass('shown');
      tr.find('td:first-child').html('<i class="material-icons">visibility</i>');
    }
  });
</script>
<style>
  .child-row-content {
    text-align: justify;
    text-justify: inter-word;
    word-wrap: break-word; /* Ensure long words are broken */
    white-space: normal; /* Ensure text wraps to the next line */
    max-width: 100%; /* Ensure content does not exceed the table width */
    padding: 10px; /* Optional: add some padding for better readability */
    /* font size */
    font-size: small;
  }
</style>
</html>







  
  




  



                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8v12Z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "..", "features": ["navigation.top", "navigation.tabs"], "search": "../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    

      <script src="../assets/javascripts/bundle.c8d2eff1.min.js"></script>
      
    
<script>
  // Execute intro.js when a button with id 'intro' is clicked
  function startIntro(){
      introJs().setOptions({
          tooltipClass: 'customTooltip'
      }).start();
  }
</script>
<script>
  

  // new DataTable('#table1', {
  //   order: [[5, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });

  // new DataTable('#table2', {
  //   order: [[3, 'desc']],
  //   "columnDefs": [
  //       {"className": "dt-center", "targets": "_all"},
  //       { width: '30%', targets: 0 }
  //     ],
  //   pageLength: 10,
  //   layout: {
  //       topStart: {
  //           buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
  //       }
  //   }
  // });
  new DataTable('#table3', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
  new DataTable('#table4', {
    initComplete: function () {
        this.api()
            .columns()
            .every(function () {
                let column = this;
 
                // Create select element
                let select = document.createElement('select');
                select.add(new Option(''));
                column.footer().replaceChildren(select);
 
                // Apply listener for user change in value
                select.addEventListener('change', function () {
                    column
                        .search(select.value, {exact: true})
                        .draw();
                });

                // keep the width of the select element same as the column
                select.style.width = '100%';
 
                // Add list of options
                column
                    .data()
                    .unique()
                    .sort()
                    .each(function (d, j) {
                        select.add(new Option(d));
                    });
            });
    },
    // order: [[3, 'desc']],
    "columnDefs": [
        {"className": "dt-center", "targets": "_all"},
        { width: '30%', targets: 0 }
      ],
    pageLength: 10,
    layout: {
        topStart: {
            buttons: ['copy', 'csv', 'excel', 'pdf', 'print']
        }
    }
  });
</script>


  </body>
</html>